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ABSTRACT
Systemic sclerosis is an autoimmune disease characterised by fibrosis and serological 
autoantibodies (Aabs), some of which are indicative of disease subtype. A degree of 
Aab mutual exclusivity gives rise to three, major serological groups. Genetic 
associations with SSc become stronger when autoantibody subgroups are considered. 
There are ethnic differences in the pattern of disease and autoantibody frequencies.
The aims of this thesis are to further understanding of the aetio-pathogenesis of SSc by; 
investigating autoantibody specificity, identifying possible genetic predetermination or 
restriction of Aab generation and exploring the relationship of these two factors with 
disease profile, course and outcome. A variety of standard serological and genetic 
methods have been used in this investigation.
Several important findings have been made in the present study: I) Although patients 
with anti-topoisomerase I antibodies (ATA) or anti-RNA polymerase III antibodies 
(ARA III) represented distinct groups, their mutual exclusivity could not be explained 
by the genetic analysis in this study: II) ATA positive SSc patients and normal controls 
showed T cell proliferative responses to recombinant topoisomerase I, and shared a 
common genetic background. This is consistent with the notion that auto-reactive T 
cells are part of the immune system repertoire and the ability to mount a T cell 
proliferative response is genetically restricted: III) HLA background, autoantibody 
profile and clinical course are ethnically variable, however associations between these 
three factors are independent of ethnicity: IV) The majority (91%) of ACA positive 
patients had IcSSc and an association with HLA DR1 and DR4: V) Consideration of the 
genetic contribution to fibrosis identified microsatellite marker associations with 
TGFp2 and TGFP3 indicating that polymorphisms exist in these genes that predispose 
individuals to SSc. Stratification according to serological groups showed similar 
associations with microsatellite marker as stratification according to skin type.
Together these results provide evidence to suggest a genetic susceptibility to specific 
autoimmune responses in SSc. Existing HLA associations are supported and new ones 
are proposed. Polymorphisms of specific fibrosis genes may exist that are associated 
with disease. Overall, the relationship between HLA-autoantibody-disease subset has 
been supported and defined to some degree. Increased understanding of this relationship 
may further elucidate the pathogenic mechanism underlying SSc and ultimately improve 
the diagnostic and prognostic value of autoantibodies as disease markers.
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1.1: Clinical features of systemic sclerosis
Systemic sclerosis (SSc) is a heterogeneous, connective tissue disease, characterised by 
fibrosis, a spectrum of degenerative changes involving the blood vessels, skin, and 
certain internal organs, and the presence of disease-specific serological autoantibodies. 
The hallmark of the disease is thickening of the skin (scleroderma) caused by increased 
deposition of extracellular matrix and excessive accumulation of connective tissue.
Disease profile and skin involvement
Raynaud’s phenomenon is usually the first symptom of SSc, and affects the vast 
majority of patients (1). Episodes are a result of intense vasospasm of peripheral 
arteries, which may be triggered on exposure to cold or emotion. The fingers (and less 
commonly the toes) become initially very pale and then blue from cyanosis secondary 
to the poor blood flow. Eventually when the blood flow returns there is redness and 
discomfort. Although Raynaud’s phenomenon is prevalent in some 30% of normal 
women only a small percentage of individuals go on to develop SSc (1).
Systemic sclerosis can be divided into 2 major variants: diffuse cutaneous (dcSSc) and 
limited cutaneous scleroderma (lcSSc), dependent primarily on the degree and extent of 
cutaneous involvement (2). Three phases can be recognised in the development of the 
disease. During the edematous phase there is often oedema (‘sausage’ swelling) and 
restriction of movement of the fingers, which can extend to involve the forearms, legs, 
feet and face. This may then be replaced gradually by thickening and tightening of the 
skin {indurative phase) over the course of several weeks or months. In the majority of 
patients (60%) these changes tend to be restricted to the fingers, hands and face in 
lcSSc, but spread at a variable rate to the forearms, upper-arms, thighs, chest and 
abdomen in the diffuse form of the disease. The skin becomes increasingly shiny and 
taut, impairing the mobility of the joints and face. In limited disease, skin thickening is 
much less prominent and the most striking finding maybe numerous telangiectasic 
lesions on the digits and face. Telangiectatic lesions are recognised as red spots, which 
blanche on pressure, resulting from a localized collection of distended blood capillary 
vessels. After several years, during the final atrophic phase the affected skin tends to 
soften and return to a normal thickness or may become thinner than normal.
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The onset of lcSSc usually follows a long duration of Raynaud’s and the skin thickening 
tends to remain minimal over many years. In contrast dcSSc, often shows an early, 
accelerated, increase in skin thickness following a short duration of Raynaud’s.
Further clinical manifestations
Fibrotic damage often occurs in internal organs in addition to the skin. Rapid 
progression in skin thickness is associated with several internal organ problems.
Pulmonary Involvement
Pulmonary disease has become the major cause of death in SSc patients (3). Pulmonary 
hypertension (PH) and pulmonary interstitial fibrosis (PF) are the two major pulmonary 
conditions occurring among SSc patients. Pulmonary disease is evaluated most often by 
pulmonary function test and chest radiograph (1). High resolution CT scanning and 
echocardiography are useful procedures for further investigating the possibility of PH 
and PF respectively. Severe PH is clinically detectable in nine percent of lcSSc patients 
where the prevailing symptom is dyspnoea and the most common physiologic 
abnormality is a reduced diffusing capacity. PH is rare in the dcSSc variant but may 
present secondary to interstitial lung disease. PF may be present in both variants of the 
disease; occurring in up to 70% of dcSSc patients, but is comparatively rare in lcSSc 
patients. Again, the major clinical feature is dyspnoea, which may be accompanied by a 
cough (4). Pulmonary function tests reveal reduced lung capacities and chest 
radiographs may show linear and reticular shadows (for review see Silver ’90) (5).
Renal Involvement
Renal disease occurs in approximately ten percent of all scleroderma patients (6), and 
was the major cause of SSc patient death until the introduction of angiotensin 
converting enzyme, (ACE), inhibiting drugs. Scleroderma renal crisis typically occurs 
early in those patients with rapid, progressive skin thickening (dcSSc) (~20%) (6;7). 
Early indicators of renal involvement include proteinuria, hypertension and impaired 
glomerular filtration. A vascular aetiology is reflected in the histopathologic changes, 
which reveal intimal thickening of the small and medium arteries accompanied by 
medial atrophy and luminal occlusion (4). Fibrosis and necrosis may also be seen in 
later stages of advanced disease.
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Gastrointestinal tract involvement
Involvement of the gastrointestinal (GI) tract organs is apparent in approximately 90% 
of patients. Of these patients, 90% will probably suffer oesophageal disease, although 
any part of the tract may be involved (8). Pathologic changes consist of fibrosis, atrophy 
and distinctive changes in vasculature with consequent problems such as malabsorption, 
dysphagia, heartburn and vomiting.
Cardiac involvement
Myocardial fibrosis is the hallmark of cardiac involvement in SSc. The fibrosis is 
patchy and distributed throughout the myocardium. Cardiac involvement is suggested to 
be prevalent in approximately 20% of patients and is seen in both subsets of the disease.
Other clinical manifestations
Skeletal muscle involvement is common in SSc (1). There is mild weakness and atrophy 
of the muscles with a minimal elevation of creatine phosphokinase. A small number of 
patients suffer inflammatory myositis, indistinguishable from polymyositis (7;9). 
Neurologic involvement is rare (1), however reports describe disease affecting the 
autonomic, peripheral and central nervous systems, which is thought to arise via a 
diversity of pathogenetic mechanisms (10).
SSc variants and overlap syndromes
‘Localised scleroderma’, and ‘Systemic sclerosis sine scleroderma’ are two further 
variants of the disease. The former is characterised clinically as isolated patches of 
inflamed, fibrotic skin (11). SSc sine scleroderma is a rare variant, which does not 
involve the skin (12). (These two variants will not be considered in this research).
In addition to having SSc, some patients also exhibit features of other CTDs. Such cases 
are termed overlap syndromes. Patients with overlap present with a combination of 
major features of more than one disease: clinically and often serologically (13). The 
most common overlap syndromes are mixed connective tissue disease (MCTD), 
scleromyositis and synthetase syndrome (14). Systemic lupus erythematosis (SLE), 
Sjogren’s syndrome (SS) and rheumatoid arthritis may also be seen in overlap with SSc.
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1.2: Classification of SSc
Scoring and classification systems
Several scoring and classification systems have evolved in the evaluation of 
scleroderma. A recent contribution by Medsger and colleagues employed a scoring 
system to assess the involvement of nine organ systems to assess disease severity (15). 
The most widely accepted classification of SSc delineates two subsets of the disease 
(dcSSc and lcSSc) (2), and is used to define SSc patient subsets in the present work. 
Using this system, the primary determinant of patient classification is the extent of 
cutaneous involvement. Visceral and serological manifestations are also considered, as 
shown in table 1.1:
Table 1.1: Classification o f  SSc disease subsets
__________________ dcSSc_____________
Truncal and acral skin involvement 
Presence of tendon friction rubs
Onset of Raynaud’s within 1 year of onset 
of skin changes
Early and significant incidence of interstitial 
lung disease, oliguric renal failure, diffuse 
gastrointestinal disease, and myocardial 
involvement
Nailfold capillary dilation and capillary 
destruction
Anti-topoisomerase-I antibodies (30%) of 
patients
Absence of anticentromere antibodies
_____________lcSSc____________
Skin involvement limited to hands, 
face, feet, and forearms (acral) or 
absent
Raynaud’s for years (occasionally 
decades)
A significant late incidence of 
pulmonary hypertension, with or 
without interstitial lung disease, 
trigeminal neuralgia, skin 
calcifications, telangiectasia
Dilated nailfold capillary loops, 
usually without capillary dropout
A high incidence of ACA (70-80%)
From LeRoy et al. 1988 (2)
A system (originally) described by Barnett et al. (’78) classifies SSc disease further. 
This system subdivides lcSSc into two parts: type I includes patients with sclerodactyly 
and type II those patients with skin changes beyond the fingers but remaining in the 
extremities. Type III includes dcSSc patients (16; 17).
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Autoantibody status
SSc is classed as an autoimmune disease. More than 90% of patients have 
autoantibodies present in their serum. Certain autoantibodies are disease specific and 
characteristic of disease subset, and thus aid diagnosis and prognosis. As they are 
strongly implicated in the aetiology of SSc, they are discussed in section 1.5.
1.3: SSc Epidemiology
Prevalence and incidence
The prevalence of SSc has been demonstrably stable since 1973, and is reported to 
affect 100-200 persons/million. The onset of disease is typically seen between the ages 
of 30-50, although can occur at any age (18). Overall, women are affected 4 times as 
often as are men (20; 22), and this sex difference is increased during the child bearing 
years. The disease is considered rare with an annual incidence of under 10/million (19). 
However, incidence rates from a number of countries vary considerably, ranging 
between one and 20/million population/year (18).
Mortality, survival and prognosis
The overall, annual, average population mortality from SSc is approximately 1 to 
3/million (18). In obtaining reliable survival statistics many methodological issues, 
encompassing patient recruitment, referral delay and loss of patients to follow-up, are 
encountered (18). However, with these factors considered, median survival figures of 
approximately 60% at five years and 50% at ten years are suggested (18). Risk factors 
for reduced survival include the presence of diffuse disease, older age of onset and 
major organ involvement (20). Advances in therapeutic intervention have led to some 
decrease in mortality.
Race and ethnicity
There is evidence to suggest that racial and ethnic background influence. disease 
susceptibility, clinical expression, and serologic markers characteristic of the disease 
(reviewed by Mayes ’96) (20). There is a higher incidence in Blacks compared to 
Whites (20-22). Black females are more likely to be diagnosed at a younger age and 
have more aggressive disease (21;22). Prevalence of specific serologic markers also
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varies with ethnic diversity, where perhaps the most frequently reported difference is 
the relative lack of ACA in Black populations (21;23;24). The precise contribution of 
genetic background and environmental factors toward these observed differences 
remain to be elucidated.
Genetic factors and geographical clustering
Numerous studies have investigated the association between HLA types and SSc, and 
associations appear stronger when clinical sub-populations and/or serologic groups are 
considered (25;26). Immunogenetic associations continue to emerge and extend beyond 
the HLA region to encompass T-cell receptor genes and a variety of candidate genes, 
which will be considered later.
The prevalence of SSc varies by geographic region and is higher in the United States 
than in Europe or Japan (27). There have also been several reports of clustering of SSc, 
including areas of Britain (28;29). The most well known cluster of SSc involves the 
Native American Oklahoma Choctaw: a population with a conserved gene pool (30). 
The Oklahoma Choctaw demonstrate a high incidence of SSc, often with anti- 
topoisomerase I antibodies (31). Studies have revealed a genetic haplotype conferring 
susceptibility to SSc and an environmental trigger has remained elusive (31). There is 
convincing evidence that certain environmental agents are involved in the development 
of at least some clinical variants of SSc and will be considered later.
1.4: Pathogenesis of SSc
The precise pathogenesis of SSc is unknown. It is likely that a number of characteristic 
vascular, immune and fibrotic events, combine in a complex manner, and result in a 
self-perpetuating cycle. The general cascade of events will be discussed presently, with 
more detailed consideration of autoimmune and genetic factors subsequently.
Endothelial activation
As early as 1975 it was proposed that endothelial cell damage and dysfunction were the 
primary cause of scleroderma (32); a phenomenon considered central to the 
pathophysiology of SSc, and the focus of intense research today. Although the precise
6
mechanism by which endothelial involvement is initiated is not known, possible inciting 
factors of activation include Raynaud’s Phenomenon, (present in the majority of SSc 
patients), retroviral and environmental contributors, which are discussed in section 
1.6.2). Characteristics of the consequent endothelial activation and injury include loss of 
vascular integrity and increased permeability, expression of leucocyte adhesion 
molecules (ICAM-1 and VCAM-1), cytokine production, and increased surface 
expression of MHC class II molecules (33). An elevated plasma level of Von 
Willibrand factor VIII, sequestered by EC granules, is further evidence of EC activation 
(34).
Immune system activation
Mediators released by the endothelium cause immune activation, (which may also be 
brought about independently via an environmental trigger) (35). In early SSc lesions 
there is an inflammatory cell infiltrate which is dominated by T-cells. Subset analyses 
of T-lymphocyte sub-populations, in the skin, have revealed an increase in the 
proportion of the CD4+ (T helper) cells (36). MHC class II expression (35;37) 
evidences the activated state of the T-cells. Further evidence of immune activation is the 
raised level of the cytokine IL-2. Also the presence of autoantibodies (discussed later) 
implies B-cell activation. Activated lymphocytes are receptive to the adhesion 
molecules present on the activated endothelium and adherence contributes to vascular 
injury (38). Granzyme 1, which is found in SSc skin, is secreted by T-lymphocytes and 
is a factor thought to be cytotoxic to the endothelium (35).
Other cells also infiltrate the tissues and include natural killer (NK) cells, mast cells and 
macrophages, monocytes, eosinophils and basophils. Natural killer cells can be 
converted to lymphokine-activated killer cells, by circulating IL-2, which maybe an 
additional means of endothelial injury. Histamine, a factor raised in endothelial cell 
capillaries in SSc, indicates the accumulation of mast cells. Soluble mediators secreted 
by the T-cells, B-cells, and non-specific inflammatory cells can not only activate and 
damage endothelial and vascular cells, but also up-regulate fibroblast activity (37). The 
activation of immune cells and vascular degeneration precede cutaneous fibrosis.
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Fibrosis
The principle cell type involved in the production of collagen and other components of 
the extracellular matrix is the fibroblast and it normally does so as part of a highly 
regulated process. Progressive fibrosis due to excessive collagen deposition is the 
classic hallmark of SSc. An abnormal fibroblast phenotype is recognised in 
scleroderma, which produces increased amounts of collagen (collagen type I, III, V, VI 
and VII, glycosaminoglycans, fibronectin, laminin, decorin, and tenasin) (4;39). Local 
factors are thought to be responsible for the activated state rather than a fibroblast defect 
since fibroblasts taken from unaffected skin of SSc patients display normal levels of 
matrix production (40) and the activated phenotype is eventually lost when the cells are 
cultured in vitro (despite displaying activity for several passages) (4).
Accumulation of inflammatory cells and various adhesion molecules, and expression or 
secretion of integrins is a consequence of endothelial injury and the inflammatory 
response. In turn this promotes the synthesis and release of various cytokines and 
growth factors. Two important cytokines that may contribute to fibrosis are 
transforming growth factor beta (TGFP) and platelet derived growth factor (PDGF). 
TGFp and PDGF mediate the proliferation and activation of vascular and other 
connective tissue cells, particularly the fibroblast (41). TGFp is an indirect mitogen for 
fibroblasts which acts via (PDGF)-a receptor interactions (41), and an over production 
of TGFp by cells in the immune infiltrate has been demonstrated (42). TGFp causes 
persistent activation of the fibroblast to produce collagen by stimulating ECM 
components and inhibiting matrix-degrading metalloproteinases. The infiltration of 
platelets into the inflammatory site results in raised levels of PDGF in the locality. 
PDGF is chemotactic to fibroblasts and promotes their proliferation and activation. 
Fibroblast proliferation and collagen production is also induced by endothelin-1, a 
factor that is raised in SSc lesions and produced by the activated endothelium (35). Thus 
the vascular injury described does not only cause activation (an autocrine pathway), but 
also gives rise to fibroblast proliferation (35).
IFNy is an inhibitor of collagen production. It has been suggested that the reduced 
secretion of this cytokine contributes to increased collagen synthesis, in a negative 
fashion (35). The fibrogenic cytokines IL-4 and TNF, released by activated T-cells, 
cause fibroblast proliferation and matrix gene expression. The activated fibroblasts may
8
themselves then release cytokine and growth factors with the potential of exerting 
paracrine or autocrine effects (41).
Breaking tolerance and autoimmunity  *
The elimination of autoreactive T cells in the thymus during development (negative 
selection) is considered the principle mechanism by which T cell autoreactivity is 
controlled. The negative selection of T-cells requires a sufficiently high concentration of 
class II bound peptide and T-cell receptor affinity. Thus, if a self-peptide is not 
presented, or presented in low amounts then T-cells specific for this peptide will escape 
deletion. The immune system of a healthy person does contain some autoreactive T and 
B cells. If these remaining autoreactive lymphocytes escape control mechanisms and 
become activated then autoimmunity will ensue.
A hypothesis regarding the mechanism by which autoreactive T cells become activated 
has been proposed by Casciola-Rosen et al. (43). They suggested that the break in 
tolerance seen in SSc was due to the unique fragmentation of autoantigen, which results 
in subsequent exposure of cryptic epitopes. It was proposed that reactive oxygen 
species, produced during ischaemic-reperfusion injury, in the presence of specific metal 
ions, which are known to accumulate inside the nucleoli of cells (Cu, Fe), might initiate 
altered cleavage of SSc specific antigens, giving rise to the immunogenic cryptic 
epitopes (43). SSc-specific autoantigens, under certain physiological conditions, are 
localised within the nucleolus. (Cellular localisation of antigen, metal ion concentration 
and the availability of metal binding sites on the antigen have been proposed as reasons 
for the observed autoantibody profiles seen in SSc (44)).
Once tolerance has been broken (i.e. the autoreactive T-cell has been activated by minor 
antigenic determinants) subsequent autoreactive B-cell activation will follow. This 
includes B-cell function as an APC, and can lead to the spreading of T cell responses to 
different epitopes of the antigen (45). In an investigation of the mechanisms controlling 
the antitopoisomerase I response in SSc, Kuwana et a l showed that T and B cell 
collaboration was essential (46). Further, they identified autoreactive T-cells to 
topoisomerase I in normal healthy controls, indicating that such cells are components of 
the normal immune system repertoire. Their findings also support the hypothesis that 
the autoimmune response in SSc is antigen-driven (46).
9
SSc associated autoantibodies.
Autoantibodies are present in the sera of more than 97% of SSc patients. They display 
associations with disease, and genetic correlations with autoantibody specificity are also 
emerging. Autoantibodies may be detected prior to disease onset, which suggests that 
they are associated with a disease-causing event (47). Possible mechanisms, (inciting 
events), giving rise to autoantibody production will be considered in section 1.6. While 
autoantibodies may not be directly pathogenic to SSc, they are certainly indicators of 
pathogenesis and useful in the diagnosis and prognosis of disease, and thus are a 
valuable area of investigation.
Anti-endothelial cell antibodies
Anti-endothelial cell antibodies (AECA) have been described in SSc patients and they 
represent a heterogeneous family of IgG class autoantibodies (48;49). Although their 
possible pathogenicity remains somewhat controversial there is mounting evidence to 
suggest that they play a cytotoxic role (48). It has been reported that the binding of 
AECA to EC induces activation of the EC and upregulation of cell adhesion molecules, 
possibly due to autocrine action by IL-1 (49). Also, EC programmed cell death is 
emerging as a central participant in the pathophisiology of vascular injury (50;51). 
Research in this area by Sgonc (’99) has involved the animal model of SSc, the UCD- 
200 chicken, whose disease includes the vascular manifestations, which is lacking in 
other animal models such as the tight skin mouse. A parallel comparative study of skin 
biopsies of UCD-200 chickens and human SSc patients revealed that EC apoptosis, is 
induced by AECA-dependent cellular cytotoxicity, and is a primary event in the 
pathogenesis of SSc (52). *
1.5: Autoantibodies and autoimmune disease
Autoantibodies directed to specific intracellular antigens are a characteristic of most 
connective tissue diseases. In SSc, distinct profiles of autoantibodies are evident. 
Autoantibodies reactive toward antinuclear antigens (ANA) may be present throughout 
the spectrum of connective tissue diseases, or may indeed be specific for SSc only. The 
particular autoantibody present is often indicative of clinical expression and disease 
course and is thus an important aid in establishing a diagnosis and predicting prognosis.
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Autoantibodies are becoming increasingly valuable for discriminating subgroups of 
patients that differ in prognosis or response to therapy.
%
Methods fo r  identifying ANA
Ouchterlony double immunodiffusion and indirect immunofluorescence are two original 
methods, still used as standard, for detecting autoantibodies, particularly for clinical 
purposes. More recent developments have given rise to more sophisticated tests such as 
immunoblotting and immunoprecipitation. All of these techniques have been used in
i
this research and are detailed in chapter 2 .
SSc A utoantibodies
Three major autoantibody groups are recognized in SSc and they tend to be mutually 
exclusive of each other. Autoantibodies comprising each group tend to be associated 
with certain subtypes of the disease a,nd may be present with other autoantibodies 
considered to be less disease specific.
Anti-topoisomerqs3 1 antibodies 
%
A nuclear antigen uniquely recognized by SSc sera is the lOOkDa enzyme topoisomerse 
I (topo-I). Topo I is localized in the nucleolus and nucleoplasm of the cell where it is 
involved in DNA replication and transcription, and the regulation of chromosome 
structure by relaxing supercoiled DNA (53;54). Anti-topoisomerase I antibodies (ATA), 
previously called anti-Scl-70, are present in approximately 22% of SSc patients and 
identify a subgroup of patients with diffuse disease and an increased risk of PF (45). 
Many ATA sera also contain autoantibodies recognising subunits of the enzyme RNA 
polymerase II, namely ARA IIA (the larger phosphorylated subunit), and ARA II0 (the 
non-phosphorylated subunit). It should be noted that while some sera only recognise 
one subunit, some recognise both (45).
Anticentromere antibodies
Autoantibodies reactive with the centromere region of cells were first described in 1980 
(55). It has emerged since that a number of centromeric proteins are targeted in SSc. 
There are three main centromere antigens recognized in SSc; CENP-A (19kd), CENP-B 
(80kd) and CENP-C (140kd) (56), and their location and predicted function are shown
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in table 1.2. Three further CENP proteins; CENP-D, CENP-E and CENP F, are less 
often recognized by autoimmune sera (57).
Table 1.2: The Major centromere autoantigens
CENP
Autoantigen
Cellular location Protein recognized and 
predicted function
CENP-A Nucleosomal Centromere specific histone H3 
variant. Suggested role in the 
packaging of centromeric DNA.
CENP-B Centromeric
hetrochromatin, beneath the 
kinetochore plate
A DNA-binding protein that 
binds to a specific 17 base pair 
sequence in human alpha satellite 
DNA -  likely to play a role in the 
formation of a specified structure 
or function of human centromere
CENP-C Inner kinetochore plate An essential component of a 
functional human centromere. 
Stabililization of the kinetochore.
Information from Okano ’96 (53), and McHugh ’96 (57)
Anti-CENP antibodies are detected in the sera of approximately 26% of SSc patients 
(45), who are most likely to suffer the limited form of the disease, and often show 
prominent vascular features (58-60). Renal manifestations are rare in ACA positive SSc 
patients.
Anti-RNA Polymerase III antibodies
The third major group of autoantibodies in SSc are those directed toward RNA 
polymerase III. RNA polymerases catalyse the transcription of different sets of genes in 
the cell. RNA polymerase III synthesizes small RNA, including 5s ribosomal RNA and 
transfer RNA, in the nucleoplasm (53). Approximately 18% of SSc patients have anti- 
RNA polymerase III autoantibodies (ARA III) and show the greatest risk of developing 
dcSSc and renal involvement (45). ARA III usually occurs together with autoantibodies 
recognising ARA I: an enzyme that synthesizes ribosomal precursors in the nucleolus. 
Further more, sera containing ARA III and ARA I often also contain autoantibodies that 
recognise ARA IIA and ARA II0 (45;53).
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Minor antinucleolar antibodies in SSc
Other antinucleolar antibodies (ANoA) are also present in SSc that identity-subsets of 
the disease, particularly those that overlap with other autoimmune conditions. Anti-Pm- 
Scl antibodies, seen in approximately four percent of patients, are often identified in 
those SSc patients with polymyositis overlap (61). The precise role of this autoantigen 
is not known but is suggested to be involved in pre-ribosomal formation (53). Anti- 
U3RNP antibodies are evident in some seven percent of SSc patients and are associated 
with an early onset of disease that usually progresses to dcSSc. (45). U3RNP is a 
protein involved in ribosomal RNA processing. Anti-Th RNP antibodies are 
occasionally identified in SSc patients (<4%), and are indicative of lcSSc and small 
bowel involvement (62).
Minor antinuclear antibodies in SSc
Less specific autoantibodies, directed toward nuclear proteins, are also often present in 
SSc sera, and include the following: Anti-Ro antibodies have been associated with 
severe disease that shows very rapid progression, and SSc patients with this 
autoantibody often have renal and pulmonary involvement. Anti-Ro antibodies are 
frequently seen concurring with other autoantibodies in SSc, including ATA. 
Antibodies reactive toward U1RNP are identified in approximately six percent of 
patients, and are associated with isolated pulmonary arterial hypertension, early disease 
onset and in patients with SLE/SSc overlap syndrome. Anti-Jo-1 (anti-histidyl-tRNA 
synthetase) antibodies are identified in less than five percent of patients, often those 
with SSc/polymyositis overlap syndrome.
Mutual exclusivity and concurrence o f  autoantibodies in SSc
The three major autoantibody groups ATA, AC A and ARA III are, almost without 
exception, regarded as mutually exclusive. As immunological techniques have become 
more sensitive, detection of these autoantibodies has become more reliable and, led to 
the recognition of other ‘minor’ autoantibody specificities now also considered 
characteristic of the disease. Analogous with this, autoantibody associations with 
clinical profile have also become more detailed and particular associations are now 
firmly recognised.
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Understanding the mechanism, giving rise to the observed autoantibody mutual 
exclusivity, is likely to provide valuable insight into the pathogenesis of the disease. In 
1988 it was suggested by Steen et al. that mutual exclusivity of serologic subgroups of 
SSc represent aetiologically distinct disease processes, or, may reflect the differences in 
a patients’ vulnerability (63). This concept has provoked much interest and in 1998 it 
was proposed that SSc might actually represent a collection of separate diseases each 
having distinct pathogenetic origins that determine disease expression, or, may be that 
different autoantibody groups emerge from a common event, which is channelled via 
the influence of genetic background (64).
Thus, the answer to the mechanism underlying the pattern of autoantibodies recognised 
in SSc, the occurrence of distinct clinical subgroups, and the apparent associations 
between the two, may be held in an underlying genetic predeterminant. It is this concept 
that forms the basis of the research detailed in this report.
1.6: The aetiology of systemic sclerosis
The precise aetiology of SSc is unknown, however a range of genetic, and 
environmental factors, have been reported to be, and are regarded as aetiological risk 
factors and triggers for the autoimmune response. Studies have demonstrated that 
autoimmune disease is more prevalent in people with a certain genetic background. 
Tissue damage and the subsequent release of self-antigens are suggested to arise from 
exposure to environmental agents, which thus predispose an individual to autoimmune 
disease.
1.6.1: Genetically related factors 
The role o f  the MHC
The HLA molecules are encoded by a cluster of genes linked on the short arm of 
chromosome 6 in a region known as the Major Histocompatibility Complex (MHC). 
These molecules form receptors, which display peptide fragments of antigen, (antigen 
presentation), on the cell surface where they can be recognised by appropriate T-cells.
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In presenting foreign antigen to T-cells, HLA molecules evoke cytotoxic T lymphocyte 
and helper T cell responses, which then regulate specific immunity. The class II 
molecules include HLA-DR, DQ and DP, each of which is encoded by distinct genetic 
loci clustered in the class II region spanning approximately one megabase, as shown in 
figure 1.1







C4B C4A BF BC E A GDP DQ DR
A B  A B A B
Class II region Class III region Class I region
(lOOOkb) (lOOOkb) (2000kb)
A representation of the human major histocompatibility complex (MHC), located on the 
short arm of chromosome 6, showing the approximate positions of distinct genes. The 
class II genes are located most centromerically. TAP: transporter of antigenic peptides; 
21-OH: steroid 21-hydroxylase enzyme; C4A and C4B complement loci; Bf: Properdin 
factor B of the alternate complement pathway; C2: complement C2; TNF: tumour 
necrosis factor; MICA: MHC class I chain-related gene.
Structure o f the MHC class 11 molecules
MHC class II molecules are highly polymorphic membrane glycoproteins, the structure 
of which is achieved by the association of two membrane bound chains; a  and (3 (65). 
Together the chains form the antigen binding-cleft. The MHC class II chains are each 
encoded by distinct loci, which are closely linked as pairs of a  and (3 genes. The
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polymorphisms of HLA DR, DQ and DP are confined largely to the antigen-binding 
groove of the functional HLA molecules, but in HLA DR, they are confined to the DR 
beta chain (DRB gene) with the DR alpha chain (DRA gene) being essentially 
monomorphic (66). HLA DQ, and DP, also contain polymorphisms but in both the beta 
and alpha chain genes. The most polymorphic sites of the binding cleft formed by the 
HLA class II molecules are shown in figure 1.2.
Figure 1.2: Polymorphic sites in the peptide-binding groove o f MHC class II  
molecules.
The ribbon diagram shows the a  carbon backbone o f the MHC class II molecule. The 
most polymorphic locations in the antigen-binding cleft are highlighted in red.
The association o f HLA class II  with disease
Susceptibility to almost all autoimmune diseases is strongly influenced by a multitude 
o f genes (67;68) and studies have demonstrated that autoimmune disease is more 
prevalent in people with certain MHC types (69, 70). The binding grooves o f the 
different allelic forms of a particular HLA molecule vary in their ability to bind a given 
peptide, depending on its net charge, size and hydrophilicity (71), and so determine an 
individuals’ immune responsiveness to particular antigens, including autoantigens.
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Thus, certain HLA genes may confer susceptibility to certain kinds of autoimmunity. 
And, more specifically, it seems determinants of specificity may be in the form of short 
stretches of amino acids in specific locations. Such limited sequences are referred to as 
shared epitopes, such as that recognised in RA (72;73). Further more, studies at the 
molecular level have identified single amino acid residues at specific locations of the 
binding groove as candidates associated with disease susceptibility.
For many autoimmune diseases HLA associations have been characterised (74). The 
contribution of MHC genes predisposing individuals to insulin dependent diabetes 
mellitus (IDDM) is undisputed (75). The disease appears in individuals, usually before 
the age of 20 and is the result of the selective destruction of the insulin-producing cells 
in the pancreas (74). HLA alleles DQB 1*0302 and DQB 1*0201 are associated with a 
strong predisposition to the disease, while DQB 1*0602 is regarded to protect or confer 
resistance. Analyses for polymorphic residues shared among alleles associated with the 
disease have identified a correlation of position 57 of the DQ beta chain with disease 
susceptibility or resistance. The alleles associated with the disease posses either alanine, 
valine or serine at position 57. In contrast, those alleles found with decreased frequency 
in IDDM have an aspartic acid residue at this locus (74). The frequency of alleles 
possessing aspartic acid varies considerably with ethnicity and studies have shown a 
relative difference in the occurrence of IDDM between ethnic groups (74).
Genetic studies have linked a predisposition of RA with the HLA-DRB1 locus. Genetic 
analysis has revealed that HLA-DRB 1*0401 and 0404, and DRB 1*0101 confer genetic 
predisposition to RA (76;77). These alleles share sequence homology, within the third 
hypervariable region of the DR beta chain, and have given rise to the ‘shared epitope’ 
hypothesis (72;73). Pemphigus Vulgaris is an autoimmune condition of the skin and is 
slightly more common in Jews, than other ethnic and racial groups. An increased 
frequency in HLA DR4 has been identified in Ashkenazi Jews with pemphigus vulgaris, 
compared with healthy controls (74). Studies also suggest that the HLA DQ locus is 
important in susceptibility to this condition where an association with HLA DQ1 has 
been identified (74).
HLA associations with myasthenia gravis have also been reported, however are not as 
well established as those associations already mentioned. An association with HLA
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DR3 in young Caucasian myasthenia gravis patients has been identified (75). Studies in 
myasthenia gravis patients have also identified an association with HLA DQ8 and DQ6. 
Mouse models have been used to demonstrate the role of class II molecules in 
experimental autoimmune myasthenia gravis. An evaluation of the role of DQ genes in 
this disease used transgenic mice expressing HLA DQ8 and DQ6. It was demonstrated 
that the HLA DQ locus affected the incidence and severity of experimental autoimmune 
myasthenia gravis, which suggested a direct role of particular HLA class II molecules in 
the modulation of the disease (75).
HLA associations have also been identified with multiple sclerosis; a chronic immune 
mediated demyelinating disease of the central nervous system. Association with the 
HLA DR2/ DQ6 extended haplotype in Caucasian multiple sclerosis patients have been 
well established. Correlation with MHC class II molecules is ethnically variable and 
association of multiple sclerosis with HLA DR1, DR3 and DR4 has been identified in 
other ethnic populations (75). HLA associations with other autoimmune conditions 
include SLE with DR2 and DR3, Hashimotos thyroiditis with DR3 and DR5 and 
Graves’ disease with DR3 (74;75).
Associations o f  HLA with SSc
In SSc a number of HLA class II alleles have been associated with increased frequency 
of SSc disease, including DR2, DR3 and above all DR5. Stronger associations have 
been identified when clinical and autoantibody subgroups have been considered, 
however there is still no absolute pattern of association. There is an apparent variability 
in associations reported from different centres. Possible reasons for discrepancies 
include ethnic variability, clinical heterogeneity, and environmental factor diversity in 
different regions or localities. A comparison of HLA/SSc association studies from 
ethnically different populations are reviewed by Reveille ’95 and Briggs and Welsh ’91 
(26;78), respectively. Allele and amino acids at particular loci associated with the three 
main serological groups in SSc subsets are presented in table 1.3.
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Table 1.3: Reported HLA associations with SSc and major SSc serological subgroups
SSc serological 
subgroup M ajor HLA associations
Associated amino acid 
residues at specific loci
Overall SSc DR5 -
ATA DR5 (DRB1*1101-1104) 
DR2
DQB1*0302, 0601
DQB1: Y: 30, DQB1: Y: 26, 
DRB 1: FLEDR: 74-248
ACA DR1
DR4 (DRB 1*0403, 0407) 
DR5
DQB1*0501, 0301
Lacking DQB1: leu: 26
ARA III DQB1*0201 (Single report). -
HLA class II alleles and amino acid loci most commonly reported in association with 
SSc and major SSc serological autoantibody groups. DQB1: Y: 30: a tyrosine residue at 
position 30 of the outer most domain; DQB1: Y: 26: tyrosine at position 26 of the 
second hypervariable region in the pi domain of the DQB1 gene; DRB1: FLEDR: 67- 
71; amino acids at positions 67-71 in the pi domain of the DRB gene; DQB1: leu: 26: 
Lacking the amino acid leucine at position 26 DQB1 pi domain. (25;63;64;79;80;80- 
86).
Due to the strong linkage disequilibrium that exists between the HLA complex genes 
the precise contribution of individual loci to disease remains difficult to dissect. In SSc, 
associations have been found with HLA-DRB 1 and DQB1 alleles implying that both 
HLA DR and DQ genes control the autoimmune response in SSc (85).
Distinct evolutionary patterns in HLA class II allele frequencies are evident in 
ethnically diverse samples (87). The different prevalence of autoantibodies observed in 
separate ethnic groups (23), may be explained by the differences in HLA repertoire. 
This would support the role of HLA in SSc autoimmunity. As genetic techniques grow 
more sensitive and sophisticated the number of polymorphisms at each locus is steadily 
increasing, giving rise to more potential associate alleles. HLA associations may grow 
stronger still, with division of ethnic and racial groups studied, and consideration of not 




As discussed earlier the majority of SSc patients are female, and the male: female 
variation is greatest during the childbearing years. The difference in gender appears to 
be attributable to female hormonal milieu or pregnancy-related events (20;72). It is 
thought that the sex hormones may influence immunological mechanisms, for example, 
it has been suggested that high concentrations of estrogens, as found during pregnancy, 
may inhibit T suppressor cells and increase B cell differentiation (88). They are also 
believed to affect cytokine production and vascular adhesion molecule expression (89). 
Masi et a l have reviewed hormonal contribution to the aetiology of SSc (88).
Microchimerism
It is now recognised that during the course of normal pregnancy, foetal cells routinely 
pass into the maternal circulation (90), where they may last for several decades (91). 
The presence of cell populations in the body, which are derived from a different 
individual, is termed chimerism. Microchimerism, which is described here, denotes low 
level of chimerism (90). Exposure to foetal cells represents an immunologic event 
because these cells express gene products that are inherited from the father, and are thus 
foreign to the pregnant women. Male DNA, identified by a Y-chromosome specific 
sequence, has been found in significantly higher concentrations in the blood of SSc 
patients who have had male offspring, compared to similar women who did not have 
SSc (92). Microchimerism has also been detected in the actual target organ in SSc. 
Artlett et al. found male DNA present in SSc skin biopsies of eleven SSc patients 
compared to none of the normal controls (93).
SSc has similarities with a known condition of human chimerism: chronic Graft Versus 
Host Disease (cGVHD), which occurs in some recipients of allogeneic marrow 
transplantation. SSc and cGVHD share clinical and serological similarities. Both 
conditions show progressive skin changes, the same internal organs are often targeted, 
particularly the gut and lungs, and often occur in overlap with Sjogren’s syndrome and 
myositis (90). ATA and anti-Pm-Scl autoantibodies have also been described in some 
patients with cGVHD (94). However, striking differences between these two conditions 
are also noted; Raynaud’s disease and renal involvement are rare manifestations in 
cGVHD (95). Chronic GVHD is well described in immunocompetent individuals who 
have received blood transfusions from family members who are HLA compatible due to
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homozygosity (92). Moreover, it has been hypothesised that HLA compatibility of a 
child is associated with subsequent SSc in the mother (96). These observations support 
the hypothesis that microchimerism may be involved in the pathogenesis of SSc.
Animal Models
There are now several animal models resembling SSc that provide evidence of a genetic 
contribution to the disease. Such models have implied the MHC and other genes in its 
pathogenesis.
Tight skin mouse (TSK1) model
The most extensively studied animal model of scleroderma is the tight-skin 1 (TSK1) 
mouse model. Mice heterozygous for the autosomal dominant mutation phenotypically 
and serologically express features of human SSc. TSK1 have thickened tight skin, and 
show typical visceral changes mainly to the heart and lungs. ANA, including ATA have 
been reported in 50% of mutant animals (97). Genetic work on this model has linked the 
mutation to mouse chromosome 2, a region synonymous to human chromosome 15q 
(98). Work by Siracusa et al. refined the location of the mutation, mapping it to the 
fibrillin 1 gene, and demonstrated duplication within the gene in the TSK1 model 
(99; 100). The work implies that the ECM gene is a potential candidate in the 
pathogenesis of SSc.
Tight skin mouse (TSK 2) model.
The tight skin 2 {TSK 2) mutation represents an animal model of cutaneous fibrosis 
similar to TSK 1 which, displays both fibrotic and inflammatory alterations similar to 
those seen in SSc (101). The mutation appears as a result of administration of the 
mutagenic agent, ethylnitrosourea, and, in contrast to the TSK 7, resides on chromosome
1. Using microsatellite markers and gene probes Christner et al. have localized the TSK 
2 mutation to a two cM region of mouse chromosome one, and suggest Col3al as a 
candidate gene (102).
The avian model
University of California, Davis, (UCD) line 200 white leghorn chickens spontaneously 
develop a syndrome which shows the entire spectrum of clinical, histopathological and 
serological features of SSc (52). Disease is evident as comb inflammations and lesions,
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dermal fibrosis, and distal polyarthritis within six weeks of hatching (103). Birds 
surviving for longer than two months show progressive development of oesophageal 
fibrosis and mononuclear infiltration of the heart and kidney and some ANA (103). 
Mating experiments of UCD line 200 chickens with FI cocks and backcrosses with 
other inbred strains have demonstrated varying penetrance of disease. These results 
indicate the presence of genes (possibly MHC) that modify the penetrance of presumed 
major genes (104).
Further genetic associations
Association of null alleles of the C4A and C4B loci with SSc, have also been reported. 
It is thought that a consequent deficiency in C4 particles may result in inadequate 
immune response, which may give rise to excessive inflammation and possibly lead to 
autoimmunity (105). The C4A and C4B genes are located between the regions of the 
MHC class I and II, and are shown in figure 1.1. Close proximity of the MHC and 
complement genes means that they are in linkage disequilibrium. It has thus been 
suggested that some apparent SSc-HLA associations may in fact be due to complement 
deficiency genes (106). In Caucasian SSc patients the haplotype carrying HLA DR3 has 
been associated with the C4 null allele (C4A*Q0) (106;107). In Japanese, associations 
with disease and autoantibody subgroup have been reported, where C4AQ0 was 
significantly increased in lcSSc and SSc patients without ATA (108).
Advances in genetic technology have given rise to an increasing number of studies 
employing the use of microsatellite markers to investigate further SSc candidate genes. 
The rational behind the use of microsatellite markers to investigate disease associated 
genetic polymorphism is centred on the principle of linkage disequilibrium (for review 
see Vyse and Todd ’96) (109). Microsatellite markers consist of 2, 3 or 4 repeated 
nucleotides and are designed to be located amid, or within a lcM distance, of the 
candidate gene of interest. If an association exists between a marker and SSc, because 
the marker has been selected specifically to be in linkage disequilibrium with the 
specific candidate gene, any association thus indicates that the gene is associated with 
SSc. This also provides evidence that a polymorphism within the chosen gene may be 
involved in SSc susceptibility.
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Susol et al. used microsatellite markers to investigate SSc genes involved in fibrosis. 
Associations between SSc and microsatellite markers for transforming growth factor 
beta (TGFP) 1, 2 and 3, B chain of platelet derived growth factor (PDGFB) and tissue 
inhibitor of metalloproteinase-1 (TIMP1) were identified, from which it was concluded 
that polymorphisms within these genes may exist that predispose individuals to SSc, 
and may even be useful in predetermining the extent and severity of fibrosis (110-112). 
However, associations of microsatellite markers near to the TGFpi, latent TGFpi 
binding protein, and TGFp receptors I and II genes were not supported in a study of 
native American SSc patients (113). Associations of TNFa and TNFp microsatellite 
polymorphisms have also been reported, and TNFa 13 has been proposed as a genetic 
marker for SSc patients with ATA (114).
Intragenic polymorphisms have also been investigated and associations have been 
reported. In a study of 230 SSc patients, Fanning et al. investigated polymorphisms of 
TNF-RII and, TNF/LTa genotype in 230 SSc patients. Clinical subgroups, lcSSc, 
dcSSc and pulmonary fibrosis, were considered, and associations with particular TNF 
and TNF-RII genotype combinations were identified (115). In Choctaw SSc patients a 
number of single base polymorphisms within the fibrillin- 1 gene have been identified 
(116), and microsatellite markers near the fibrillin-1 gene have been found to be 
associated with SSc (117). More recently these researchers further investigated an 
Amerindian haplotype HLA DR2 (DRB1*1602) previously associated with SSc. Using 
polymorphic microsatellite markers, they identified an extended haplotype (HLA DR2 
(DRB1*1602, DQA1*0501, DQB1*0301, DPB1*1301) that was significantly 
associated with SSc in the American Choctaw. When the regions immediately flanking 
the HLA region were investigated no other significant associations were found (118).
With advances in genome science there is fast mounting evidence of a genetic 
contribution to SSc susceptibility, which appears to extend beyond the HLA.
Family studies and exclusive populations
Over 99% of SSc patients report no first-degree relative who has been diagnosed with 
SSc and 98% report no other affected family member of any degree of blood relation 
(20). However, although such cases are rare, there are reports in the literature describing 
multi-case SSc families. Twin studies are of particular relevance to this issue and
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provide an astute means of investigating the relative contribution of genetic and 
environmental factors to the aetiology of SSc.
Feghali et al. studied 34 twin pairs, one or both of which had systemic disease. The 
overall concordance rate for SSc in these twins was estimated to be 5.9%, with no 
significant difference in the rate between identical or fraternal twins. In contrast, 
concordance for the presence of ANA was 100% in identical and 63.6% in fraternal 
twins. In the same study, HLA typing confirmed previously reported autoantibody 
associations in the SSc patients. Of note though, none of the healthy twins displayed 
SSc-specific autoantibodies (119). In a study of three monozygotic twin pairs, who were 
discordant for disease, autoantibodies were identified in each affected twin. Genotyping 
revealed the expected HLA allele, for the relative autoantibodies identified (120). HLA 
association with autoantibody, in the diseased twin, supports the hypothesis of MHC 
genes contributing to disease susceptibility. However, discordance for disease between 
the twin pairs implies that additional factor(s), possibly environmental, are also 
important in SSc aetiology. Similar findings of ANA positivity have been reported in 
the spouses of scleroderma patients (121). A study of SSc patients, which identified 
eleven SSc patients with AC A, also identified AC A in two relatives of the probands. 
The two relatives, one identical twin sister and one sister, both had SSc (122). On 
consideration of the HLA background of these individuals, McHugh et a l concluded 
that the presence of at least one HLA DQB1 allele encoding for leucine of position-26 
of the first domain appeared necessary, but not sufficient for the generation of ACA 
( 122).
As discussed earlier, the Full-blooded Choctaw Native Americans, residing in South- 
Eastern Oklahoma are a population of individuals who demonstrate the highest 
incidence of SSc. Indeed as Harley and Neas said “Something about the environment of 
Oklahoma or the genetic composition of the Oklahoma Choctaw must be increasing the 
risk of SSc” (30). Thus, such exclusive populations provide a unique means of research 
into elucidating the aetiopathogenesis of SSc. The Native American Choctaw share a 
conserved gene pool and a genetic haplotype has been identified in the Oklahoma 
Choctaw as a significant risk factor for SSc (31; 123). However, the frequency of this 
haplotype, observed in another group of Choctaws living in another state, was 
comparable. These results strongly suggest the role of the environment in the
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development of SSc, however as yet a significant environmental risk factor has not been 
revealed (31; 123).
Population, family and twin studies have shown that genetic factors exert a significant 
effect on predisposition to autoimmune disease (124), and provide evidence to support 
the concept that inherited genetic factors play a role in the development of SSc, and 
possibly the ability to produce certain autoantibodies. However they also suggest that a 
major factor in disease development involves an acquired environmental exposure, the 
nature of which remains indeterminate.
Cancer
There are reports to suggest that there is an increase in cancer among patients with SSc 
(125;126). Studies have indicated possible associations between SSc and a variety of 
malignancies, particularly those of the lung (125; 126). Older age of diagnosis of SSc 
has been found as a significant risk factor for cancer (126), and associations have been 
made with SSc specific autoantibodies. ACA, independent of titre, has been identified 
as a significant risk factor for cancer in a Japanese SSc population. (127). ATA has also 
been associated with the development of cancer in SSc patients, and has not been 
associated with cancer in patients without scleroderma (128). In a report of two cases of 
SSc patients who developed adenocarcinoma of the lung, ATA titre levels were 
increased considerably at the time cancer was diagnosed, and were reactive with 
multiple epitopes of topo-I (129). Some topo-I fragment-specific reactivities detected 
after the diagnosis of cancer had not been present before. One explanation for this, as 
suggested by the group, could be representative of epitope spreading (129).
1.6.2: Environmental related factors
An increasing number of environmental factors have been proposed to contribute to the 
induction of autoimmune disease and need to be considered in the aetiology of SSc. 
Such factors include exposure to various chemical and microbial agents, and 
biochemical environments.
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Exposure to environmental agents
Several environmental agents are now recognised as predisposing or eliciting factors in 
some patients with SSc. Exposure to some environmental agents is thought to cause 
tissue damage, which may result in the release of self antigens; making available cryptic 
self peptides. These agents mainly comprise silica dusts, organic solvents and some 
drugs, and also include those listed in table 1.4.
Table 1.4: Environmental agents considered as predisposing or eliciting factors in
some patients with SSc
Environmental agent Details
Chlorinated hydrocarbons Trichloroethylene, perchloroethylene
Organic solvents:
Hydrocarbons Aromatic and aliphatic hydrocarbons
Chlorinated ethylenes Vinyl chloride. Possibly exposure to 
unreacted vinyl chloride monomer
Polymerisation of epoxy resins; Possible causative agent; Bis(4-amino-3- 
methylcyclohexyl)methane
Drugs Some appetite suppressants 
Pentazocine, cocaine, bleomycin
Silica dusts Exposure such as inhalation from mining
Silicone Cosmetic breast surgery
Quartz/metal dust Uranium mining
Haustein & Ziegler ( ’85) (130), Silman & Hochberg ( ’95) (131)
The majority of these substances are reported to induce a scleroderma-like disease (SD), 
which can be distinguished from idiopathic SSc in a number of ways. One distinct 
difference between idiopathic and environmental SSc resides in the sex ratio, which is 
1:1 in the former (132). The extent and type of skin involvement in SD is more 
generalised, often with joint contractures and fibrotic nodules (133). Manifestations 
often involve the liver, kidney, nervous system and muscles as a consequence of toxic 
damage by the environmental agent (133). There is usually cessation or reversibility of 
the disease after early discontinuation of the exposure. Serologically there is an absence 
of autoantibodies in SD patients, with the exception of SD induced by silica or silicon.
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Silica and silicone
Crystalline silica (or quartz) is an abundant mineral found in sand, rock and soil. 
Reports of SSc associated with silica dust mainly detail miners, quarrymen, sandblasters 
and sandstone sculptors and grinders (131). Individuals in these occupations have a 
higher risk of developing an SSc disease, clinically indistinguishable from idiopathic 
SSc, which is thought to occur as a result of inhalation of silica particles of respirable 
size (<10uM) (134). The relative risk of developing SSc for silica dust-exposed 
individuals has been estimated at 74-fold compared to the normal population over 40 
years of age (133). The precise mechanism by which silica causes SSc is unknown, but 
it is thought that phagocytosis of silica crystals by pulmonary alveolar macrophages, 
and the subsequent spread with phagocytosis by endothelial cells, results in a cycle of 
endothelial and macrophage activation; thus stimulating cytokine release, leading to the 
vascular, immune and fibrotic features characteristic of SSc (discussed earlier) 
(132; 134). Whilst ATA are the predominant autoantibodies present in silica-associated 
SSc (135), ATA and ACA have been identified in silica-exposed patients and are 
associated with the expected clinical subtype of disease (133; 136).
Silicone breast implants have also been implicated as a causal agent of SSc. Although 
this remains a debatable topic, there is literature to support such an association. Two 
case reports describe the onset of SSc following silicone gel breast implantation 
(137; 138). Both reports describe disease regression in these patients after elective 
removal of the implants. Additionally, in the later study, the remaining three women in 
the study who did not have their implants removed, died secondary to progressive 
visceral involvement (138). Maclaughlin et al. reported a significantly increased 
incidence of SSc in Denmark in women after breast implant surgery (139), however 
such associations are not always supported (140).
In trying to explain why some individuals exposed to silica develop disease and others 
do not one may again begin to consider immunogenetic background. HLA DRB 1*0301 
has been identified as a susceptibility component in ATA positive, silica exposed 
individuals (141). Also, in post implant SSc patients, a significantly low frequency of 
the amino acid residue leucine at position 26 of the first domain of the HLA-DQB1 
allele was observed. These results were consistent with those reported for Caucasian 
women with idiopathic SSc and ACA autoantibodies (142). Both studies conclude that
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whilst the initiating event for the development of silica associated SSc is distinct from 
that of idiopathic SSc, it is not clear whether the ensuing diseases are distinguishable 
(141 ;142).
Exposure to solvents and related compounds
Exposure to solvents has been implicated as a causal factor in the development of SSc 
since the first description of such a case by Rein in 1957 (143). Since then, many case 
reports have been published associating the exposure to organic compounds, 
particularly organic solvents with the development of SSc and are reviewed by Silman 
and Hochberg (’96) and D’Cruz (2000), (131 ;132), respectively.
A scleroderma-like disease has been well described in workers exposed to un-reacted 
monomer of the chlorinated ethylene, vinyl chloride (VC), whilst cleaning VC 
polymerisation reactors (130). It has been hypothesised that exposure may lead to the 
formation of epoxy intermediate products (epoxides/peroxides) with the liberation of 
free radicals. These products are detoxified, in vivo, by molecular derangement or, by 
binding to proteins or nucleic acids, giving rise to structurally altered proteins, which, it 
is thought may induce a pathologic (auto)immune response in genetically susceptible 
individuals (130; 133), as discussed earlier. An increased prevalence of HLA DR3 and 
DR3/B8 haplotype has been reported in patients with VC disease (144).
Other case reports have implicated solvents with a similar chemical structure to VC, 
such as perchlorethylene and trichloroethylene (145). Trichlorethylene penetrates the 
skin and the metabolites are neuro- and hepatotoxic, resulting in a variety of symptoms 
including scleroderma-like lesions of the skin (130). Contact with aromatic and 
aliphatic hydrocarbons, principally toluene, benzene, xylene and white spirits, and also 
the vapour of epoxyresins, have also been associated with scleroderma (130-132).
Drug induced scleroderma
The development of scleroderma has also been reported in some patients following the 
use of specific drugs. These include the long-term use of appetite suppression drugs and 
the antitumour agent, bleomycin. Again, the mechanism by which disease occurs is not 
clear, however, bleomycin is known to stimulate collagen production by normal skin 
fibroblasts (146). The development of scleroderma, in young men, following the use of
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cocaine has also been reported (147). Cocaine is known to cause vasoconstriction and it 
is hypothesised that this may act as the first step in the disease pathogenesis in these 
patients (131).
A genetic determinant has not been associated with scleroderma development following 
drug use per se (148), however genetic associations have been reported in other 
autoimmune conditions. Work at our institution identified HLA DR4, DR2 and the 
presence of at least one HLA DQB1: Y: 30 allele as a susceptibility factor for 
developing a lupus-like syndrome following long-term use (>6 months) of minocycline 
(149).
Microbial agents and molecular mimicry
One hypothesis of autoimmunity proposes that it develops as a result of stimulation by a 
microbial product (150). This concept suggests that a microbial peptide may share 
structural and sequence homology with a self-peptide and can stimulate pathogenic self­
reactive specific T-cells to cause autoimmunity. This phenomenon is referred to as 
‘molecular mimicry’. There is evidence to suggest that molecular mimicry may play a 
role in the development of the autoimmune response in some SSc patients. The B cell 
epitope comprising amino acids 121-126 was reported to have homology to the UL70 
protein of human cytomegalovirus by Muryoi et a l (’92). This lent further support to 
the observation by the earlier report by Maul et al. (’89), who identified homology of 
amino acids 741-746 of the same protein with the p30gag retroviral protein (151). 
Additional regions of homology between some SSc autoantibody targets and viruses 
have been reported and are reviewed by White ’96 (37).
Free radicals, cryptic peptides and apoptosis
Endothelial damage, caused by ischaemic reperfusion, has largely been attributed to free 
radicals. Ischaemia, experienced during episodes of Raynaud’s, or by exposure to the 
environmental agents implicated in the pathogenesis of SSc discussed earlier, are 
thought to give rise to free radicals. During ischaemia, xanthine dehydrogenase may 
convert to xanthine oxidase, which gives rise to the release of free radicals (02-and 
H2O2) (152). Endothelial cells are thought to be susceptible to superoxide injury during 
reperfusion. Free radicals are believed to damage capillary walls by peroxidation of 
lipid components of the endothelial cell membrane and/or degradation of collagen and
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hyaluronic acid, components of the basement membrane (152). Endothelial damage is 
hypothesised to lead to a chronic (auto)immune response in susceptible individuals 
culminating in SSc (152) as discussed earlier. Optimum treatments for Raynaud’s is an 
active area of investigation (153), and therapeutic intervention with free radical 
scavengers, such as allopurinol, has been suggested to help slow the progression of SSc, 
if such susceptible individuals could be identified.
The generation of cryptic epitopes forms the basis of one explanation for the break in 
tolerance and consequent autoimmunity culminating SSc. As mentioned earlier, 
Casciola-Rosen et al. hypothesised that reactive oxygen species arising from ischaemic 
reperfusion may, in the presence of appropriate metals, induce novel fragmentation of 
autoantigens, (specifically Topo I and RNA polymerase II), resulting in immunocryptic 
epitopes with the potential of initiating autoimmunity (43). During apoptosis, many of 
the autoantigens targeted in the SSc autoimmune response become concentrated in 
surface blebs and are cleaved, by granzyme B in vitro, and, during cytotoxic 
lymphocyte granule-induced death, generating unique peptide fragments (154). It is 
hypothesised that the unique peptides may be internalised by APCs and presented, 
causing the activation of autoreactive T-cells and autoimmunity (155).
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1.7: The present study
Whether in fact autoantibodies are agents of pathology or not, remains a debatable 
topic. However, autoantibodies are certainly markers of disease in SSc, and are thus a 
valuable source of information with regard to the pathogenic mechanism culminating 
SSc and autoimmune disease. Currently, serological autoantibody identification of SSc 
patients is one of the most useful diagnostic and prognostic tools available. As 
discussed, a number of ANA, are specific for SSc and are indicative of disease subtype 
and manifestation. A degree of autoantibody mutual exclusivity is also recognised: 
giving rise to the three, so called, major serological groups. Further autoantibody 
specificities are characteristic of SSc and although not considered disease specific, they 
have been associated with patterns of disease development and may indicate potential 
cases of disease overlap.
Genetic associations are also recognised in SSc and as discussed, HLA allele and amino 
acid loci associations with autoantibody specificity have been reported. However, 
although some broad correlations have been established, this area tends to fall subject to 
a degree of ambiguity. Racial and ethnic variations are now appreciated to be a 
contributory factor to this, and need to be considered, particularly when population 
comparisons are to be made.
1.8: Study Aim
In the present study, an investigation into the autoantibody, clinical and genetic status of 
SSc patients was undertaken, with an aim to further identify the associations of each of 
these aspects, with SSc, and to investigate a potential relationship between these three 
factors. This idea is represented in figure 1.3:
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A representation of the proposed ‘Genetic-Autoantibody-Clinical profile ’ triad- 





2.1: PATIENTS AND CONTROLS
For this study four main groups of individuals were included:
1. Two hundred and twenty nine British Caucasian SSc patients attending; the 
RNHRD CTD clinic, Bath (n=100) or the Hope hospital, Salford (n=129)
2. Forty five South African Black SSc patients attending a tertiary hospital on the 
Witwatersrand, South Africa
3. Control cohort one: 250 normal, healthy, ‘control’ individuals attending the 
Southwest region blood transfusion centre.
4. Control cohort two: 196 normal healthy ‘controls’ from the Norfolk family 
Health Service Authority Register
2.1.1: Clinical Diagnosis
A clinical diagnosis of SSc was assigned when the minimum requirements, defined by 
the ARA preliminary criteria for the diagnosis of SSc, were satisfied. The criterion, 
published by the ARA, provides a standard for definite or certain disease in order to 
permit comparison of groups of patients from different centres. The published criteria 
are accepted as the worldwide standard for research purposes (156).
ARA preliminary criteria fo r  the diagnosis o f  SSc
Either the major criterion or at least 2 of the minor criteria must be met for a diagnosis 
of SSc (97% sensitivity and 98% specificity).
Major criterion; scleroderma proximal to the metacarpophalangeal joints
Minor criteria; i) sclerodactyly
ii) Digital pitting scars of the fingertips, or loss of substance of the 
distal finger pad
iii) Bibasilar pulmonary interstitial fibrosis
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2.1.2: Disease classification and scoring
Disease ‘subtype’ classification
Throughout this study disease has been classified as a subtype, either limited cutaneous 
SSc (lcSSc), or, diffuse cutaneous SSc (dcSSc) (2). LcSSc was defined as cutaneous 
sclerosis not extending proximal to the elbows or knees, with or without facial 
involvement, while dcSSc was defined as cutaneous sclerosis extending proximal to the 
elbows or knees.
Scoring system fo r  skin involvement
The disease subdivision described above was further classified, based on the extent of 
cutaneous involvement, according to a modified version of Barnett’s classification 
system (16). LcSSc patients were assigned as either; type 1) Sclerodactyly only or, type 
2) Skin involvement limited to the hands, forearms, face and neck, and dc-SSc patients 
were classed as type 3) Diffuse skin involvement
Diagnosis and scoring ofpulmonary fibrosis
Pulmonary fibrosis was assessed by; measuring forced vital capacity (FVC), diffusing 
capacity (DLCO), and/or scarring on chest X-ray. FVC is obtained from maximal 
forced expirations into a recording spirometer (and compared to predicted values 
according to age, sex, race and height). Any significant shadowing of the lungs 
characteristic of bibasilar pulmonary fibrosis, apparent by X-ray examination, was also 
recorded, according to the severity scoring system as follows:
Score Test Result
0 Normal diffusion capacity
1 DLCO 70-80% predicted, FVC 70-80% predicted, bibasilar dry
crepitations (discontinuous dry crackles, usually bilateral, almost 
exclusively on inspiration, which indicates interstitial lung disease)
2 DLCO 50-69% predicted, FVC 50-69% predicted. Pulmonary
hypertension (peak systolic pressure 30-59mmHg)
3 DLCO <50% predicted, FVC<50% predicted. Pulmonary hypertension 
(peak systolic pressure 60+ mmHg)
4 Oxygen required
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2.2: DNA BASED TECHNIQUES
2.2.1: Isolation and quantification of DNA from whole blood 
Isolation o f  DNA from  whole blood
DNA was prepared from whole blood, which had been collected into tubes containing 
EDTA. After centrifugation at 1200r.p.m (Beckman GPR centrifuge) for lOmin, the 
‘buffy’ layer (containing the white cells) was carefully pipetted into a clean tube. Eight 
ml of red cell lysis buffer (0.144M NH4CI, lOmM NaHCOa) were added and after 
20min the tube was centrifuged as before. The red cell lysate was removed and the 
pellet resuspended in 3ml nuclei lysis buffer (lOmM Tris HC1 pH8.2, 0.4M NaCl, 2mM 
Na2EDTA pH8.0), lOOpl proteinase K (lOmg/ml in buffer; 2mM Na2EDTA, 1% w/v 
SDS), and lOOpl 20% SDS. After the samples had been incubated in a water bath, for 3 
hours at 55°C, 1ml of 5M NaCl was added and the tube shaken vigorously for 20sec. 
The tube was centrifuged as before and the supernatant collected into a universal vial, 
(care was taken to leave the pellet undisturbed). To the supernatant 8ml of absolute 
alcohol were added and the contents mixed by repeated gentle inversion of the tube. The 
precipitated DNA was removed by winding onto the end of a sealed Pasteur pipette and 
excess alcohol squeezed out on the side of the tube. The DNA was transferred to an 
Eppendorf tube and dissolved in lOOpl of double distilled filter purified water (ddEEO) 
and stored at -25°C. DNA was quantified by spectrophotometry, as detailed below.
Quantification o f  DNA by Spectrophotometry
Nucleotides in solution absorb light in the ultraviolet (UV) region of the spectrum, with 
a maximum absorption around a wavelength of 260nm. Proteins also absorb UV light 
but at the 280nm wavelength. Therefore, nucleic acids can be quantified, and the purity 
of a preparation estimated by measuring the absorption at both 260 and 280nm 
(spectrophotometry) and comparing the results to those obtained from pure solutions. 
The term optical density (OD) is commonly used instead of absorbance.
Preparation o f  samples fo r  spectrophotometry
DNA samples to be quantified and assessed for purity, (typically 15 at a time), were 
removed from the freezer and allowed to thaw at room temperature. Eppendorf tubes 
were labelled appropriately and 250pl of ddH20  were placed into each tube. Once 
thawed, the DNA samples were mixed thoroughly by vortexing for 20sec. A 2.5pi
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aliquot of DNA sample was pipetted into each of the allocated Eppendorf tubes. Care 
was taken to dispense the entire sample from the tip by sucking the solution up and 
down a few times. (If the DNA sample was very viscous then 100-200pl of ddH20 
were added to the sample, which was thoroughly mixed by vortexing and then placed in 
the fridge for a couple of hours. This procedure was repeated until the sample reached a 
‘workable’ viscosity). Tubes were vortexed for lOsec and placed in the fridge for 
30min.
Spectrophotometry o f  samples
The spectrophotometer (LKB, Blothrom, Ultraspec II) was calibrated for reading 
wavelengths of 260 and 280nm, using ddH20  as the ‘blank’, according to the 
manufacturer instructions.
The first DNA sample was pipetted into a clean cuvette (Helm, model 105.201-QS) and 
placed into the spectrophotometer. The OD 260nm, (measure of nucleic acid content), 
was recorded first, followed by the OD 280nm (measure of protein contaminants). A 
third reading, the ratio OD of 260/ 280 indicated the purity of the sample. A reading of 
1.8 identified pure DNA samples. Samples with a ratio of 1.8 (+/-0.1) were of sufficient 
purity for the work intended. Ratios of samples not falling within this range were 
purified, according to the procedure detailed below.
Calculation to determine the concentration and quantity o f  DNA
DNA concentration was calculated as follows:
OD 260nm X 50 X dilution factor = Xpg/pl 
1000
The quantity of DNA in a sample was calculated by multiplying ‘X’ from the above 
calculation by the total sample volume (Ypls).
Purification o f  DNA samples
A low OD ratio indicates protein contamination of nucleic acids. Any such 
contaminations were eliminated by treatment with phenol and chloroform as follows: 
To the DNA suspension an equal volume of phenol (Appligene, Oncor, France) was
36
added. The mixture was shaken in a closed tube until an emulsion had formed (this 
served to denature any protein). The tube was centrifuged for 15sec at 13000rpm (MSE 
microfuge), and the upper phase was transferred to a fresh Eppendorf tube, (the lower 
organic phase and interface were discarded appropriately). An equal volume of 1:1 
mixture of phenol and chloroform (Appligene, Oncor, France) was added to the retained 
layer, which was then mixed, spun, and separated as before. To the subsequent retained 
‘upper’ layer a 1/10 volume of three molar sodium acetate was added followed by 2 
volumes of absolute alcohol (Sigma Chemical Co.). The tube was agitated and spun for 
a third time, after which as much fluid as possible was taken off with care taken not to 
disturb the DNA pellet. The pellet was washed with alcohol twice more and left to air 
dry. Once dry the DNA was dissolved in lOOpl of sterile ddH20.
2.2.2: MHC class IIHLA DRB1 and DQB1 typing by PCR-SSP
The polymerase chain reaction (PCR) is a technique for the in vitro amplification of 
specific DNA sequences by the simultaneous primer extension of complementary 
strands of DNA. Two primers, each complementary to opposite strands of the region of 
DNA, which have been denatured by heating, are employed. The primers are designed 
such that each primer extension (synthesis of a complementary strand in the 5’ to 3’ 
direction) reaction directs the synthesis of DNA towards the other. Reaction cycles 
result in the amplification of the region of DNA of interest (i.e. between the primers).
HLA-DRB1 and HLA-DQB1 alleles have been identified using a PCR based method 
with sequence specific primers (SSP).
Primers fo r  the amplification o f  HLA DRB1 alleles
Ten 5'-primers and 16 3'-primers, combined in 20 primer mixes, were used for 
identifying HLA DRB1 alleles. Also in each PCR reaction a pair of primers specific for 
non-allelic sequences was included. The latter primers amplified the third intron of 
DRB1 genes and functioned as an internal amplification control (appendix II) 
(157;157;158;158).
Allele specific amplification of DRB1*04 alleles was carried out using one 5' primer 
and eight 3' primers combined in 8 (5'+3') primer mixes with control primers in each
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reaction (113). Allele specific amplification of DRB1*01 alleles was established using 
four 3' primers and one 5' primer combined in 4 reactions (159).
Primers fo r  the amplification o f  DQB1 alleles
Eleven 5' primers and eleven 3' primers combined in 14 primer mixes were used for the 
identification of DQB1 alleles. Two 5' and two 3' primers were combined to further 
distinguish between alleles HLA DQB1*0301 and 0304 (appendix II) (160).
Reaction Mixes
The PCR reaction mixtures (lOpl) consisted of 300ng genomic DNA in lpl reaction 
buffer (200mM (NH4)2SC>4, 750mM Tris-HCl, pH9.0 at 25°C), MgCl2 1.5mM, 
125pM of each dATP, dGTP, dCTP and dTTP, 0.25 pM sequence specific primers, 
0.15pM control primers (C3 and C5), 1.9pl sucrose cresol red (60% sucrose, ImM 
cresol red), and 0.25 units Taq (Thermoprime +, Advanced Biotechnologies).
Cycling Parameters
PCR amplifications were carried out in a PTC-200 DNA Engine (MJ Research). DNA 
was amplified by 30 cycles at three temperatures, with an additional denaturing step and
extension step. The process was started with a 2min denaturation at 96°C, followed by
10 cycles consisting of denaturation at 96°C for 25 sec, annealing at 65°C for 50 sec
and extension at 72°C for 30 sec. The process was then 'stepped down' to denaturation
at 96°C for 10 sec, annealing at 61°C for 50 sec and extension at 72°C for 30 sec for 20
cycles. The process was completed by a lOmin incubation at 72°C followed by chilling
at 40C.
Agarose gel electrophoresis fo r  visualisation o f  amplification
PCR products were visualised by horizontal electrophoresis in 2% ethidium bromide 
agarose gels. The gels were made by adding 3g agarose (Flowgen agarose) to 150ml 0.5 
X Tris Borate EDTA (TBE) (45mM Tris Base, 45mM boric acid, ImM EDTA pH8.0) 
and boiling the mixture in a Pyrex flask placed in a microwave oven, with occasional 
stirring, until the agarose had dissolved. After being left to cool to approximately 50°C 
ethidium bromide was added to a final concentration of 0.5pg/ml. The molten gel was
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poured immediately into a gel tray and 15 or 20 well combs slotted into place. The gel 
was left to set.
The PCR reaction mixtures were loaded into the 4 X 1.5mm wells. The sucrose cresol 
red acted as loading solution. Gels (25x13 cm, 4x20 wells) were run at 150V in 0.5 X 
TBE buffer for approximately 45min. Gels were examined under UV illumination (UV 
transilluminator-UVP), recorded and documented using the computer photographic 
package ‘Imigdoc’.
2.2.3: SSc candidate gene analyses using microsatellite markers
Research into the investigation of SSc candidate genes using microsatellite markers was 
carried out at the ARC epidemiolgy unit at the University of Manchester. The 
experimental procedures used for this work and described below, had previously been 
optimised by Elene Susol and colleagues.
Collection o f  DNA samples
DNA samples were collected from patients as described in method 2.2.1.
DNA Quantification
Semi-automated techniques for genotyping microsatellite markers require DNA of a 
known concentration, thus all DNA samples to be typed were firstly quantified by 
fluorimetry. This was done using the Hoefer Mini Fluorimeter (TKO 100), which 
allows the quantification of dsDNA by measuring excitation and emission spectra of a 
fluorescent dye (Hoechst 33258) in the presence and absence of dsDNA. Thus DNA 
concentration was calculated according to details set out in the manufacturer 
instructions.
Before each session it was necessary to calibrate the fluorimeter. Firstly the fluorimeter 
was zeroed using 2ml working dye solution (50ul H33258 stock solution in 5ml filtered 
10 X TNE (lOOmM Tris, 10M EDTA. 1M NaCl pH7.4), 45ml filtered distilled water 
(0.45pm pore filter, Acrodisc) pipetted into a clean cuvette. Standard DNA (2pl of 
1 mg/ml calf thymus DNA; Clonetech) was then added to the cuvette, which, was
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returned to the fluorimeter and the reading adjusted to 1000 (equivalent to a DNA 
concentration of lpg/ml). This procedure was repeated 3-4 times until the DNA 
standard reproducibly read 1000.
PCR using microsatellite markers
Proteins involved in fibrosis that are thought play a role in the pathogenesis of SSc were 
investigated. Microsatellite markers mapping within or close to the corresponding 
candidate genes of interest had carefully been selected by colleagues in Manchester and 
are detailed in table 2 .1.












TGFP3 D14S277 FP: TTGCTTTCACTCCCCATT
RP: TGCACTTGAAGATTCAGATAAG
150-170 FAM
TGFpi D19S400 FP: ATGACAGCTCTAGGAAG
RP: CGGTATGTCTTTATCAGCAG
195-230 FAM
PDGFB D22S284 FP: GCTCTCTTGAGGTCGTTACA
RP: ATGGGTATTTAACTTCTCTACA
76-112 TET
Col5A2 D2S389 FP: TAAAGCCTAGTGGAAGA
RP: GCT G AGTT AAC AGTT AT C AAC A
179-229 TET
PDGFB *PDGFB FP: AGAGGTGAATTTGCAAGTGA 
RP: AHGTGATGGTTATTACTGCAG
75-108 HEX
TGFp2 D1S419 FP: CGCATGTAAGTTGGGG
RP: AGCTGGTCCTGTCTGGAT
152-204 HEX
TIMP1 DXS426 FP: CCTTCATCTACCAAGATA
RP: CTGC ACTCC AGCCTGAATAA
271-317 HEX
Microsatellite markers used for the investigation of candidate ‘fibrosis’ genes. All 
markers were located within lcM of the relative candidate genes with the exception of 
♦PDGFB which was located within the gene. Forward primers were labelled with 
fluorescent dye (FAM; blue, TET; green, HEX; yellow, TAMRA; red), fp; forward 
primer, rp; reverse primer.
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Reaction mix fo r  PCR using microsatellite markers
PCR was carried out in a Hybaid Omnigene thermocycler using 96 well plates. The total 
volume of each PCR reaction was lOpl and the precise composition of each mix is 
detailed in table 2 .2 :
Table 2.2: Reaction mixes fo r  PCR using microsatellite markers
Component Stock
concentration
Amount added to PCR Final concentration/ 
amount in reaction mix
DNA lOng/pl 5 pi 50ng
Bioline NH4 lOx lpl IX
reaction Buffer
Bioline MgCl2 50mM 0.3pl 1.5mM
(0.2pl, D19S400 mix (l.OMm, D19S400 mix
only) only)
Bioline d'NTPs 50mM 0.5pl O.lmM
Bioline Taq DNA 5 units/pl 0.04pl 0.2 units
polymerase
Forward primer 50pol/pl 0 .2pl lOpmol
Reverse primer 50pmol/pl 0 .2pl lOpmol
Sterile betaine 4M *2.5pl 1M
Sterile autoclaved Make each reaction to
distilled water 10pi, total volume
Details of the composition of each single reaction mix for PCR using microsatellite 
markers. Sterile betaine was only added to reactions containing microsatellite marker 
D14S277 or D19S400.
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Cycling parameters fo r  PCR using microsatellite markers
Each reaction mix was covered with a drop of paraffin and plates were located into the 
PCR machine. PCR was carried out as follows:
1 cycle 45 seconds at 95°C
35 cycles 45 seconds at 95°C
1 minute at 55°C or 56°C for D14S277 and D19S400 
45 seconds at 72°C
1 cycle 5minutes at 72°C
After the PCR procedure was complete, products of each microsatellite marker set for 
each individual patient were pooled together and analysed using ABI semi-automated 
gene scanner technology (detailed below). However, to determine the appropriate 
volume of each PCR product to be pooled, firstly, it was necessary to measure the PCR 
products’ fluorescence intensity. This was done by selecting three random samples from 
each PCR and analysing them by running a ‘test gel’, using the ABI semi-automated 
gene scanner technology, as described below.
Genotyping using the ABI-Semi-automated gene scanner
Genotyping was carried out using an ABI Prism 377 DNA sequencer. Briefly, this 
procedure involves vertical polyacrylamide gel electrophoresis of fluorescently labelled 
PCR products. The products are detected by an argon ion laser beam and information is 
downloaded to a computer equipped with software for characterisation of PCR product 
size and allele identification.
Vertical polyacrylamide gel electrophoresis fo r  A B I 3 7 7 DNA sequencer
Two glass plates were thoroughly cleaned with distilled water and 70% isopropanol 
using white tissue paper. 0.2mm spacers were placed between the plates, which, were 
then orientated correctly and assembled into the gel cassette. Care was taken to ensure 
that the bottom edges of the plates were even. A four percent acrylamide gel was made 
(30ml 4.0% acrylamide (Severn Biotech Ltd.), 240pl, 10% ammonium persulphate and
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12pl of TEMED (Amresco)), and poured between the plates using a syringe. The flat 
edge of a 36-well comb was immediately positioned between the top of the plates and 
left for two hours to allow the gel to polymerise. Once the gel had set, the comb was 
removed, rinsed and the toothed edge was reinserted between the plates, down towards 
the top of the gel, thus creating wells into which the samples were to be loaded.
From this stage the operating instructions for the ABI prism 377 DNA sequencer were 
carefully followed, and the procedure is described below.
The gel cassette (containing the gel) was located in the ABI prism 377 DNA sequencer 
and secured. To ensure that the scanning region was clean a plate check was carried out. 
The buffer tanks were filled with lxTBE (45mM Tris Base, 45mM boric acid, ImM 
EDTA pH8) and the gel set to run until it reached 51°C.
Preparation o f  samples fo r  loading into the gel
One pi of PCR product was added to 2.5pi of prepared loading solution (20pl of 
fragment size standard solution; Prism Genescan 350 TAMRA, N,N,N’,N’- 
Tetramethyl-6-carboxyrhodamine, Applied Biosystems, with 80pl of loading dye; few 
granules of Blue Dextran 2000 in 80pl Ultra Pure Grade Formamide, Amresco). DNA 
was denatured by heating for 2min at 95°C and then samples were immediately placed 
onto ice.
Running the A B I Prism 377DNA Sequencer Genescanner gel 
Each sample was loaded into the wells and the gel set to run at 51°C for two hours, 
(3000V, 60mA, 200W), to allow the DNA fragments to separate according to size. The 
ABI gene scanner laser continuously scanned the lower portion of the gel. As each 
DNA fragment was scanned, the tagged fluorescent dye was excited and the light 
emission collected and separated according to wavelength onto a camera. Each 
fluorescent dye (TAMRA, TET, HEX and FAM) emits light at different wavelengths; 
so all four emissions could be recorded and deciphered simultaneously, with one pass of 
the laser. Information was processed electronically by the ‘data collection programme’ 
and downloaded into files for GeneScan analysis.
43
Genotyping o f alleles
Firstly, it was necessary to size the DNA fragments. To do this, each lane of the gel was 
tracked on an image of the gel, generated by the GeneScan Analysis software. 
Subsequently, sample files and electropherogram plots for the DNA fragments in each 
lane of the gel were generated, and the TAMRA standard fragments were checked. This 
data was then used to size the microsatellite marker PCR products.
The software package, Genotyper was used to assign alleles, using the data, which had 
been generated by the GeneScan Analysis (previously). Microsatellite alleles, 
represented as peaks of fluorescence on the electropherogram, were sized (base pairs). 
Upper and lower size limits of each allele were defined and an allele identified 
according to a three-digit code (101, 102 etc.). A macro, which had been designed 
previously, was used, which automatically analysed all samples from gel runs. Two 
control samples were included on all gels to ensure consistency in genotyping by this 
method. However, all genotyping was checked manually to ensure that alleles had been 
correctly identified by the software (hence the term ‘semi-automated genotyping’). 
Genotyping results were copied to Microsoft Excel spreadsheets for analysis.
2.3: TISSUE CULTURE TECHNIQUES
Basic Tissue culture
Standard aseptic practice was employed whilst working in the tissue culture laboratory 
and precautions appropriate for the materials being used were taken. Procedures were 
carried out in class II tissue culture cabinets with lamina flow of filtered air. Any non- 
sterile materials and solutions were autoclaved prior to use.
2.3.1: Preparation of tissue-culture media
Rosewell Park Memorial Institute (RPMI) media
A fifty ml volume of a 1 OX concentrate of RPMI media, without sodium bicarbonate or 
glutamine, was diluted in 375ml ddH20  and supplemented with 15ml sodium 
bicarbonate solution (7.5% w/v), 5ml penicillin/streptomycin solution (10000 I.U./ml 
and lOOOOpg/ml respectively), and 5ml glutamine solution (200mM), (all Life
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technologies Ltd, Paisley, U.K.). Double distilled H2O was added to a final volume of 
500ml for serum-free media. Alternatively 50ml of heat-inactivated foetal calf serum 
(FCS) were added for ‘RPMI+10% FCS’ media.
Methionine-deficient media
One pot of non-sterile powdered RPMI (Sigma Chemical Co. Ltd.); deficient in sodium 
bicarbonate, glutamine, methionine, leucine and lysine was dissolved in 775ml of filter- 
purified water, according to the manufacturers instructions. The solution was sterilised 
by passing through a bottle top filter (cellulose acetate membrane, 0.22pm pore size; 
Becton Dickinson Labware), attached to a vacuum pump. The medium was then 
supplemented with 30ml sodium bicarbonate solution, (7.5% w/v), 10ml 
penicillin/streptomycin solution (10000 I.U/ml and lOOOOpg/ml respectively), 10ml L- 
glutamine solution (200mM) (All; Life Technologies Ltd, Paisley, U.K.), and 5ml 1- 
Leucine (200x solution for tissue culture; Sigma Chemical Co. Ltd.). The volume was 
made up to 1 litre with ddH20  for ‘serum-free methionine-deficient RPMI’, or with 
50ml dialysed FCS (d-FCS; prepared according to the method below), for ‘Methionine- 
deficient RPMI + 5% d-FCS’.
Preparation o f  dialysedfoetal calf serum
Preparation o f  dialysis tubing
A 900mm piece of dialysis tubing (Sigma Chemical Co. Ltd.) was washed under 
running tap water, for 3-4 hours to remove the glycerine coating. Sulphur compounds 
were then removed as follows; approximately 300ml of EDTA-bicarb, (200mM sodium 
bicarbonate, 5mM EDTA), was poured into a glass beaker and brought to boiling point 
on a hot plate. The tubing was plunged into the solution for 5min, and then rinsed with 
ddH20 . The boiling and rinsing steps were repeated once more after which the tubing 
was used immediately.
Dialysis o f  FCS
Two knots were secured in one end of the tubing and FCS poured in from the open end 
until the tubing was approximately three quarters full. The open end was then similarly 
secured. After rinsing the tubing with phosphate buffered saline (PBS, prepared 
according to manufacturers instructions (Oxoid Unipath Ltd, Basingstoke, U.K.)) to
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remove any spillages of FCS, the tubing ‘sausage’ was placed into a beaker containing 
31 of chilled PBS. The beaker was placed on a magnetic stirrer at an ambient 
temperature of 4°C for 8 hours. Then PBS was exchanged for a fresh 31 of PBS, and the 
tubing left for a further 8-12 hours. Then the PBS was exchanged once more, as before, 
and left for another 8 hours. After a total of approximately 30 hours dialysis, the tubing 
was rinsed in PBS, cut open and the d-FCS tipped from the tubing into a clean 50ml 
polypropylene tube (Falcon brand). The d-FCS was immediately filter-sterilised by 
pushing steadily through a bottle top filter (pore-size 0.22pm: Millipore), into a sterile 
glass bottle, with a 10ml syringe.
2.3.2: Cell culture and maintenance 
Initiation o f  cells
The non-adherent K562 cell line, derived from a human chronic myelogenous 
leukaemia, were recovered either from storage under liquid nitrogen in Bath or, if stores 
were depleted, from growing cultures supplied by ECCAC (No. 89121407).
Resuspension o f  frozen cells
Frozen vials of cells were rapidly defrosted in a water bath (37°C), and the cell 
suspension was then washed twice in warm RPMI + 10%FCS medium before culture.
Maintenance o f  cells
K562 cells were maintained in approximately 30ml RPMI + 10%FCS, in 75cm2 tissue 
culture flasks (Falcon brand), between 8-30 million cells/flask, and incubated in a 5% 
carbon dioxide humidified incubator set at 37°C.
Freezing cells fo r  storage
Approximately 100ml of confluent cells were needed for the preparation of five, 1ml 
aliquots of K562 cells for freezing. The appropriate volume of cells were pooled into 
50ml polypropylene tubes and centrifuged at 1200r.p.m for lOmin (Beckman/GPR). 
The supernatant was poured off and the cells resuspended in 0.5ml RPMI + 30% FCS 
and pooled into one tube. A small sample of the cells was put onto a haemocytometer 
and counted. After calculation the appropriate volume of RPMI + 30% FCS was added
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to give a concentration of 10X106cells/ml. An equal volume of 20% 
dimethylsulphoxide (DMSO) in RPMI + 30% FCS was then added to the suspension 
and mixed in (final concentration 5X106cells/ml). One ml aliquots (approximately 5) 
were pipetted into cryovials, which were placed into a polystyrene box and frozen at - 
80°C for at least 10 hours prior to storage in liquid nitrogen.
2.4: SEROLOGICAL BASED TECHNIQUES 
2.4.1: Preparation and storage of serum samples
Serum samples were obtained as follows: 7ml of blood was collected into a standard, 
glass blood sample tube. The sample was left to stand until the blood had clotted 
(approx. 30min), after which the tube was centrifuged at 3000r.p.m. for lOmin (Hereaus 
Labofuge 6000 Centrifuge). The serum fraction of the sample was drawn off with a 
pipette and dispensed, in 1ml aliquots, into serum storage vials. Serum samples were 
stored at -20°C.
Detection o f  autoantibodies
The presence of antinuclear antibodies was studied by indirect immunofluorescence of 
Hep-2 cells (BioDiagnostics, Upton-upon-Sevem, U.K.). The fine specificity of 
antinucleolar antibody was investigated by immunoprecipitation of S-radiolabelled 
cell extract by SDS-PAGE. Ouchterlony double immunodiffusion was also used.
2.4.2: Indirect immunofluorescence
Serum was incubated against a fixed substrate to allow binding of autoantibodies to 
their respective antigen(s). A secondary antibody conjugated to fluorescein was then 
incubated against the substrate-antibody. Slides were mounted and studied under a 
fluorescence microscope. The presence of antinuclear antibodies were recognised by 
particular patterns of fluorescence.
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Detection o f  antinucleolar and anticentromere autoantibodies
Sera were thawed at room temperature and diluted 1 in 40 with PBS (Oxoid Ltd., 
Hampshire, England). Refrigerated multiple well HEp-2 slides (Binding Site, 
Birmingham, U.K.) were placed in a humidity chamber and left to come to room 
temperature. Thirty pi of diluted serum were pipetted onto the wells and the slide 
returned to the humidity chamber and incubated for 30min. Slides were rinsed with PBS 
and then placed in a PBS bath for 5min. Slides were removed from the bath, carefully 
dried between the wells with a tissue and returned to the chamber. Twenty pi of anti­
human polyvalent immunoglobulin fluorescein isothionate conjugate (FITC) (Sigma 
Chemical Co. Ltd., F6506) were diluted 1 in 150 with PBS and added to each of the 
wells. After 30min incubation in the humidity chamber, slides were washed as before 
and coverslips mounted. Slides were read under a fluorescence microscope to identify 
antinucleolar and anticentromere positive sera.
2.4.3: Ouchterlony double immunodiffusion
An antigen rich tissue extract and serum from a patient are allowed to diffuse towards 
each other in a horizontal agarose gel. When the patient serum contains autoantibodies, 
which recognise ‘antigen’ contained in the extract, then a line of precipitation is formed 
by the antigen/antibody complex (zone of equivalence).
An adaptation of the method described by Isenberg and Maddison (‘87) was used (161). 
An 8cm2 glass plate was cleaned with ethanol and placed on a levelling table. Onto the 
plate 12ml of 1%, molten, agarose gel containing 5pg/ml penicillin/streptomycin 
solution (10 000 IU/ml and 10 000 pg/ml respectively) were poured. The gel was left at 
room temperature to set. Circular wells were punched, precisely, into the gel using cork 
borers, in the formation shown in figure 2 .1:
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Figure 2.1: Arrangement o f wells punched into agarose gels
° n °0 U 0  o o
Seven wells of 4mm diameter evenly surrounded one central well of 7mm diameter. 
Each smaller well was equidistant from the other, and positioned 1.5mm away from the 
central well, to form 1 rosette. (When testing sera against topo-I extract (TIE) 6 smaller 
wells only were used).
Agarose plugs were removed by careful ‘teasing out’ using a capillary tube. Twenty pi 
of test or standard serum were pipetted into each of the small, outer wells, immediately 
followed by the addition of 80pl of tissue extract (20pl for TIE) to the larger central 
well. A petri dish lid was placed onto the levelling table, covering the plate and gel, and 
left for 12 hours.
The gel was viewed against a black background illuminated by a strong desk lamp. Gels 
were examined, after 12 and 14 hours incubation, and any precipitin lines on the gel 
were recorded and interpreted. Possible precipitin patterns and interpretations are shown 
in figure 2 .2 .
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Figure 2.2: Interpretation o f precipitin patterns
Extract 
(Ag) ,
Possible precipitin patterns are represented as follows; ‘a. ’ represents a line o f partial 
identity. This occurs when a particular antigen is recognised by Abs present in both 
sera, and a separate antigen is recognised by antibodies occurring in only 1 serum. ‘b. ’ 
shows a line o f identity. This indicates that both sera contain Abs that recognise exactly 
the same antigenic particle. At ‘c ’ all lines cross, showing lines o f  non-identity, 
indicating that adjacent sera contain Abs of different specificities. The precipitin line 
beside well 4 represents a sera with a low titre of Abs. Repeating the experiment with 
more serum accommodated in a slightly larger well may allow for the identification of 
autoantibody specificity.
Each serum sample was tested against 3 tissue extracts, which contained a broad 
spectrum of antigens (rabbit thymus extract (RTE) (Pel Freez Ltd, Arkansas, U.S.AJ 
Bradshaw Biologicals, Market Harborough, U.K.); containing U1RNP, sm, La and Pm- 
Scl antigens; calf thymus extract (CTE), prepared in house by BIRD Diagnostics, (Bath, 
U.K.), which contained Jo-1, and an Scl-70 extract (TIE) (Biodiagnostics Ltd), which 
contained topo-I). For each extract used a number of sera of known specificity (and of 
relative specificity to the particular extract), were included on the gel as positive 
controls. Each serum sample was tested a number of times: with each extract, and 
alongside sera of various specificities, until the resulting precipitin line was identified.
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2.4.4: Immunoprecipitation of proteins by SDS polyacrylamide gel electrophoresis
The method used was based on the original method described by Craft, Mimori and 
Olsen (‘88) (162). Serum was incubated with Sepharose beads to which protein-A was 
bound (Protein-A Sepharose CL). IgG present in the serum bound to the protein-A via 
the Fc fragment. The beads were washed free of any unbound material and re-incubated 
with a radiolabelled human cell extract. Any unbound material again was washed away. 
Bound antigens were then removed from the Sepharose protein-A, reduced and 
denatured by boiling in standard Llaemmli sample buffer. Constituent polypeptides 
were then separated by vertical SDS-PAGE followed by detection by autoradiography 
and identification according to banding pattern.
Radiolabelling o f  K562 cells with 35S-labelled L-methionine
Precautions appropriate to the nature and quantities of radiochemical used were 
observed throughout.
Three 600ml tissue culture flasks (Falcon brand, 3045) of K562 cells were grown to 
semiconfluency in RPMI +10%FCS. Four hundred ml of cell suspension (enough to 
provide approximately 80 million cells) was divided into 50ml centrifuge tubes and 
spun at lOOOr.p.m. for 7 min. The supernatant was poured off and the pellets 
resuspended in 2-3ml serum-free methionine-free RPMI. The suspension was pooled 
into one tube and a sample was counted on a haemocytometer to calculate the number 
of cells. The volume was made up to 50ml and the tube agitated to fully resuspend and 
wash the cells. The cells were pelleted as before, the supernatant poured off and the 
pellet resuspended in 10ml methionine free + 5% d-FCS. The cells were recounted and 
the appropriate volumes were transferred into sterile 250ml flasks (20 million 
cells/flask), to which methionine free + 5% d-FCS was added to a final volume of 90ml. 
The final cell density was 2-2.5 million cells/ml. Flasks were placed in an incubator for 
30min to deplete the cells of methionine. Approximately 160pl of S-labelled L- 
methionine solution (6.7pM, lOmCi/ml NEN Biologicals, NEN Dupont, Stevenage, 
U.K.) was added to the flasks, enough to give a final activity of 20pCi/ml. The flasks 
contents were swirled gently to mix and the flasks were returned to the incubator for 
overnight incubation.
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Preparation o f  the 35S-radiolabelled K562 cell extract
When possible, during the preparation of the cell extract, materials being used were kept 
on ice.
After overnight incubation the cells were examined to check that they were still viable. 
If they appeared ‘unhealthy’ for any reason or dead the protocol was not continued any 
further and the cells were discarded. If the cells appeared satisfactory then the cell 
suspension was divided into two 50ml (Falcon) centrifuge tubes, and spun for lOmin at 
lOOOrpm. The supernatant was poured off and the cell pellet resuspended by brief 
vortex in ice cold Tris Buffered Saline (TBS) (lOmM Tris.CL pH7.4, 150mM NaCl). 
The suspension was pooled into one tube and spun at lOOOr.p.m for 10 min. The 
supernatant was poured off, and the pellet resuspended in 8ml of cell lysing 
Immunoprecipitation Buffer (IPP) (lOmM Tris.CL pH 8.0, 500mM NaCl, 0.1% nonidet 
P-40) by brief vortex. The suspension was sonicated (Soniprep 150 MSE), with the 
sonicator set to mark (setting) 3, for 3 x 45 second blasts separated by 2 X 20 second 
intervals, after which the suspension was transferred to sterile 1.7ml Eppendorf tubes 
(lOOOpl/tube). The Eppendorf tubes were centrifuged in a Beckman GS-15R/F2402 at 
12000 r.p.m, for 20min at 1°C to remove insoluble debris. The supernatant was then 
transferred to fresh Eppendorf tubes and stored at -70°C. The pellets were discarded.
Incubation o f  sera with protein Sepharose A beads
Known standard control sera and test serum samples were removed from -25°C storage 
and allowed to thaw at room temperature. Protein-A Sepharose CL-4B (Sigma chemical 
company Ltd.) was weighed out; enough for 2mg per serum sample. The Sepharose was 
prepared for use by removing the inactivating cyanogen bromide according to the 
manufacturers instructions. An appropriate volume of IPP was added to the Sepharose 
to reach a final concentration of 4mg/ml. The IPP was added a couple of ml at a time in 
order to ensure that all the Sepharose was transferred to a clean polypropylene tube 
(Falcon). The tube was tightly closed and put on end over rotation in a cold cabinet 
(4°C) for 1 hour for the Sepharose to hydrate. One point seven ml volume Eppendorf 
Safe-Twist tubes (Original Eppendorf, 22408) were labelled with a serum ID code, and 
500pl of Sepharose suspension was added to each tube. Ten pi of serum were added to 
the respective tube containing the Sepharose suspension and securely closed. The tubes
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were incubated overnight in the cold cabinet with end over rotation to charge the 
Sepharose with immunoglobulin.
Incubation o f immunoglobulin-charged beads with S35-radiolabelled cell extract
The following was carried out on ice wherever possible.
After incubation samples were subjected to a series of washes in order to remove 
unbound material. The tubes were pulse spun at 13000rpm for 10 seconds. The 
supernatant was removed from each Eppendorf tube with care taken not to disturb the 
pellet. Each pellet was resuspended in 500pi ice cold IPP buffer and then each tube 
vortexed briefly. This process was repeated until the tubes had been spun 4 times. After
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the 4 spin the supernatant was removed and each pellet was resuspended in 400pl IPP 
buffer. The tubes were briefly vortexed to resuspend the pellet. One hundred pi 
(approximately 1-1.5 million cells) of the prepared radiolabelled cell extract were added 
to each Eppendorf tube. The tubes were resealed and incubated in a cold cabinet for 2 
hours with end over rotation.
After incubation the samples were washed as follows: Tubes were pulse spun, and the 
supernatant removed as before. Five pi of ice-cold IPP buffer were added to each 
sample and resuspended by brief vortex. This process was repeated 3 times, so the tubes 
had been spun a total of 4 times. After the 4th spin the supernatant was removed. Special 
care was taken to remove as much of the buffer as possible without disturbing the pellet. 
Pellets were resuspended in 40pl Llaemmli denaturing sample buffer (62.5mM Tris 
HCL pH 6 .8, 10% glycerol, 5% B-mercaptoethanol, 0.0025% (w/v) bromophenol blue) 
by brief vortex. The tubes were spun briefly in the microfuge. The Eppendorf tubes 
(beads and sample) were stored at -70°C.
Assembly o f  apparatus fo r  polyacrylamide gel electrophoresis
Plates were washed under running water, dried, and cleaned with ethanol. The gel 
apparatus (Hoefer SE 600 Series) was assembled according to the manufacturer 
instructions. Appropriate spacers were used for the required gel thickness. For the 
following, 1ml thick spacers, and 15 well, 1ml thick combs were used.
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Producing and pouring the acrylamide gel
The lower, 10% acrylamide Tower’ gel (appendix III) was prepared, and poured 
between the plates, leaving a space of approximately 3cm from the top of the plates. 
The gel was overlaid with water saturated butan-2-ol (60ml butan-2-ol and 40ml 
ddH20, shaken and allowed equilibrate) and left to polymerise. The upper 5% 
acrylamide gel was prepared (appendix III).
When the lower gel had set the top was rinsed free of butan-2-ol and any unpolymerised 
solution by rinsing between the tops of the plates with ddH20 . Tissue was used to soak 
away residual drops. The upper gel was poured onto the top of the lower gel to 
approximately 0.5cm from the top of the plates. A 15 well comb was pushed into the 
top of the upper gel. The upper gel was left to set.
Sample preparation
The Safe-Twist Eppendorf tubes containing the samples (prepared in the method 
entitled “Incubation of immunoglobulin charged-beads with S35-radiolabelled cell 
extract”) were plunged into a beaker of boiling water for 5 min, ensuring that the neck 
of the tubes remained above the surface of the water.
Gel loading and electrophoresis
After the gel had set the comb was removed. The top of the gel was rinsed thoroughly 
with ddH20  to remove any excess unpolymerised solution. The wells were then drained 
of water, using tissue to absorb the last drops, and then filled with running buffer 
(25mM Trizma base, 190mM glycine, 0.1% (w/v) SDS) Twenty pi of each prepared 
sample was underlayed into each of the allocated wells. Ten pi of high molecular 
weight colour marker were loaded into one well. The apparatus was fully assembled and 
attached to a power pack according to the manufacturer instructions. The gels were run 
at 30mAmps constant current until the bromophenol blue tracer dye (contained in the 
denaturing sample buffer) had moved through the 5% upper gel and into the 10% lower 
gel, when it was increased to 60mAmps for the duration. The run was terminated when 
the dye front approached the bottom of the plates.
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Gel processing and drying
The apparatus was dismantled and the gel plates carefully prised apart. A scalpel blade 
was used to carefully cut away the upper gel, which was discarded. The lower portion of 
the gels were soaked in 0.5M sodium salicylate for 15 min, to enhance, followed by 
fixing in a fixative solution (methanol: water: glacial acetic acid, 4.5:4.5:1) for at least 
0.5 hours. Gels were then placed onto a piece of blotting paper which had been cut to a 
size approximately 1cm2 larger to ease handling. A piece of cellophane (Cellophane 
membrane backing, BioRad Laboratories) about the same size as the blotting paper was 
placed over the exposed side of the gel. The Gel ‘sandwich’ was then placed onto the 
gel dryer (Rapidry gel dryer ATTA Electrophoresis) at 70°C for 1.5 hours.
A utoradiography
The gel was exposed to photographic film (e.g. XASR-1 or XAR-2 from Kodak) and 
left for 1-5 weeks. The film was developed and the lanes labelled.
2.4.5: Immunoblotting
Immunoblotting or, Western Blotting, is used to identify specific antigens recognised by 
antibodies, according to their apparent molecular weights. The prepared antigen source 
is solubilised, separated by SDS-PAGE, and then electrophoretically transferred to a 
nitrocellulose membrane. Following this, the membrane is cut into strips, which are 
incubated firstly in a protein rich solution to block remaining (non-specific) binding 
sites, and then with a diluted sample of serum. Autoantibodies that recognise linear 
epitopes bind to the denatured antigens. The strips are then incubated with an alkaline 
phosphatase-conjugated anti-human immunoglobulin, followed by incubation with the 
appropriate alkaline phosphatase substrates, which results in ‘coloured’ product where 
conjugate has bound. The consequent bands are indicative of the molecular weights of 
the antigenic subunits recognised by autoantibodies in the sample serum.
Immunoblotting was carried out according to the method described by McHugh, James 
and Maddison (‘88) (163), with some modification.
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Antigen preparation fo r  immunoblotting -  unlabelled K562 cell extract 
A nuclear sonicate of K562 cells was prepared. To all buffers ImM 
phenylmethylsulphonyl fluoride, lOmM idoacetamide, and lOmM EDTA were added. 
K562 cells were grown to semi-confluency. Cells were washed twice in 0.01M 
Phosphate buffered with 0.15M saline (PBS) (pH7.4). Cells were then solubilized at a 
concentration of 5X107 cells/ml in PBS containing 0.5% Triton X-100 for 30 min on 
ice. The tube was then spun at 5000g for 15 min at 4°C to pellet the nuclei. The 
supernatant was retained as the cytoplasmic fraction. The nuclei were resuspended in 
ImM NaPC>4, pH7.0, and sonicated at least 10 times for lOsec until all the nuclei had 
disintegrated (as determined by light microscopy). The insoluble material was removed 
by centrifugation at 500g for 15 min at 4°C and the supernatant retained as the soluble 
nuclear fraction. One ml aliquots of the nuclear extract was pipetted into Eppendorfs 
and stored at -80°C until use.
SDS PAGE o f (unlabelled) K562 cell extract fo r  immunoblotting and electrophoretic 
transfer
The K562 cell sonicate (antigen source) was separated on a 12.5% polyacrylamide gel 
(according to the method entitled “gel loading and electrophoresis”) with minor 
modification as follows; A comb with one large well and one small well was used. 200- 
300pl of sample, (which had been prepared according to the method “sample 
preparation”), was added to the large well and 15 pi of molecular weight marker were 
added to the small well.
Electrophoretic Transfer onto nitrocellulose membranes
Transfer buffer (20mM Trizma base, 150mM glycine, 20% (v/v) methanol, 0.1% SDS) 
was freshly prepared using a lOx concentrate of Transfer Buffer Solution (200mM 
Trizma base, 150mM glycine). One hour prior to transfer, sheets of nitrocellulose 
membrane (BioRad laboratories), (cut to slightly larger than gel size), were placed in a 
container of ddH20  to soak and subsequently washed in two changes of water and two 
changes of transfer buffer.
After SDS-PAGE, gels were carefully removed from the glass plates, and the stacking 
gel trimmed away with a scalpel blade. Gels were then placed into the transfer buffer 
and left for lOmin to equilibrate. Nitrocellulose membrane, blotting paper, and fiber
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pads, which had been cut to the dimensions of the gel, were also put into the transfer 
buffer to soak. The gel cassettes were assembled, whilst fully submerged in the transfer 
buffer, as follows; one fiber pad, two sheets of blotting paper, one SDS-polyacrylamide 
gel, one nitrocellulose membrane, two sheets of blotting paper, one fiber pad. To ensure 
the correct direction of movement of proteins (i.e. from the gel onto the nitrocellulose 
membrane), care was taken to check that the cassettes were assembled in such a way 
that the membrane was closest to the anode (+) side of the cassette and the gel was 
closest to the cathode (-) side of the cassette. Air bubbles caught between the gel and the 
membrane prevent a clean contact thus result in poor transfer. Any air bubbles were 
removed by gently rolling them out with a glass tube. Cassettes were firmly closed with 
the fitted clasp.
The gel sandwich was inserted into the running tank, which was then completely filled 
with transfer buffer. The cooling coil, which was attached to a cold water supply, was 
inserted into the vacant slot between the cassettes and a stir bar, (‘flea’), was dropped 
into the tank, which helped to maintain uniform conductivity and temperature during 
electrophoretic transfer. The lid was pressed onto the top of the apparatus and the cables 
plugged into the power supply. The transfer was run for 2 hours at 250mA constant 
current. After this time the apparatus was partially dissembled so that a comer of the 
membrane could be checked to see that transfer of the coloured molecular weight 
markers had occurred. If they hadn’t, then the transfer was incomplete, and the 
apparatus was re-assembled and run for a while longer.
Once the transfer was complete, the apparatus was fully dissembled. The gels were 
discarded and the nitrocellulose membranes were rinsed in ddH20 . The membranes 
were then stained with Ponceau S to check for protein content. This was done by 
immersing the membrane in Ponceau S solution (0.2% Ponceau S, 1% (v/v) acetic acid) 
and agitating on a moving platform, for 5min, at room temperature. The membranes 
were then de-stained by subsequent washings with ddH20  over a 10 min period and then 
left to dry on a clean piece of blotting paper.
Immunoblotting
After staining with Ponceau S, the nitrocellulose membranes were orientated and a 
pencil line drawn about 5mm from the bottom edge. The membrane was cut into strips
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approximately 5mm in width, and the strips numbered according to the order in which 
they were cut. Strips were placed (1/well) into a (20 well) blotting tray (BioRad 
laboratories) and blocked with blotto (5% skimmed milk powder in PBS) (2ml/well); 
this served to block non-specific protein-binding sites and was carried out for 2 hours 
on a moving platform.
The blotto was carefully poured off and another 3ml added to each well, followed by 
30pl of sample or prototype sera to allocated wells and incubated, at room temperature, 
on the moving platform for a further 2 hours at room temperature. After this time the 
liquid was poured off and the strips subjected to 3, lOmin washes with PBS.
Strips were then incubated with the second antibody (anti-human IgG/IgM developed in 
goat, conjugated to alkaline phosphatase; Sigma Chemical Co. Ltd.), which was added 
at a concentration of 1/1000 (2pl in 2ml blotto/well). The blotting tray was returned to 
the moving platform for a further 2 hours, after which the strips were washed as before, 
drained, and then covered with 2ml/well blotting buffer (0.1M tris, 0.1M NaCl, 5mM 
MgCl2, pH9.6 with HC1).
Developing the nitrocellulose strips
One hundred ml of developing solution (50ml blotting buffer, lOOpl BCIP and lOOpl 
NBT) were placed into a clean flat glass dish. The substrates, 200pi 5-bromo-4-chloro- 
3-indolyl phosphate solution (BCIP; 50 mg/ml in dimethylformamide (DMF)), and 
200pl nitroblue tetrazolium solution (NBT; 50mg/ml in 70% (v/v) DMF) were added 
and the dish was agitated to swirl and mix the contents. Strips were individually 
removed from the wells and placed into the developing solution. The prototype sera 
(positive and negative controls) helped to gauge when the optimal development, 
(satisfactory contrast between positive bands and negative background), of strips was 
achieved. When the strips of membrane reached this point they were taken out of the 
developing solution, rinsed in tap water and left on a clean sheet of blotting paper to 
dry.
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2.4.6: T-cell proliferative responses to full length human topoisomerase I 
recombinant protein
The following procedure was carried out by Jean Whyte, and not by myself. However, 
the results from her work are relevant to the present study and have been included. The 
following is a description o f the methods she employed in order to generate the results 
contained in this report.
Generation o f  fu ll length recombinant topoisomerase I  protein from  a Baculovirus 
expression system
The purification and characterisation of the recombinant human topo I expressed in 
Baculovirus has been previously described (164). Briefly, insect (Sf9) cells were 
infected with a high titre virus stock. At 5Oh post infection the cells were harvested, 
lysed with triton X-100, and the nuclei isolated. The DNA was precipitated from the 
nuclei following lysis in high salt (1M NaCl), with a final concentration of 6% PEG 
8000. The supernatant was subjected to successive chromatography and the final pooled 
fractions were dialysed and stored at -20°C. Purified topo-I migrated as a single band of 
lOOkD using polyacrylamide gel electrophoresis. The purified protein was identified by 
sera containing anti-topo I autoantibodies on immunoblots, and was enzymatically 
active as determined by the ability to relax supercoiled DNA.
Proliferation o f  lymphocytes using topoisomerase I
All procedures were carried out in sterile conditions until the cells were harvested. 
Lymphocytes were isolated from whole blood as follows; 20ml of blood were mixed 
with an equal volume of room temperature PBS and carefully layered onto 15ml of
TM
lymphoprep (Nycomed Pharma AS, Norway). The tube was spun for 30 min at 450g. 
The buffy coat was collected and diluted up to 40mls with ambient temperature RPMI 
medium. Cells were harvested at 350G for 5 min and washed once in 25ml RPMI 
medium, resuspended in 10ml of medium and counted using trypan blue. Concentration 
was adjusted to 1 X 106 cells/ml.
Flat bottomed 96 well plates (Falcon 3072) containing the antigen, topo I, were 
prepared. All wells were prepared in quadruplicate. Anti-human CD3 antibody was used 
as a positive control, and the antigen was omitted for negative controls. Fifty pi of either
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antigen in medium or medium alone were added to each of the designated wells 
followed by 100 pi of the cell suspension.
Plates were placed in the CO2 incubator at 37°C, (5% CO2, 95% humidity) for 7 days. 
Cells incubated with anti-CD3 antibodies were pulsed with luCi [ H] thymidine and 
harvested on days 3,4,5,6, and 7. Cells incubated with topo-I were pulsed similarly and 
harvested on days 5,6, and 7. Filters were counted in a liquid scintillation counter. 
Proliferation was expressed as a stimulation index (SI; c.p.m. in the presence of antigen 
divided by c.p.m. in the absence of antigen).
2.5: STATISTICAL ANALYSES
Statistical analyses were performed by Chi-squared analysis of 2 x 2 contingency tables. 
In cases where N was less than 100 and/or any cell was less than 10, Yates correction 
was applied. When N<20, or 20<N<40 and the smallest expected value was less than 5 
Fishers exact test was used. Bonforroni correction was applied to data that had been 
subject to multiple testing and to results showing previously unreported associations. 
Where significant P values were identified (p <0.05), odds ratio and confidence 
intervals were also calculated.
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CHAPTERS 3 - 6 
RESULTS
CHAPTER 3
MHC ASSOCIATIONS WITH AUTOIMMUNE 
RESPONSES TO TOPOISOMERASE I AND RNA
POLYMERASE III
3.1: INTRODUCTION
At first glance there appears to be a relatively weak genetic contribution to the 
development of SSc. There is certainly a lack of consensus concerning the contribution 
of HLA class II alleles in SSc. Many centres worldwide have reported abnormal 
prevalence of particular HLA alleles associated with SSc, although as yet, there is no 
clear pattern. Alleles frequently reported to be associated with SSc in Caucasians 
include HLA-DR1 (80;165), DR3 (165-167) and DR5 (165;168). HLA-DR2 and HLA- 
DR4 have been implicated in Japanese studies (169). Different associations do tend to 
be observed in non-Caucasian populations, thus, the variability in reported HLA 
associations in SSc, may reflect ethnic differences in the groups studied. This suggests 
that the division of ethnic groups is important in the consideration of HLA (and 
autoantibody) associations in SSc. HLA DQB1 associations have mainly been reported 
in association with autoantibody subgroups of SSc and will be addressed in the relevant 
section later.
Genetic polymorphism of HLA class II molecules determines the chemical surface of 
the peptide-binding groove and is the principle determinant of the specificity and 
affinity of peptide binding and T-cell recognition. T-cell recognition of (auto) antigens 
would provide help for B cells in the development of an (auto) antibody response. The 
selective and differential binding capacity for certain peptides, due to HLA class II 
polymorphism, introduces a mechanism for restricting immune responses. T-cell 
proliferative assays have demonstrated that presentation of topoisomerase-I peptides can 
be restricted by HLA class II alleles (46). This supports the hypothesis that T cell 
response to topo-I is not associated with disease but restricted by HLA class II alleles. 
Differential binding affinities in the peptide-binding groove could therefore restrict the 
production of autoantibodies, and it is this concept, which forms the basis of association 
between certain HLA class II alleles and autoantibodies in patients with SSc.
HLA class II associations with SSc become stronger if autoantibody-defmed subgroups 
of disease are studied.
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Studies in HLA and A T  A in SSc
HLA DRB5, is frequently associated with SSc and includes the alleles DRB1*1101- 
1104 and *1201-1202. HLA DRB1*1101-1104 is the most commonly reported allele 
associated with ATA and SSc in Caucasians (81). In Japanese however HLA 
DRB1*1502 is often reported (85; 170). The HLA DQB1 allele often associated with 
ATA positive SSc patients is HLA DQB 1*0301, not only in Caucasians (American) 
(84; 171 ;171) and American Blacks (84), but also American Choctaws (31) and 
Japanese, in which an association with DQB 1*0601 is also reported (85). Fanning et al 
reported a decrease of HLA-DQB1*05 in ATA positive patients in comparison to ATA 
negative patients, but not an increase in the previously reported allele HLA DQB 1*0301 
(64).
HLA associations have been supported by T-cell proliferation studies. A report by 
Kuwana et al. showed that in vitro T cell proliferation to recombinant topoisomerase-I 
was mostly restricted by HLA-DRB1, specifically the 1501/2, 1101/3/4 and 0701 alleles 
in Caucasoids (172).
It has been proposed that specific amino acid residues at certain positions common to 
particular HLA-DRB1 and HLA-DQB1 alleles have close associations with ATA 
responses. Reveille et al (’92) reported that an HLA-DQB1 allele bearing the polar 
uncharged amino acid residue tyrosine at position 30 of the outermost domain of the 
DQB1 chain (HLA-DQB1: 30:Y) was found in all American Caucasian and American 
Black ATA SSc patients (84). This observation was not supported in an alternative 
American Caucasian population reported by Morel (’94) (171), or in Japanese (85). 
However the latter group suggested that a tyrosine residue at position 26 of the HLA 
DQB1 chain (HLA-DQB1: 26:Y) and the amino acid sequence FLEDR from position 
67 to 71 of HLA-DRB1, (HLA-DRB1: 67FLEDR71) was important in ATA production 
(85). HLA-DRB1: 67FLEDR71 was also reported to be of increased frequency in a UK 
Caucasian population in ATA SSc patients (64).
Another sequence thought to be significant in the production of ATA is HLA-DQB1 
71TRAELDT77’ present on all HLA-DQB1*06, (except *0606), and *03 alleles, and is 
reported to have been increased in American and UK Caucasians (64;84;171).
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Studies in anti-RNA polymerase antibodies and HLA
To date, there is only one publication regarding HLA associations with anti-RNA 
polymerase (ARA) autoantibodies (64). In the mentioned study, two autoantibody 
groups have been considered: ARA I/II/III and ARA I/III. When allele frequencies of 
the two groups were analysed, in comparison to each other or, combined and compared 
to the remaining ARA negative group, no significant associations were identified. When 
the groups were compared independently to their respective negative groups a 
significant increase in HLA-DQB 1*0201 was reported in the ARA I/II/III group. This 
allele is linked with DRB 1*0301 which was observed to be raised but did not reach 
significance (64).
Mutual exclusivity o f  autoantibodies
Previous studies carried out at Bath have identified three main groups of ARA sera, 
ARA I/III, ARA I/II/III and ATA/ARA II (+/- other autoantibody), which are 
considered to be mutually exclusive (173). Mutual exclusivity of ARA III and ATA 
groups are generally supported by other studies (64;85). A difference in HLA 
associations between mutually exclusive groups would support the hypothesis in this 
study regarding the role of HLA in autoantibody production. One report (which also 
considers the mostly mutually exclusive group ACA) did not find any striking 
association of HLA that could explain the observed mutual exclusivity of autoantibody 
groups (64). However, a crucial factor in this study was the consideration that ATA and 
ARA were entirely mutually exclusive, which is contrary to reports from Bath (173). 
Thus for HLA associations to be found it is necessary to identify those autoantibody 
groups which are truly mutually exclusive.
This chapter explores HLA class II associations with ATA and ARA III in SSc.
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3.2: CHAPTER AIMS
The overall objective of the work detailed in this chapter was to identify any HLA- 
DRB1 and HLA-DQB1 characteristics that may distinguish autoantibody subgroups 
(ATA and ARA III), and their mutual exclusivity in SSc. This was investigated by 
means of the aims set out below:
I. To identify any associations of HLA DRB1 and/or DQB1 alleles, (at the allele
level or with previously reported amino acids at particular loci), with 
autoantibody subgroup, in an ATA positive and an ARA III positive SSc 
population.
II. To investigate the contribution of HLA towards ATA and ARA III mutual
exclusivity.
III. To investigate whether HLA class II alleles determine an individuals’ ability to
mount a mononuclear cell proliferative response to topoisomerase-I.
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3.3: MATERIALS AND METHODS
Patients and controls
Two hundred and thirty two patients fulfilled the established criteria for SSc (156), and 
were accepted into the study. All patients were Caucasian.
Five healthy individuals with no clinical evidence of an autoimmune disorder, 
(independent from the main cohort of normal controls detailed below), and three 
patients with SLE, were included in the T cell proliferation study.
The ‘normal controV population
Blood samples, for DNA isolation, were obtained from 250 donors attending the 
Southwest region blood transfusion centre. DNA was isolated from these samples.
Detection o f  autoantibodies
Indirect immunofluorescence (method 2.4.2) was used to screen all patients for anti- 
cytoplasmic antibody, antinuclear antibody (ANA) and antinucleolar antibody (ANoA) 
reactivity’s. Autoantibody specificities of ANA and ANoA positive sera were identified 
by 35S-immunoprecipitation (method 2.4.4). Where deemed necessary results were 
confirmed by Ouchterlony double immunodiffusion (method 2.4.3) (with the exception 
of ARA). For each method, comparisons were made with prototype reference sera.
HLA-DRB1 and HLA-DQB1 typing
HLA-DRB1 and DQB1 alleles were identified by PCR-SSP (method 2.2.2). HLA- 
DRB1 and DQB1 typing was performed on all the samples.
T cell proliferation responses to recombinant topoisomerase-I
T cell proliferation assays to recombinant topoisomerase-I were carried out according to 
method 2.4.6
Statistical Analysis
Statistical analysis was performed by X2 analysis of 2 x 2 contingency tables with 
correction where appropriate, according to that described in the main materials and 
methods, 2.5. The data in table 3.1 has also been analysed using the relative
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predispositional effects (RPEs) (174) method to identify allele association sequentially 
according to individual allele strength.
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3.4: RESULTS
3.4.1: Serological profile of patients
Of the 232 SSc patients accepted into the study, 37 (16%) were ATA positive. Twenty- 
two patients had autoantibodies to topoisomerase-I only. Ten patients were ATA and 
ARA II positive: (ATA + ARA II: 8, ATA + ARA II + anti-Ro: 1, ATA + ARA II + Jo- 
I: 1). Four patients had ATA and anti-Ro antibodies: (ATA + anti-Ro: 2, ATA + anti-Ro 
+ anti-Jo-I: 1, ATA + anti-Ro + anti-La: 1). One patient was ATA and anti-UlRNP (+/- 
sm) positive.
Twenty-Seven (11.5%) patients were ARA III positive (ARA I/III: 6, ARA I/II/III: 20, 
ARA III: 1).
3.4.2: HLA-DRB1 and DQB1 phenotype frequencies in ATA positive patients
HLA-DRBl and DQB1 phenotype frequencies in ATA positive patients 
HLA-DRB1 and DQB1 phenotype frequencies of ATA positive SSc patients were 
compared with normal controls and ATA negative SSc patients. Analysis was also 
carried out within the ATA group with regard to the presence or absence of ARA II.
DNA was available from 28 of the 37 ATA positive patients (ATA: 17, ATA + ARA II 
phosphorylated (ARA II0), + Ro: 1, ATA + ARA II0 + Jo-1: 1, ATA + ARA II0: 4, 
ATA + ARA II0 + ARA IIA:2, ATA + Ro: 1, ATA + Ro + Jo-1: 1, ATA + Ro + La: 0 
and ATA + U1RNP +/-Sm: 1), on which HLA-DRBl and DQB1 typing was carried 
out.
ATA positive patients vs. normal controls
Comparison of HLA-DRBl phenotype frequencies between ATA positive patients and 
controls showed an increase in HLA DR5 in ATA positive patients (9/28 patients vs. 
48/250 controls, p=0.1, table 3.1) although this was not significant (Table 3.1). 
However, when the DR5 subgroups (DRB1*11 and 12) were considered, a significant 
increase in DRB1*11 was identified in patients (p <0.05 vs. controls), whilst the
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DRB1*12 constituent of DR5 showed a negligible change in frequency compared to the 
controls (0/28 vs. 7/250, p=0.36) Although there was an increase observed in 
DRB1 *0101-0103, (10/28 patients vs. 53/250 controls, p<0.1) and a reduction in HLA 
DRB1*04 (6/28 patients vs. 88/250 controls, p<0.1) these differences from the control 
population did not reach significance.
There were no significant differences in the frequency of HLA-DQB1 alleles in ATA 
positive patients compared to controls. HLA-DQB 1*0501 and 0602 were reduced in the 
ATA positive group to some degree (9/28 vs. 52/250, p=0.16; 10/28 vs. 60/250, p=0.17 
respectively).
ATA positive patients vs. ATA negative patients
A comparison of the phenotype frequency of ATA positive SSc patients with the 
remaining SSc patients, (ATA negative), showed significant differences (Table 3.1). 
HLA DR5 was significantly increased in ATA positive patients compared to ATA 
negative patients (9/28 ATA+ vs. 17/153 ATA-, p<0.005). When the patients 
comprising DR5 were considered in their subgroups the significant difference was 
present in the DRB1*11 constituent, and not DRB1*12 (9/28 vs. 14/153 p<0.001). 
HLA-DRBl*0301-0303 was significantly decreased in ATA positive patients (4/28 
ATA+ vs. 58/153 ATA-, p<0.01).
Significant differences were also observed in HLA-DQB 1 frequencies between these 
two groups. HLA-DQB 1*0602 was significantly increased in ATA positive patients 
(10/28 ATA+ vs. 25/156 ATA-, p<0.02), as was HLA DQB1*0301 (13/28 ATA+ vs. 
42/156 ATA-, p<0.04). HLA-DQB1*0201 was reduced in frequency in ATA positive 
patients compared to ATA negative patients, however this difference did not reach 
significance (8/28 ATA+ vs. 42/156 ATA-, p<0.1).
A relative predispositional effects analysis (174) was also carried out to sequentially 
compare allele frequencies in ATA positive patients and in the controls, to determine 
their predispositional, protective, or neutral effects relative to each other. However, for 
HLA-DRBl and DQB1, no allele could be identified as having a significantly greater 
effect than any other allele, in this population, by this analysis (tables 3.2 and 3.3).
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3.4.3: HLA DRB1 and DQB1 phenotype frequencies in ARA III positive patients
HLA-DRBl and DQB1 phenotype frequencies of ARA III positive SSc patients were 
compared with normal controls and ARA III negative SSc patients (Table 3.4). Analysis 
was also carried out within the ARA III group with regard to the presence or absence of 
ARA II.
DNA was available from 16 of the ARA III positive patients (ARA I/III: 3, ARA 
I/II/III: 13, ARA III: 0) on which HLA-DRBl and DQB1 typing was carried out.
ARA III positive patients vs. normal controls
There were no significant differences in phenotype frequencies when ARA III positive 
patients were compared with controls (Table 3.4).
ARA III positive patients vs. ARA III negative patients
No significant differences in HLA-DRBl or DQB1* frequencies were observed 
between the ARA III positive and ARA III negative population (Table 3.4).
3.4.4: Analyses of reported HLA-DQB1 amino acid associations with SSc 
HLA-DQB 1 amino acid positions in ATA SSc patients 
HLA-DQB 1 :3 0 :Y
Of the HLA-DQB 1 alleles investigated in this study, 5 had a tyrosine residue at position 
30 (HLA-DQB 1*0601, 0602, 0301/4, 0302 and 0303). The possession of at least one 
HLA-DQB 1: 30:Y allele was significantly increased in ATA positive patients compared 
to ATA negative patients (25/28 ATA+ vs. 101/156 ATA-, p<0.025) and was not 
significantly increased in ATA positive patients compared to normal controls (p=0.13).
H LA-DQB171TRAELDT7
HLA-DQB 1 71TRAELDT77.was increased in ATA positive patients compared to controls 
although this observation did not reach significance (p<0.1). When ATA positive 
patients were compared to ATA negative patients the occurrence of HLA-DQB 1
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7iTraeldt77 was sign iflcantly increased in the ATA positive group (27/28 vs. 113/156,
p<0.025).
DQB1: 26: Y
The possession of at least one HLA-DQB 1: 26:Y positive allele was significantly 
increased in ATA positive patients compared to ATA negative patients (13/28 ATA+ 
vs. 44/156 ATA-, p=0.05). There were no significant differences in frequency observed 
at this locus when ATA positive patients were compared to controls.
HLA-DQB 1 amino acid positions in ARA III SSc patients 
HLA-DQB1:30:Y
There were no significant differences in the frequency of HLA-DQB 1: 30: Y in ARA III 
positive patients compared to controls or compared with ARA III negative patients.
H LA-DQB17ITRAELDT7
A reduction in the phenotype frequency of HLA-DQB 1:71TRAELDT77 was observed in ARA 
III positive patients compared to controls, although this failed to reach significance 
(10/16 ARA III+ vs. 210/250 controls, p=0.06). No significant differences were 
observed when the phenotype frequencies of alleles positive for this locus were 
compared between ARA III positive patients and ARA III negative patients.
D Q B 1:26: Y
No significant differences were observed in the occurrence of alleles possessing HLA: 
26 :Y in ARA III patients compared to controls or when compared to ARA III negative 
patients.
3.4.5: Heterogeneity of autoantibody groups
It is possible that the current autoantibody grouping may still represent a heterogeneous 
group, which could be further defined by HLA. Therefore consideration of HLA 
‘within’ an autoantibody group may identify subgroups. Identification of HLA
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associations within an autoantibody group (with regard to other autoantibodies present) 
would identity an autoantibody subgroup which may in turn be associated with a 
particular (more defined) clinical profile.
HLA phenotype frequencies were considered by comparisons within the ATA group 
with regard to ARA II (thus; AT AJ ARA 11+ vs. AT AlARA II negative) and the ARA III 
group also with regard to ARA II, (ARA I/II/III vs. ARA I/III).
Further division o f  the ATA group
Twenty-seven patients were ATA positive /ARA II negative of which 20 were HLA 
typed, and 10 patients were ATA/ARA II positive of which eight were HLA typed. 
Fishers exact test was used due to the small number of individuals and the resulting p 
values identified a non-significant reduction of HLA-DRBl*1101-1104 in the 
ATA/ARA II negative group (ATA/ARA II negative; 4/20 vs. 5/8 ATA/ARA II+, 
p=0.06) (Table 3.6).
Further division o f  the ARA I I I  group
Twenty patients were ARA I/II/III positive of which 13 were HLA typed. Six patients 
were ARA I/III positive, of which 3 were HLA typed and one patient was ARA III only 
positive and DNA was not available from this patient. Therefore, statistical analysis 
within this group was fairly meaningless due to the sample size. However, using Fishers 
exact test HLA-DRBl*0701-0702 appeared to be increased in the ARA I/III only group 
compared to ARA I/II/III group (ARA I/II/III 2/13 vs. 2/3 ARA I/III only positive 
patients, p=0.07) (Table 3.7).
3.4.6: Mutual exclusivity of autoantibodies
As mentioned earlier, specific autoantibodies are considered mutually exclusive, and 
give rise to recognised serological ‘autoantibody’ groups. An HLA association 
identified in one autoantibody group compared to a negative association in another 
would help to explain, and support, the observed mutual exclusivity of autoantibody 
groups.
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ATA positive patients vs. ARA III positive patients
The comparison of HLA-DRBl and DQB1 phenotype frequencies between ATA and 
ARA III positive patients did not show any significant differences. HLA DRB1*1501- 
1502 was raised in ATA positive patients compared to ARA III positive patients (2/16 
ARA III vs. 10/28 ATA, p = 0.09, (p=0.18 corrected)), and DRB 1*0301-0303 was 
reduced in ATA positive patients compared to ARA III positive patients (6/16 ARA III 
vs. 4/28 ATA, p = 0.07, (p corrected = 0.16)). The HLA-DQB1 alleles 0201 and 0602 
showed the greatest differences in frequencies when the groups were compared, 
however, these results also, did not reach significance (p=0.15 (pcorrected=0.20) and p=0.09 
(pcorrected—o^16) respectively). HLA-DRBl*1501-1502 and 0301-0303 are in linkage 
disequilibrium with HLA-DQB 1*0201 and 0602 respectively. These results may 
become significant if the groups were larger.
HLA-DQB1:30:Y
The possession of at least one allele possessing HLA-DQB 1: 30:Y was significantly 
increased in ATA positive patients when compared to ARA III positive patients (25/28 
ATA + vs. 9/16 ARA III +, pcorrected<0.05).
HLA-DQB1:71TRAELDT77
The possession of at least one allele possessing HLA-DQB 1:71TRAELDT77 was significantly 
increased in ATA positive patients when compared to ARA III positive patients (27/28 
ATA + vs. 10/16 ARA III +, pcorrec,ed =0.01).
HLA-DQB1:26:Y
When the frequency of the possession of at least one HLA-DQB1: 26:Y positive allele 
was compared between ATA positive patients and ARA III positive patients, no 
significant differences were observed.
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3.4.7: Investigation of T cell proliferative responses to recombinant topoisomerase 
I
Patients and methods
Four patients with SSc, three patients with SLE and five healthy individuals with no 
clinical evidence of an autoimmune disorder were included in the T cell proliferation 
study. For all the individuals, T cell proliferation assays were performed. Autoantibody 
analysis and MHC class II typing were also carried out.
T cell proliferative responses to recombinant topoisomerase I
A T cell response to anti-CD3 antibodies was observed in all subjects. The maximum 
stimulation was observed on day 4 over the range of concentrations used. The SI in all 
subjects was greater than 8 (data not shown).
A proliferative peripheral blood mononuclear cell (PBMC) response to topo I was 
observed in a dose dependent manner in both a patient with anti-topo I antibodies and in 
a normal control but not in a patient with anti-centromere antibodies (Figure 3.1). In 
further experiments a concentration of 20 pg/ml of topo I was used to measure the 
proliferative response of a range of anti-topo I antibody positive and negative patients 
and controls.
A proliferative PBMC response to soluble topo I was present in 9/16 individuals (Table 
3.8). A positive response was found in 3/3 ATA positive patients with SSc, one of five 
SSc patients without ATA, none of the three SLE patients and all of five normal 
controls. The greatest proliferative response (SI =10) was observed in a normal control. 
In all subjects with a SI greater than three the optimum response was seen on day 7.
HLA class II  type and T cell response to topoisomerase I
The above results suggest that a proliferative response to topo I may not be associated 
exclusively with disease status or the presence of anti-topo I antibodies. Therefore, it 
was considered whether there might be an association between the response, to topo I, 
and the presence of particular HLA-DRBl and HLA-DQB 1 alleles alone, or in 
combination.
73
The HLA-DRBl and HLA-DQB 1 status of the individuals studied for a proliferative 
response to topo I is shown in Table 3.8. An increase in HLA-DRB1*1101-1104 was 
observed in responders compared to non-responders (33% vs. 0%). Conversely, an 
increase in HLA-DR4 was observed in the non-responders (71.4% vs. 22% in 
responders). HLA-DQB 1*0302 was slightly increased in the responders compared to 
the non-responders (16.7% vs. 7.1%). There was an increase in the HLA-DQB1*0201 
allele in the non-responders (71.4% vs. 22% in responders). However, none of these 
differences were significant after correction for the number of variables tested.
As mentioned previously, Kuwana et al. found that all SSc patients and healthy controls 
with any of HLA-DRBl *1501,2 (DR15), DRB1*1101,3,4 (DR11), or DRB1*07 (DR7) 
alleles exhibited T cell responses to topo I recombinant fusion proteins (172). The 
results here are in general agreement in that seven of the nine responders had at least 
one of these HLA-DRBl alleles. However, two of seven non-responders also had HLA- 
DRBl *1501 alleles.
HLA-DQB 1 :30:Y and T cell response
It was investigated whether the ability to respond to topo I was determined by HLA- 
DQB1: 30:Y status. All but one responder had at least one HLA-DQB1: 30:Y allele. 
However, five of seven non-responders also had at least one HLA-DQB 1: 30: Y allele. 
Of interest, HLA-DQB 1: 30: Y homozygosity was present in five of nine responders and 
in nought of the seven non-responders (p < 0.03) (Table 3.8). One interpretation of this 
finding is that a protective factor on a non-HLA-DQBl: 30:Y allele may help prohibit a 
response to topo I.
There may be interaction between HLA-DRBl and HLA-DQB 1 alleles that determines 
the ability to mount a T cell response to topo-I as has been suggested by Kuwana et al. 
(85). We considered whether the possession of an HLA-DRBl allele or common 
sequence shared by HLA-DRBl alleles might confer susceptibility, and a non-HLA- 
DQBl: 30:Y allele may be protective. However, there was no combination of HLA- 
DRBl alleles with HLA-DQB 1: 30:Y alleles observed in our responders or non­
responders that supported this model (which may be due to the small numbers of 
individuals studied as some initial trends were apparent).
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The possibility that HLA-DQB 1: 30:Y alleles may confer susceptibility whereas HLA- 
DRBl alleles such as HLA DR4 may be protective was then considered. Furthermore, it 
was considered whether homozygosity for HLA-DQB 1: 30:Y alleles may override the 
‘protective’ effect of HLA-DR4. This model was applied to the present data and that of 
Kuwana et al. (172) (Table 3.9). The model could explain responsiveness to topo I in 
15/16 of the patients detailed here and in 49/55 patients described by Kuwana et al. 
(172).
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Table 3.1: Comparison o f HLA-DRBl and DQB1 phenotype frequencies o f  ATA 
positive patients with ATA negative patients and normal controls
Allele Controls ATA positive ATA negative
HLA DRB1* (n=250) (%) (n=28) (%) (n=153) (%)
0101-0103 (DR1) 53 (21.2) 10 (35.7) 37 (24.2)
1501-1502 (DR2) 65 (26.0) 10 (35.7) 28 (18.3)
1601-1602 (DR2) 6 (2.4) 0 (0.0) 2 (1.3)
Sum DR2 71 (28.4) 10 (35.7) 30 (19.6)
0301-0303 (DR3) 53 (21.2) 4*4 (14.3) 58*4 (37.9)
0401-0411 (DR4) 88 (35.2) 6 (21.4) 51 (33.3)
1101-1104 (DR5) 41*1 (16.4) '(32.1) 14*3 (9.2)
1201-1202 (DR5) 7 (2.8) 0 (0.0) 3 (2.0)
Sum DR5 46 (19.2) 9*2 (32.1) 17*2 (11.1)
1301-1305 (DR6) 54 (21.5) 4 (14.3) 20 (13.1)
1401-1410 (DR6) 5 (2.0) 0 (0.0) 5 (3.3)
0701-0702 (DR7) 63 (25.2) 5 (17.9) 30 (19.6)
0801-0805 (DR8) 13 (5.2) 1 (3.6) 10 (6.5)
0901 (DR9) 4 (1.6) 1 (3.6) 2 (1.3)
1001 (DR 10) 2 (0.8) 0 (0.0) 2 (1.3)
HLA DQB1 * (n=250) (n=28) (n=156)
0201 (DQ2) 88 (35.2) 8 (28.6) 75 (48.1)
0401 (DQ4) 0 (0.0) 0 (0.0) 0 (0.0)
0402 (DQ4) 10 (4.0) 0 (0.0) 8 (5.1)
0501 (DQ5) 52 (20.8) 9 (32.1) 32 (20.5)
0502 (DQ5) 9 (3.6) 0 (0.0) 1 (0.6)
0503 (DQ5) 5 (2.0) 1 (3.6) 4 (2.6)
0601 (DQ6) 3 (1.2) 0 (0.0) 2 (1.3)
0602 (DQ6) 60 (24.0) 10*5 (35.7) 25*s (16.0)
0603/8 (DQ6) 27 (10.8) 2 (7.1) 11 (7.1)
0604 (DQ6) 28 (11.2) 2 (7.1) 10 (6.4)
0301 (DQ7) 91 (36.4) 13*6 (46.4) 42*6 (26.9)
0302 (DQ7) 51 (20.4) 5 (17.9) 42 (26.9)
0303 (DQ7) 31 (12.4) 4 (14.3) 12 (7.7)
Comparisons of HLA-DRBl* and HLA-DQB 1* phenotype frequencies in ATA 
positive SSc patients compared to ATA negative patients and normal controls, p values 
with OR(CI) are: *'<0.05: 0.4(0.1-0.9), *2<0.005: 3.7(1.4-9.6), *3<0.001:4.7(1.7-12.3), 
*4<0.01: 0.27(0.09-0.82), *5<0.02: 2.9(1.2-7.0), *6<0.04: 2.3(1.0-5.4) when compared.
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Table 3.2: Relative predispositional effects analysis o f HLA-DRBl alleles in ATA
positive SSc patients
HLA-DRBl* allele
All alleles (n =56) 
Observed Expected X2
0101-0103 10 6.3 2.2
1501-1502 11 8.2 1
1601-1602 0 0.7 0.7
0301-0303 5 6.7 0.4
0401-0411 7 10.6 1.2
1101-1104 11 4.8 8
1201-1202 0 0.8 0.8
1301-1305 5 6.4 0.3
1401-1410 0 0.6 0.6
0701-0702 5 8.4 1.4
0801-0805 1 1.7 0.3
0901 1 0.5 0.5
1001 0 0.3 0.3
X2= 17.7 
Degrees of freedom = 12 
P = 0.1 (not significant!
The table shows the predispositional effects analysis for HLA-DRBl alleles in ATA 
positive SSc patients. Using this analysis, no particular allele could be identified as 
having a significantly greater effect in this group of patients than the other alleles.
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Table 3.3: Relative predispositional effects analysis o f HLA-DQB 1 alleles in ATA
positive SSc patients
HLA-DQB 1* allele
All alleles (n =56) 
Observed Expected X2
0201 7 11.5 1.8
0402 0 1.3 1.3
0501 9 6.2 1.3
0502 0 1.0 1.0
0503 1 0.6 0.3
0601 0 0.3 0.3
0602 12 7.6 2.5
0603/8 2 3.2 0.45
0604 2 3.2 0.45
0301 14 11.4 0.6
0302 5 6.0 0.2
0303 4 3.5 0.07
X2= 10.27 
Degrees of freedom =11 
P = 0.5 (not significant^
The table shows the predispositional effects analysis for HLA-DQB 1 alleles in ATA 
positive SSc patients. Using this analysis, no particular allele could be identified as 
having a significantly greater effect in this group of patients than the other alleles.
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Table 3.4: HLA-DRB1 and DQB1 allele phenotype frequencies ofARA III  positive
and negative patients and normal controls
Allele Controls ARA III positive ARA III negative
HLA DRB1* (n=250) (%) (n=16) (%) (n= 165) (%>
0101-0103 (DRl) 53 (21.2) 6 (37.5) 49 (29.7)
1501-1502 (DR2) 65 (26.0) 2 (12.5) 36 (21.8)
1601-1602 (DR2) 6 (2.4) 0 (0.0) 2 (1.2)
Sum DR2 71 (28.4) 2 (12.5) 38 (23.0)
0301-0303 (DR3) 53 (21.2) 6 (37.5) 60 (36.4)
0401-0411 (DR4) 88 (35.2) 5 (31.3) 59 (35.8)
1101-1104 (DR5) 41 (16.4) 2 (12.5) 16 (9.7)
1201-1202 (DR5) 7 (2.8) 0 (0.0) 3 (1.8)
Sum DR5 46 (19.2) 2 (12.5) 19 (11.5)
1301-1305 (DR6) 54 (21.5) 1 (6.3) 25 (15.2)
1401-1410 (DR6) 5 (2.0) 1 (6.25) 1 (0.6)
0701-0702 (DR7) 63 (25.2) 2 (12.5) 31 (18.8)
0801-0805 (DR8) 13 (5.2) 1 (6.3) 9 (5.5)
0901 (DR9) 4 (1.6) 0 (0.0) 3 (1.8)
1001 (DR 10) 2 (0.8) 0 (0.0) 2 (1.2)
HLA DOB1 * (n=250) (n=16) (n=169)
0201 (DQ2) 88 (35.2) 8 (50.0) 76 (45.0)
0401 (DQ4) 0 (0.0) 0 (0.0) 0 (0.0)
0402 (DQ4) 10 (4.0) 1 (3.3) 7 (4.1)
0501 (DQ5) 52 (20.8) 4 (25.0) 55 (32.5)
0502 (DQ5) 9 (3.6) 0 (0.0) 1 (0.6)
0503 (DQ5) 5 (2.0) 1 (6.25) 4 (2.4)
0601 (DQ6) 3 (1.2) 0 (0.0) 1 (0.6)
0602 (DQ6) 60 (24.0) 2 (12.5) 33 (19.5)
0603/8 (DQ6) 27 (10.8) 1 (6.25) 12 (7.1)
0604 (DQ6) 28 (11.2) 0 (0.0) 12 (7.1)
0301 (DQ7) 91 (36.4) 4 (25.0) 51 (30.2)
0302 (DQ7) 51 (20.4) 4 (25.0) 43 (25.4)
0303 (D07) 31 (*2.4) 1 (6.3) 14 (8.3)
Comparisons of allele phenotype frequencies of ARA III positive SSc patients with 
normal controls, and with ARA III negative patients showed no significant differences.
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Table 3.5: Comparison o f HLA-DRB1 and DQB1 phenotype frequencies o f ARA III
positive and A T  A positive patients
Allele ARA III positive ATA positive
HLA DRB1* (n=16) (%) (n=28) (%)
0101-0103 (DRl) 6 (37.5) 10 (35.7)
1501-1502 (DR2) 2 (12.5) 10 (35.7)
1601-1602 (DR2) 0 (0.0) 0 (0.0)
Sum DR2 2 (12.5) 10 (35.7)
0301-0303 (DR3) 6 (37.5) 4 (14.3)
0401-0411 (DR4) 5 (31.3) 6 (21.4)
1101-1104 (DR5) 2 (12.5) 9 (32.1)
1201-1202 (DR5) 0 (0.0) 0 (0.0)
Sum DR5 2 (12.5) 9 (32.1)
1301-1305 (DR6) 1 (6.3) 4 (14.3)
1401-1410 (DR6) 1 (6.3) 0 (0.0)
0701-0702 (DR7) 2 (12.5) 5 (17.9)
0801-0805 (DR8) 1 (6.3) 1 (3.6)
0901 (DR9) 0 (0.0) 1 (3.6)
1001 (DR 10) 0 (0.0) 0 (0.0)
HLA DQB1* (n=\6) (n=28)
0201 (DQ2) 8 (50.0) 8 (28.6)
0401 (DQ4) 0 (0.0) 0 (0.0)
0402 (DQ4) 1 (3.3) 0 (0.0)
0501 (DQ5) 4 (25.0) 9 (32.1)
0502 (DQ5) 0 (0.0) 0 (0.0)
0503 (DQ5) 1 (6.3) 1 (3.6)
0601 (DQ6) 0 (0.0) 0 (0.0)
0602 (DQ6) 2 (12.5) 10 (35.7)
0603/8 (DQ6) 1 (6.25) 2 (7.1)
0604 (DQ6) 0 (0.0) 2 (7.1)
0301 (DQ7) 4 (25.0) 13 (46.4)
0302 (DQ7) 4 (25.0) 5 (17.9)
0303 (DQ7) 1 (6.3) 4 (14.3)
The comparison of HLA-DRB1* and DQB1 phenotype frequencies between ATA and 
ARA III positive patients showed no significant differences. However, an increase in 
HLA-DRB1 *1501-1502, and a reduction in DRB1 *0301-0303, was observed in ATA 
positive patients. Variation in HLA-DQB1 phenotype frequencies were also observed in 
the HLA-DQB1 *0201 and *0602 alleles.
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Table 3.6: Comparison o f HLA-DRB1 and DQB1 phenotype frequencies within the
ATA positive group
Allele ATA +/- other Aab. ATA + ARA II
HLA DRB1* (n=20) (%) (n=8) (%)
0101-0103 (DR1) 8 (40.0) 2 (25.0)
1501-1502 (DR2) 9 (45.0) 1 (12.5)
1601-1602 (DR2) 0 (0.0) 0 (0.0)
Sum DR2 9 (45.0) 1 (12.5)
0301-0303 (DR3) 1 (5.0) 1 (12.5)
0401-0411 (DR4) 5 (25.0) 1 (12.5)
1101-1104 (DR5) 4 (20.0) 5 (62.5)
1201-1202 (DR5) 0 (0.0) 0 (0.0)
Sum DR5 4 (20.0) 5 (62.5)
1301-1305 (DR6) 2 (10.0) 2 (25.0)
1401-1410 (DR6) 0 (0.0) 0 (0.0)
0701-0702 (DR7) 3 (15.0) 2 (25.0)
0801-0805 (DR8) 1 (5.0) 0 (0.0)
0901 (DR9) 0 (0.0) 1 (12.5)
1001 (DR 10) 0 (0.0) 0 (0.0)
HLA DQB1* (n=20) (n=8)
0201 (DQ2) 5 (25.0) 3 (37.5)
0401 (DQ4) 0 (0.0) 0 (0.0)
0402 (DQ4) 0 (0.0) 0 (0.0)
0501 (DQ5) 7 (35.0) 2 (25.0)
0502 (DQ5) 0 (0.0) 0 (0.0)
0503 (DQ5) 0 (0.0) 1 (12.5)
0601 (DQ6) 0 (0.0) 0 (0.0)
0602 (DQ6) 9 (45.0) 1 (12.5)
0603/8 (DQ6) 1 (5.0) 1 (12.5)
0604 (DQ6) 1 (5.0) 1 (12.5)
0301 (DQ7) 8 (40.0) 5 (62.5)
0302 (DQ7) 3 (15.0) 1 (12.5)
0303 (DQ7) 2 (10.0) 2 (25-0) ....
No significant differences were observed when phenotype frequencies of ATA patients 
also possessing ARA II were compared with those patients who were ATA positive but 
ARA II negative.
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Table 3.7: Comparison o f HLA-DRB1 and DQB1 phenotype frequencies within the
ARA III group with regard to ARA II
Allele ARA I/II/III ARA I/III
HLA DRB1* (n=13) (%) (n=3) (%)
0101-0103 (DR1) 5 (38.5) 1 (33.3)
1501-1502 (DR2) 1 (7.7) 1 (33.3)
1601-1602 (DR2) 0 (0.0) 0 (0.0)
Sum DR2 1 (7.7) 0 (0.0)
0301-0303 (DR3) 6 (46.2) 0 (0.0)
0401-0411 (DR4) 4 (30.8) 1 (33.3)
1101-1104 (DR5) 0 (0.0) 0 (0.0)
1201-1202 (DR5) 0 (0.0) 0 (0.0)
Sum DR5 0 (0.0) 0 (0.0)
1301-1305 (DR6) 1 (7.7) 0 (0.0)
1401-1410 (DR6) 1 (7.7) 0 (0.0)
0701-0702 (DR7) 2 (15.4) 2 (66.7)
0801-0805 (DR8) 1 (7.7) 0 (0.0)
0901 (DR9) 0 (0.0) 0 (0.0)
1001 (DR10) 0 (0.0) 0 (0.0)
HLA DQB1* (n=13) (n=3)
0201 (DQ2) 5 (38.5) 2 (66.7)
0401 (DQ4) 0 (0.0) 0 (0.0)
0402 (DQ4) 1 (7.7) 0 (0.0)
0501 (DQ5) 3 (23.1) 1 (33.3)
0502 (DQ5) 0 (0.0) 0 (0.0)
0503 (DQ5) 1 (7.7) 0 (0.0)
0601 (DQ6) 0 (0.0) 0 (0.0)
0602 (DQ6) 1 (7.7) 1 (33.3)
0603/8 (DQ6) 1 (7.7) 0 (0.0)
0604 (DQ6) 0 (0.0) 0 (0.0)
0301 (DQ7) 4 (30.8) 0 (0.0)
0302 (DQ7) 3 (23.1) 1 (33.3)
0303 ffiQT) . 0 (0.0) 1 (33.3)
Numbers of individuals for the comparisons made here were too small for analysis to be 
conclusive (p values for Fishers exact test showed no significant differences). However, 
an increase in HLA-DRB 1*0701-0702 in the ARA I/III group can be observed.
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Figure 3.1: Effect o f recombinant Topoisomerase I  on the 


















■  A TA  positive patient
□  Healthy control
□  A C A  positive control
1.25
Topoisomerase-1 concentration (pg/ml)
Dose-response curve o f mononuclear cells to recombinant topo I at day seven in an anti- 
topo-I antibody positive SSc patient (■), an anticentomere antibody positive SSc patient 
(□) and a healthy control ( g i ) .  Bars represent range of recordings performed in triplicate. 
Anti-CD3 responses at day four were greater than eight SI in mononuclear cells from all 
subjects.
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Table 3.8: T-cellproliferation responses to topoisomerase I  in patients with 






















0302, 0301 Yes (H)
3 Normal
control

















6 SSc ACA 3.5 1501, 1501 0602, 0602 Yes (H)
7 SSc ATA 5.7 1501,0301 0602, 0201 Yes
8 SSc ATA 3 0901,
1101-1104
0301,0303 Yes (H)









2 1501,0301 0201,0201 No
11 SLE Anti-UIRNP 2 1501,0404 0602, 0201 Yes
12 SLE Neg 1.1 0301,
0401-0411
0201, 0302 Yes
13 SLE Anti-UIRNP 1.6 0401,
1201-1202
0201,0301 Yes
14 SSc ACA 1.9 0101,0101 0501,0201 No
15 SSc ACA 2.8 1302, 0401 0604, 0301 Yes
16 SSc ACA 2.1 0401-0411,
1301-1302
0603/8,0301 Yes
H = homozygous for HLA-DQB1: Y: 30.
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Table 3.9: Distribution o f responders and non-responders with regard to HLA- 










(n -  15)
DQB1: 30:Y positive (+/+ or 
+/-) and DR4 negative (-/-)
6 37 0 3
DQB1: 30:Y positive (+/+) and 
DR4 positive (+/+ or +/-)
2 2 0 2
DQB1: 30:Y positive (+/-) and 
DR4 positive (+/+ or +/-)
0 2 5 6
DQB1: 30:Y negative (-/-) and 
DR4 negative (-/-)
1 1 2 4
The distribution o f individuals according to the proposed model where: The presence of 
an HLA-DQB1: 30:Y allele is necessary for the production o f anti-topo I. The response 
is suppressed in the presence o f HLA-DR4 alleles except where there is homozygosity 
for DQB1: 30:Y antibodies in which case the suppressive effect o f DR4 alleles is 
overcome. The highlighted quadrants show the individuals falling in the appropriate 
categories in relationship to their T-cell response/non-response and HLA type. In total 
87% (64/73) individuals from the current study and the data reported from a Japanese 
population (172) fall into the appropriate categories defined by this model. The presence 
o f the expected allele combination favouring a response was present in 47 o f 51 
responders and in 5 o f 22 non-responders (p < 0.001).
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3.5: DISCUSSION
SSc is characterised by a highly specific autoantibody response that is directed to 
selective intracellular antigens. Furthermore, there are three main serologically defined 
subgroups of SSc that are mutually exclusive and distinguish clinical subsets (64). 
Therefore, it may be expected that the rather weak genetic associations reported for 
scleroderma in general become stronger if autoantibody-defined clinical subgroups are 
considered. One of the major autoantibody responses in SSc is to topoisomerase I (topo 
I). An autoantibody response to topo I defines a group of scleroderma patients with a 
high prevalence of lung disease (63;64,175;176). Of interest, ATA are also found in 
high frequency in silica-associated scleroderma where lung disease is extremely 
common (135). Genetically determined factors including immune response genes may 
be important in influencing disease susceptibility to an environmental trigger as has 
been observed with a vinyl chloride induced scleroderma-like syndrome (144). The 
study of an autoantibody-defined subgroup may define a common genetic background 
regardless of whether any causative environmental agent has been identified or not.
Previous studies have shown associations of MHC class II alleles and the presence of 
ATA (63;64;80;84;85;171;177). The most commonly associated allele with ATA is 
HLA-DR5 originally reported in association with the diffuse form of the disease (63) 
and found in 70% of ATA positive patients studied by Genth et al. (80) and in 82% of 
anti-topo I patients studied by Morel et al. (171).
Significant associations of HLA-DRB1 and DQB1 alleles with ATA have been 
identified in this study. The results confirm the commonly reported association of HLA- 
DR5. More recent studies have reported an increase in the HLA-DR11 subtype of HLA- 
DR5 and in particular an association with the HLA-DRB1*1104 allele (64; 171). These 
results also support an association with HLA-DRB 1*1101-1104 alleles rather than with 
the HLA-DR12 subtype (DRB1* 1201 -1202). No significant association with HLA-DR2 
was observed in the ATA group, as has been previously reported (166; 177). Also, the 
reduction in HLA-DR4 that was noted in the study by Morel et al (171) was not 
observed in this study. A negative association of HLA-DRB 1*0301-0303 was observed 
in ATA positive patients compared to ATA negative patients, (p<0.01), an association 
which has not been reported before.
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There have been more controversial reports of associations between HLA-DQB1 alleles 
and ATA. The previously reported association of HLA-DQB1*0301 with ATA 
(31 ;84; 171) was confirmed. There was also a significant association identified with 
HLA-DQB 1*0602 in ATA positive individuals. However, these results could not 
confirm the previously reported negative association of HLA-DQB 1*05 in ATA 
positive patients compared to ATA negative patients reported by Fanning et al. (64).
As mentioned in the introduction to this chapter, there is only one report that includes 
HLA associations with ARA. There were no striking HLA associations identified in the 
ARA III group, which is in agreement with the report by Fanning et a l (64).
At the amino acid level, Reveille et al. reported that all ATA positive patients had an 
HLA-DQB 1 allele encoding for the amino acid tyrosine at position 30 at the second 
hypervariable domain and an increase in the TRAELDT sequence at positions 71-77 of 
the third hypervariable domain. The association between HLA-DQB 1: 30: Y alleles and 
ATA has been supported (178), however, more recent studies seem to confirm the 
association with the HLA-DQB 1: 71TRAELDT77 sequence but not with the DQB1: 30:Y 
allele (64;171). The results here indicate significant increases in HLA-DQB1: 30:Y, 
alleles, and, in agreement with other studies (64;84;171), there was an increase in the 
HLA-DQB 1: 71TRAELDT77 sequence. The increase in HLA: DQB1: 26:Y alleles, as 
reported in a Japanese population Kuwana ’93 (85), was also found in this study. None 
of these loci were significantly associated with the ARA III group.
With regard to the investigation of existing autoantibody group heterogeneity, no HLA 
associations were identified when ATA and ARA III subgroups were considered. 
Comparisons made in this study could not confirm findings reported by Fanning et al. 
regarding a significant increase in HLA-DQB 1*0201 in ARA I/II/III patients compared 
to ARA I/III positive patients (64)
A modest difference in HLA background was identified in the mutually exclusive 
autoantibody groups considered here. HLA-DQB 1: 30:Y was significantly increased in 
ATA positive patients compared to ARA III patients (p<0.05). No other significant 
differences were observed in allele frequencies or in the frequencies of the amino acid 
loci considered. Thus, in this study, mutual exclusivity of these autoantibody groups
87
could not be explained by HLA-DRB 1 or DQB1 background. That is not to say that the 
observed mutual exclusivity is not determined by HLA background; associations with 
alternative loci, such as DPB1, or a combination of loci need to be examined in order to 
fully assess HLA contribution to autoantibody mutual exclusivity.
Recent studies have been able to demonstrate T cell responses to some of the 
autoantigens commonly targeted by patients with related autoimmune rheumatic 
diseases. For instance T cell proliferative responses to small ribonucleoproteins (179) 
and nucleosomes have been identified (180). Of interest these responses were present 
not only in patients with the corresponding autoantibody but were present in healthy 
individuals of a certain MHC class II background (179). Of direct relevance to the 
current study Kuwana et al. reported T cell responses to recombinant forms of topo I in 
patients with anti-topo I antibodies and in some healthy controls (85). In the latter study 
DRBl*1501/2, DRB1*1101,03,04 and/or DRB1*07 alleles were common to all 
responders regardless of disease. Kuwana’s group went on to show that HLA-DR- 
restricted direct contact between CD4 + T cells and B cells was important for anti-topo I 
antibody synthesis in an in vitro culture system (46).
In the present study proliferative mononuclear cell responses to topo I were not 
confined to those patients who had anti-topo I antibodies present in the serum but were 
also demonstrable in normal individuals which is similar to the findings of Kuwana et 
al (172). Unlike Kuwana et a l (172) two of the eight responders did not have HLA- 
DR15, DR11 or DR7 related alleles. However, there was a non-significant increase in 
HLA-DRB 1* 1101-4 alleles in responders that together with the results from the 
autoantibody association studies suggests that at least HLA-DR11 related alleles may 
facilitate a T cell-driven ATA response. Also noteworthy was a significant increase in 
homozygosity for HLA-DQB 1: 30: Y alleles in responders and a trend for a reduction in 
HLA-DR4 in non-responders. Intriguingly, a model in which HLA-DQB 1: 30:Y alleles 
facilitate a topo I response and HLA-DR4 suppress such a response could account for 
88% of patients reported here and in the report from Kuwana et a l (172). This reverse 
situation in which HLA-DR alleles protect from HLA-DQ mediated effects has some 
support from studies of collagen-induced arthritis in HLA-DQ8 transgenic mice 
(181 ;182).
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Our finding of T cells in healthy individuals proliferating to topo I is consistent with 
other reports of T cell responses to intracellular autoantigens reported by Kuwana et al. 
(172) as mentioned above. The presence of such autoreactive T cells suggests either a 
breakdown of T cell tolerance to topo I in certain individuals or more likely a failure to 
establish tolerance during the process of thymic maturation. Topo I is a highly 
conserved DNA binding protein that is not normally secreted or expressed on the cell 
surface. However it has been shown that certain intranuclear particles may be 
translocated to the cell surface during the process of apoptosis (183). In addition, topo I 
appears to be susceptible to cleavage by reactive oxygen species in a metal cation- 
dependent manner (43). Such modification, perhaps driven by the generation of reactive 
oxygen species as a result of ischaemia reperfusion injury, may result in uniquely 
expressed cryptic epitopes becoming exposed to the immune system initiating a T cell 
driven immune response. The context in which apoptosis occurs may determine the type 
of autoantigen fragment generated (154), and set the necessary conditions for T and B 
cell collaboration leading to autoantibody generation.
The consistent finding of an association between anti-topo I antibody responses and 
HLA-DR5 associated alleles is supported in the present study. HLA associations have 
been identified in patients with regard to their autoantibody status and these associations 
were stronger when particular amino acid loci were considered. However, the relative 
importance of HLA-DR and HLA-DQ gene complementation remains unclear. The 
effect of environmental triggers associated with SSc on autoantigen processing and 
fragmentation is an area worth further study considering the close associations between 




ETHNIC VARIATION IN THE SYSTEMIC SCLEROSIS 
AUTOIMMUNE RESPONSE
4.1: INTRODUCTION
Autoantibody frequency, mutual exclusivity and co-existence in SSc 
Autoantibodies are detected in more than 90% of SSc sera (24). The majority of these 
sera contain autoantibody specificities to one of the three main serologic autoantibody 
groups: ACA, ATA or ARA III. Typically, ACA is reported to occur in some 28% of 
SSc patients (45;63;184;185), and ATA and ARA III are detected in approximately 25% 
(45;63). These three classes of autoantibody demonstrate disease specificity and as 
discussed in chapter three, are generally considered to be mutually exclusive (64;85).
There are also other, more minor, serologic groups occurring in SSc sera, which do not 
demonstrate such mutual exclusivity. These include anti-Pm-Scl antibodies, which 
occur in around four percent of patients, anti-UlRNP, detected in approximately six 
percent of patients (45; 185) and anti-Ro antibodies occurring in up to nine percent of 
patients (45). Anti-Ro and ATA are often seen to accompany one another in the same 
serum (45). Anti-U3RNP antibodies have been reported to occur in approximately 
seven percent of SSc patients (45; 186).
Other autoantibody specificities, including ARA II, ARA I and anti-La are not disease 
specific and frequently (and characteristically) accompany each of the three main SSc- 
associated autoantibodies. Overall, ARA III, ATA, ACA, anti-Pm-Scl and anti-U3RNP 
are considered mutually exclusive, with rare exceptions. Anti-Ro and anti-UlRNP are 
reported to not normally occur with anti-U3RNP, ARA III or ACA (For review see 
Harvey and McHugh ’99 (45))
Autoantibody subgrouping ofpatients fo r  the current study
For the purpose of the study in this chapter, patients were grouped according to the 
autoantibody(ies) for which they tested positive. Because many patient sera contained 
multiple autoantibody specificities, it was necessary to stratify sera according to 
autoantibody status to enable constructive analysis to be carried out. Specificities 
comprising one of the major autoantibody groups (ACA, ATA, ARA III) were given 
first ranking followed by anti-U3RNP, anti-Ro, anti-Pm-Scl, anti-Jo-1, anti-UlRNP, 
anti-La, and sera lacking detectable autoantibody. Patients were grouped according to 
first level of stratification.
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Racial differences in the frequencies o f scleroderma related autoantibodies and 
disease subtype
As mentioned, several SSc-ANAs are highly disease specific and are associated with 
clinical subgroups of disease. It has been demonstrated that ethnic variability can 
influence the type of SSc that a given patient will develop (81), and thus, 
unsurprisingly, the frequencies of autoantibodies are reported to vary with regard to 
racial differences (24). The most striking variations are seen in the ACA and anti- 
U3RNP serological groups. ACAs are associated with the limited form of the disease 
and are considerably decreased in Blacks compared to Caucasian SSc patients (23; 187). 
Conversely, anti-U3RNP autoantibodies, a minor serologic group associated with severe 
disease, are detected more frequently in Black than in Caucasian SSc patients 
(24; 186; 187).
HLA-SSc associations and race
Ethnic variation in the study population is one factor, which may contribute to the lack 
of consensus of HLA alleles associated with scleroderma. HLA frequencies associated 
with SSc do vary in different races. For Caucasoids, there is general consensus for DR1, 
DR3 and DR5 association with SSc (26). In contrast, for the Japanese, HLA DR2 and 
DR4 are most frequently reported (169). However, when autoantibody suubgroups are 
considered HLA associations become more defined. ATA is often reported in 
association with DR5 (81), and ACA with DR1 (86). Of consideration in the present 
study is whether the differences in HLA frequencies can explain the variance in ANA 
incidence and disease subtype, in alternative races.
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4.2: CHAPTER AIMS
The objectives of the work described in this chapter were; to identify any similarities 
and differences of SSc disease profile in two races, and to identify any HLA 
characteristics that are associated with the above observations, which may further 
support the role of HLA in SSc. The investigation was carried out by means of the aims 
set out below:
I. Analysis and comparisons of autoantibody specificities of British Caucasian and
South African Black SSc patient populations.
II. Analysis and comparisons of specific clinical manifestations in the two races
and subsequent consideration of autoantibody and HLA-DRB 1 and/or DQB1 
association.
III. To identify any associations of HLA-DRB 1 and/or DQB1 alleles with
autoantibody subgroup in South African Black SSc patients and a comparison
with a British Caucasian SSc population.
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4.3: MATERIALS AND METHODS
Patients
Forty-five South African Blacks (SAB) and 229 British Caucasians (BC) fulfilled the 
established criteria for SSc (156) and were included in the study detailed in this chapter.
Detection o f  autoantibodies
The presence of serum autoantibody was investigated in all of the patients. Patient sera 
were screened for anti-cytoplasmic antibody, ANA and ANoA reactivities by IF 
(method 2.4.2). ANA and ANoA positive sera were further examined by S- 
immunoprecipitation (method 2.4.4) to identify autoantibody specificities. Autoantibody 
patterns precipitating only a single band, and when autoantibody specificities 
precipitating multiple bands were observed but without a known positive control sera on 
the same gel, the results were confirmed by Ouchterlony double immunodiffusion 
(method 2.4.3) (with the exception of ARA). For each method, comparisons were made 
with prototype reference sera.
HLA-DRB 1 and HLA-DQB1 typing
HLA-DRB 1 and HLA-DQB 1 alleles were identified by PCR-SSP genetic typing 
according to method 2.2.2. Details regarding the patients from whom DNA was 
available will be included in the relevant sections.
Statistical analysis.
Statistical analyses were performed according to method 2.5
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4.4: RESULTS
4.4.1: Analysis and comparisons of autoantibody status of British Caucasian and 
South African Black SSc patient populations
Prevalence o f autoantibodies in the South African Black (SAB) and British 
Caucasian (BC) SSc patient populations
Autoantibody status was investigated in 45 SAB and 229 BC SSc patients. The number 
of patients testing positive for each autoantibody is represented in the histogram (Figure 
4.1).
Eleven autoantibody specificities were identified in the SAB patients, however, 22% of 
patients precipitated unidentified autoantibody/ies/ only. Anti-Ro was the most 
frequently detected identified autoantibody (22%). Seven percent of patients lacked 
detectable serological autoantibody. In the BC SSc patient population the same eleven 
autoantibody specificities and anti-Jo-1 were identified. Only eight percent of patients 
possessed an autoantibody that was not identified. The most frequently detected 
autoantibody in this population was ACA. Eight percent of patients lacked any 
detectable autoantibody.
When the two populations were compared significant differences in the frequency of 
autoantibodies were apparent. The greatest difference was identified in the frequency of 
anti-U3RNP. The presence of this autoantibody was significantly raised in SAB 
compared to BC SSc patients (<1% BC vs. 17.8% SAB, p<0.0083). Figure 4.2 is an 
example of the immunofluorescence pattern of this autoantibody seen in the SAB 
patients. ACA autoantibody frequency also showed significant variation between the 
two populations. This autoantibody was detected in 39% of BC patients compared to 
nine percent of SAB patients (pcorrected=0.0002). Figure 4.3 shows the classic 
immunofluorescence pattern of ACA positive sera, and is an example from a BC 
patient. Other significant differences were identified in the anti-UlRNP group, which 
was increased in SAB compared to BC (18% vs. 7% respectively, pcorrected <0.05), ARA 
II showed an increase in BC compared SAB (15% vs. 2.5%  respectively, pcorrected 
<0.05), and anti-Ro, which was increased in SAB compared to BC (22% vs. 1% 
respectively, p<0.05).
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Patient autoantibody specificity and mutual exclusivity in BC and SAB populations
Patients were classed into serological groups according to their autoantibody profile, as 
explained in the introduction to this chapter, and details are shown in table 4.1. Figures 
4.4 and 4.5 show the numbers of patients in each serological group for BC and SAB 
patient populations, respectively. Sixty seven percent of Caucasian patients were 
included in the three ‘major serological groups’ compared with only 26.5% of SAB 
patients (pO.OOOl). Details of the remaining serological groups are contained in table 
4.1. For Caucasians, the largest serological group was ACA (39%). (This was expected 
as this autoantibody was most prevalent in this population and comprises one of the 
major serological groups). Thirty-seven patients (17%) were ATA positive, and five of 
these patients were also anti-Ro positive. Ten patients were ATA and ARA II positive 
(which included one of the patients who was anti-Ro positive). Twenty seven (12%) of 
patients were ARA III positive. One of the patients in this group was also anti-Ro 
positive. In the SAB population the largest serological group was the anti-U3RNP group 
comprising 8 (18%) patients. The second largest groups were anti-Ro and ATA, each 
containing 6 (13%) patients.
A variety of combinations of autoantibody specificities were identified in each 
population. However, it can be seen that, (with the exception of one patient), the 
observed mutual exclusivity of autoantibodies is in concordance with reports, in both 
populations. ACA, ATA and ARA III do not occur together in either the BC or SAB 
patients. ARA III, ATA, ACA, anti-Pm-Scl and anti-U3RNP are also all mutually 
exclusive in the individuals studied here. ARA III and ACA are not seen to occur with 
anti-Ro or anti-U3RNP, however, unusually anti-Ro and anti-U3RNP were both 
identified in the serum from one patient.
Unidentified autoantibodies
Both populations included patients whose sera contained autoantibodies, which were 
not identified, and a significantly greater number were detected in the SAB patient 
group (BC 8%, SAB 22%, p=0.008). Unidentified immunoprecipitation patterns varied 
in the BC population, but in the SAB patients some showed similar patterns to each 
other, suggesting the same autoantigen(s).
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4.4.2: Analysis and comparisons of specific clinical manifestations in a British 
Caucasian and a Black South African population, and subsequent consideration of 
autoantibody and HLA association
Although it would be appropriate to consider a range of clinical manifestations in this 
study, sufficient clinical data were only available from both populations for disease 
subtype and pulmonary fibrosis. These two manifestations will be considered presently.
Disease Subtype in the two races
In the BC cohort 78% (170/217) patients were defined as having lcSSc, thus the 
remainder, 22%, had dcSSc. In the SAB population 36% (15/42) patients were defined 
with lcSSc and the remaining 64% dcSSc. These results show a significant increase in 
dcSSc in SAB compared to BC (pO.OOOl).
Serological autoantibody association with disease subtype
In BC SSc patients ACA was significantly associated with the lcSSc (pO.OOOl). Ninety 
eight percent (83/85) of individuals who were ACA positive had limited disease. In 
contrast, 77% (20/26) of BC patients in the ARA III group had dcSSc, and there was 
also a significant association of this autoantibody with diffuse disease (pO.OOOl, 
p0 .0005 B.Co,T). The distribution of patients in the ATA group was fairly even with 
respect to disease subtype, 49% (16/33) dcSSc, 51% lcSSc, however, overall dcSSc was 
associated with ATA positivity (pO.OOOl). All patients in the anti-PmScl group (n=8) 
and the anti-UlRNP group (n=12), and 89% (8/9) patients in the anti-Ro group had 
lcSSc, although these autoantibody groups were not significantly associated with either 
disease subtype. The majority of patients with unidentified autoantibody(ies) and 
autoantibody negative patients had lcSSc (77% and 71% respectively).
In SAB, disease subtype was not significantly associated with any of the autoantibody 
groups.
Serological autoantibody association with pulmonary fibrosis 
Clinical information regarding pulmonary fibrosis (PF) was available from 38/45 of the 
SAB patients, 26% (10/38) of whom had PF. Twenty eight percent did not show any 
clinical signs of interstitial lung disease. Autoantibody specificities of the patients from
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whom details regarding PF were not available included, 1 patient with unidentified 
autoantibody specificity, 4 patients in the anti-UlRNP serological group, and 2 patients 
in the anti-U3RNP serological group. Fifty percent of SAB patients with PF were 
classed in the unidentified-autoantibody serological group and PF was significantly 
associated with this serological group (p=0.03 Fishers exact test). However significance 
was lost when Bonferroni correction was applied (p=0.12). Of interest, 3/4 patients 
positive for ATA only, (i.e. did not possess any other, accompanying, 
autoantibody(ies)), had PF. The remaining two patients with PF included one anti- 
U1RNP and one anti-U3RNP positive SSc patient.
Clinical information regarding pulmonary fibrosis (PF) was available on 97/100 (97%) 
BC patients. (The three BC patients for whom PF was not defined were ATA positive). 
Thirty five point five percent (34) BC patients had PF. The ACA autoantibody group 
showed a negative association with PF (pO.OOOl), and in contrast, ATA autoantibody 
was significantly associated with PF (p=0.02). No further significant associations were 
identified in any of the other autoantibody groups in the BC SSc population.
4.4.3: HLA associations with SSc, and within SSc autoantibody subgroups, in 
South African Black and British Caucasian SSc patients
Comparison o f  HLA-DRB1 and DQB1 phenotype frequencies o f  British Caucasian 
and South African Black SSc patients with their respective, ethnically matched, 
normal control population .
Allele frequencies of SSc patients varied significantly, in both ethnic groups, when 
compared to their respective ethnically matched control population (table 4.4). BC SSc 
patients showed a significant increase in HLA-DRB 1*0301-0303 (BC SSc 64/179 vs 
53/250 BC controls, p=0.01 with B. corr.) and significant decreases in alleles 
comprising HLA DQ6 and DQ3 (BC SSc 59/179 vs 115/250 BC controls and BC SSc 
100/179 vs 173/250 BC controls, p= 0.05 with B. corr.), respectively. In contrast to 
these findings, SAB SSc patients showed a significant increase in HLA DR2 and more 
specifically in the HLA-DRB 1* 1501 -1502 alleles compared to SAB controls (SAB SSc 
patients 11/40 vs 6/86 SAB controls, p=0.05 with B. corr.). HLA-DRB1* 1301-1305
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was also significantly increased in the SAB SSc patients compared to the SAB control 
population (SAB SSc patients 17/40 vs 15/86 SAB controls, p=0.03 with B. corr.).
HLA-DQB 1 typing for the SAB SSc patients was of low resolution, thus for analysis to 
be carried out effectively all other populations have been divided according to the same 
level of specificity. Significant differences in allele frequencies were identified in the 
SSc populations from both ethnic groups when they were compared to their respective 
control populations. HLA DQB 1*0301 and DQ6 were significantly decreased in the BC 
SSc patients compared to BC Controls (BC SSc 59/179 vs 115/250 BC controls, p=0.01 
with B. corr.). In the SAB SSc population HLA DQB1 *0501 -0504 was significantly 
increased compared to the SSc control population (SAB SSc patients 13/40 vs 11/86 
SAB controls, p=0.03 with B. corr.).
Comparison o f  HLA allele frequency with regard to autoantibody subgroup
For each autoantibody subgroup, comparisons of HLA frequencies were made, within 
each population, (autoantibody positive compared with the respective remaining 
(autoantibody) negative group, for that population). A comparison of the findings for 
each ethnic population will be made and discussed at the end of this chapter. The HLA 
frequencies of ATA and ARA III autoantibody subgroups in the BC population have 
been investigated in chapter 3, so the details will not be repeated here.
HLA and ATA
Table 4.5 shows comparisons of HLA-DRB 1 and DQB1 allele phenotype frequencies of 
ATA positive with ATA negative SAB SSc patients. No significant differences in 
phenotype frequencies were identified between the SAB ATA positive group and the 
SAB ATA negative group, however this group was small, (n=6). The equivalent data 
for the BC group is shown in table 3.1 in chapter 3, where the details are discussed.
HLA and ACA
HLA details for ACA positive and ACA negative, SAB and BC SSc patients are shown 
in table 4.6. The SAB ACA positive group was too small for any meaningful statistical 
analysis. However, Fishers exact test indicated that there were no significant differences 
in HLA allele frequency between the SAB ACA positive and negative groups. 
Significant differences were detected in the BC SSc patients group. HLA-DRB1*0101-
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0104 was significantly increased in ACA positive compared to ACA negative patients 
(BC ACA+ 42% vs. 23% BC ACA-, p=0.009). HLA-DRB 1*0401-0411 was also 
increased in BC ACA positive patients compared to the respective negative group (BC 
ACA+ 47% vs. 29% BC ACA -, p=0.01; p=0.13 with B.corr). HLA-DRB 1*0301-0303 
was significantly decreased in BC ACA positive compared with ACA negative patients 
(BC ACA+ 20% vs. 45% BC ACA-, p=0.001, p=0.013 with B.corr).
With regard to the DQB1 locus, HLA-DQB 1*0501-0504 and *0401-0402 were 
increased in BC ACA positive compared to BC ACA negative patients (ACA+ 45% vs. 
28% ACA-, p=0.01; ACA+ 10% vs. 2% ACA-, p=0.03) respectively, however, 
significance was lost for both loci when Bonforroni correction was applied.
HLA and anti-U3RNP
The number of patients comprising the anti-U3RNP serological group was small, thus 
statistical analysis was not considered conclusive (table 4.7). However, HLA DR5 was 
increased in SAB anti-U3RNP positive patients compared to SAB anti-U3RNP negative 
patients (p=0.04). Of note, both of the BC anti-U3-RNP positive patients were HLA- 
DRB1*0301 and HLA-DQB1*0201 positive.
HLA and anti-Ro
When HLA-DRB 1 allele phenotype frequencies of SAB patients in the anti-Ro 
serological group were compared with patients not in this group, some differences were 
observed, however they were not significant. HLA-DRB 1*0301-0303 and 1001 were 
increased in SAB anti-Ro positive patients (p=0.07 and 0.09 respectively), and HLA 
DR5 was decreased in SAB anti-Ro positive patients (p=0.07). One significant 
difference identified in the BC anti-Ro serological group was a significant increase in 
HLA-DRB 1*0301-0303 (p=0.04). No significant differences in HLA-DQB1 frequency 
were observed in the SAB or BC patients in the anti-Ro serological group compared to 
patients not in this group. The results are presented in table 4.8.
HLA and ARA III serological group
Only two SAB patients belonged to the ARA III serological group and they had 
different HLA types. The BC ARA III HLA details are considered and discussed in 
chapter 3.
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HLA and disease subtype
No significant HLA associations with disease subtype were observed. In the SAB 
patient population HLA-DRB1*1001 and HLA-DQB 1*0201-0203 were raised in lcSSc 
patients compared to dcSSc (lcSSc 4/15 vs. 0/23, p=0.01 and 5/15 vs. 1/23, p=0.02 
respectively), however, when Bonforroni correction was applied these values were no 
longer significant. HLA-DRB 1*0401-0411 was increased to some degree in lcSSc 
compared to dcSSc BC patients (p=0.06).
HLA and pulmonary fibrosis
No significant associations with HLA-DRB 1 or DQB1 alleles were identified in SAB or 
BC SSc PF positive patients compared with PF negative patients in each respective race. 
However, HLA DR5 was increased in SAB PF patients compared to SAB patients 
without PF.
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Figure 4.1: Prevalence o f autoantibody specificities in South African Black (SAB) and British Caucasian (BC) SSc patients
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Percentages of South African Black and British Caucasian SSc patients recognising identified and unidentified autoantibody specificties, and those 
in which no autoantibodies were detected. The greatest differences in autoantibody prevalence between populations were observed in the anti- 
U3RNP and ACA groups (p<0.0083 and ptorrecled=0.0002 respectively). Other significant differences were in anti-U lRN P and ARA III (both
p corrected< ( )  Q 5 )  ^  ( p < 0 . 0 5 ) .
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Figure 4.2: Indirect immunofluorescence pattern produced by an anti-U3RNP 
positive, South African Black, SSc patient
A clumpy, nucleolar, fluorescence pattern, characteristic o f anti-U3RNP positive sera
Figure 4.3: Indirect immunofluorescence pattern produced by an ACA positive,
British Caucasian, SSc patient
ACA fluorescence; a pattern o f discrete dots in interphase cells that line up on 
metaphase plate in dividing cells
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Table 4.1: Autoantibody specificities o f  South African Black and British Caucasian SSc patients, and classification according to serological
group
Autoantibody Specificy(ies) No. of
British Caucasian












ACA 88 36.8 3 6.7
ACA, Positive undentified 1 0.4 89 38.9 1 2.2 4 8.9 ACA
ATA 22 9.2 4 8.9
ARAII, ATA, Anti-Ro 1 0.4 0 0.0
ATA, ARA II, Anti-Jo-1 1 0.4 0 0.0
ATA, ARA II 8 3.4 1 2.2
ATA, Anti-Ro 2 0.85 37 16.2 0 0.0 6 13.3 ATA
ATA, Anti-Ro, Anti-Jo-1 1 0.4 0 0.0
ATA, Anti-Ro, Anti-La 1 0.4 0 0.0
ATA, Anti-Ro, Anti-La, Anti- 1 2.2
U1RNP 0 0.0
ATA, Anti-UIRNP +/-sm 1 0.4 0 0.0
ARA I/III 6 2.5 1 2.2
ARA I/II/III 20 8.4 0 0.0
ARA III, Ro 0 0.0 27 11.8 1 2.2 2 4.5 ARA III
ARA III 1 0.4 0 0.0
Anti-U3RNP, Positive 2 4.5
undientified 0 0.0
Anti-Ro, Anti-La, Anti- 2 0.85 0 0.0
U3RNP 2 0.9 8 17.8 Anti-U3RNP


















Anti-Jo-1 6 2.5 0 0.0
Anti-Jo-1, Anti-U 1RNP +/-sm 1 0.4 7 3.1 0 0.0 0 0.0 Anti-Jo-1
Anti-La, Anti-Pm-Scl 1 0.4 0 0.0
Anti-Pm-Scl, positive 
unidentified 0 0.0 8 3.5 1 2.22 1 2.23 Anti-Pm-Scl
Anti-Pm-Scl 7 2.9 0 0.0
Anti-Ro 1 0.4 2 4.5
Anti-Ro, Anti-La 4 1.7 2 4.5
Anti-Ro, Anti-La, Anti-Jo-1,
Anti-U 1 RNP +/-sm 1 0.4 0 0.0
Anti-Ro, Anti-La, Anti-Pm-Scl 1 0.4 9 4.0 0 0.0 6 13.33 Anti-Ro
Anti-Ro, Anti-Pm-Scl 1 0.4 0 0.0
Anti-Ro, Anti-La, Anti-U 1 RNP 0 0.0 1 2.2
Anti-Ro, Anti-U 1 RNP 1 0.4 1 2.2
Anti-La 2 0.85 2 0.9 0 0.0 0 0.0 Anti-La
Anti-U 1 RNP +/-sm 12 5.0 4 8.9
Anti-U 1 RNP, Positive 0 0.0 12 5.25 1 2.2 5 11.11 Anti-U 1 RNP
unidentified
None of the above. 17 7.1 17 7.4 10 22.3 10 22.22 Anti-?
Lacking detectable autoantibody 19 8.0 19 8.3 3 6.7 3 6.67 No Aab.
Autoantibody specificities detected in British Caucasian and South African Black SSc patients’ serum. Patients have been grouped serologically 
according to the details described in the text.
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■  Anti-U 1 RNP
■  Anti-?
□  No Aab.
The pie chart shows the number of British Caucasian patients in each serological group. The majority of patients (64%) are included in one of the 
major one of the major serological groups (ACA, ATA, or ARA III).
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Figure 4.5: Serological grouping o f South African Black SSc patients.
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B A nti-U  1 RNP
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□  No A ab.
Percentages of Black South African SSc patients’ classified into each serological autoantibody group. The largest serological groups were Anti-U3- 
RNP (18%), and anti-Ro and ATA (both 13%). Only 26% patients were classed into, either the ACA, ATA or ARA III serological groups.
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Table 4.2: Serological autoantibody association with disease subtype in British














ACA 831 (49.7) 2 (4.3) 1 (6.7) 2 (7.4)
ATA 173 (10.2) 16 (34.0) 1 (6.7) 5 (18.5)
ARA III 62 (3.6) 20 (42.6) 0 (0.0) 2 (7.4)
Anti-U3RNP 2 (1.2) 0 (0.0) 3 (20.0) 4 (14.8)
Anti-Jo-1 6 (3.6) 1 (2.1) 0. (0.0) 0 (0.0)
Anti-Pm-Scl S (4.8) 0 (0.0) 0 (0.0) 1 (3.7)
Anti-Ro 8 (4.8) 1 (2.1) 3 (20.0) 2 (7.4)
Anti-La 0 (0.0) 2 (4.3) 0 (0.0) 0 (0.0)
Anti-U 1 RNP 12 (7.2) 0 (0.0) 1 (6.7) 4 (14.8)
Anti- 13 (7.8) 2 (4.3) 5 (33.3) 5 (18.5)
unidentified 
No Aab. 11 (6.6) 3 (6.4) 1 (6.7) 2 (7.4)
Three serological autoantibody groups showed significant associations with disease subtype 
in the British Caucasian population, p values with OR(CI) are as follows; 1 pO.OOOl: 
22.2(5.2-94.6), 2 pcorrected<0.0005: 0.2(0.1-0.5), 3p<0.0001: 0.05(0.01-0.1). No significant 
associations were identified in the South African Black SSc population. Aab group, 
serological autoantibody group; BC, British Caucasian; SAB, South African Black; lcSSc, 
limited cutaneous SSc; dcSSc, diffuse cutaneous SSc.
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Table 4.3: Serological autoantibody association with pulmonary fibrosis in British















ACA 32 (9.09) 39 (60.94) 0 (0.0) 4 (14.29)
ATA 12-* (36.36) 10 (15.63) 3 (30.0) 3 (10.71)
ARA III 7 (21.21) 6 (9.38) 0 (0.0) 2 (7.14)
Anti-U3RNP 1 (3.03) 0 (0.0) 1 (10.0) 3 (10.71)
Anti-Jo-1 1 (3.03) 3 (4.69) 0 (0.0) 0 (0.0)
Anti-Pm-Scl 2 (6.06) 0 (0.0) 0 (0.0) 1 (3.57)
Anti-Ro 3 (9.09) 2 (3.13) 0 (0.0) 6 (21.43)
Anti-La 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Anti-U 1 RNP 1 (3.03) 2 (3.13) 1 (10.0) 2 (7.14)
Anti­ 2 (6.06) 1 (1.56) 51 (50.0) 4 (14.29)
unidentified 
No Aab. 1 (3.03) 1 (1.56) 0 (0.0) 3 (10.71)
South African Black patients with unidentified autoantibody(ies) showed a significant 
association with pulmonary fibrosis; 1 p=0.03: 6(1.2-30). ACA positive British Caucasian 
patients showed a negative association with pulmonary fibrosis; 2 pO.OOOl: 0.06(0.01-0.23), 
and ATA positive patients had a positive association; 3 p=0.02: 3.08(1.1-8.2). SAB, South 
African Blacks: BC, British Caucasian: Aab, autoantibody.
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Table 4,4: A comparison o f HLA-DRB1 and DQB1 phenotype frequencies o f British
Caucasian SSc patients and South African Black SSc patients with their respective,
ethnically matched, control populations.
Allele BC Controls BC SSc SAB SSc SAB Controls
Patients Patients
HLA DRB1* (n=250) (%) (n=179) (%) (n=40) (%) (n=86) (%)
0101-0103 (DR1) 53 (21.2) 55 (30.7) 4 (10.0) 2 (1.7)
1501-1502 (DR2) 65 (26.0) 38 (21.2) l l 4 (27.5) 64 (6.4)
1601-1602 (DR2) 6 (2.4) 2 (1.1) 0 (0.0) 0 (0.0)
Sum DR2 71 (28.4) 38 (22.2) l l 5 (27.5) 65 (6.4)'
0301-0303 (DR3) 531 (21.2) 641 (35.7) 13 (32.5) 28 (24.3)
0401-0411 (DR4) 88 (35.2) 64 (35.7) 3 (7.5) 5 (4.1)
1101-1104 (DR5) 41 (16.4) 24 (13.4) 10 (25.0) 28 (24.0)
1201-1202 (DR5) 7 (2.8) 3 (1.7) 5 (12.5) 6 (4.7)
Sum DR5 46 (19.2) 27 (15.1) 15 (37.5) 33 (28.7)
1301-1305 (DR6) 54 (21.5) 25 (14.0) 176 (42.5) 156 (13.2)
1401-1410 (DR6) 5 (2.0) 4 (2.2) 1 (2.5) 3 (2.4)
0701-0702 (DR7) 63 (25.2) 34 (19.0) 4 (10.0) 9 (7.6)
0801-0805 (DR8) 13 (5.2) 11 (6.2) 2 (5.0) 4 (3.0)
0901 (DR9) 4 (1.6) 3 (1.7) 0 (0.0) 2 (1.7)
1001 (DR10) 2 (0.8) 2 (1.1) 4 (10.0) 3 (2.4)
HLA DOB1* (n=250) (%) (n=183) (%) (n=40) (%) 00IIG (%)
0201-0203 (DQ2) 88 (35.2) 81 (44.3) 7 (17.5) 19 (16.9)
0401-0402 (DQ4) 10 (4-0) 9 (4.9) 10 (25.0) 23 (20.2)
0501-0504 (DQ5) 66 (26.4) 63 (34.4) 137 (32.5) l l 7 (9.8)
0601 (DQ6) 3 (1.2) 1 (0.6) 0 (0.0) 0 (0.0)
0602-4/8-12/14 (DQ6) 1152 (46.0) 592 (32.2) 17 (42.5) 37 (31.8)
0301-4/11-12 (DQ7) 1733 (69.2) 1003 (54.6) 4 (10.0) 23 (19.6)
Significant differences in allele phenotype frequencies were observed between SSc 
patients when compared to their respective ethnically matched control population. P 
values with Odds Ratio and confidence intervals are shown. British Caucasians: , pcorrected 
= 0.01: 0.5(0.3-0.7),2’3 pco,wted = 0.01: 1.7(1.2-2.7). South African Blacks: 4’5 pcorrected = 
0.05: 5.0(1.7-14.9),6 7 pcorrected = 0.03: 3.4(1.4-8.0). (South African Black control data 
obtained from ‘HLA 1991; Proceedings of the 11th International histocompatibility 
workshop and conference’ (230)).
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Table 4.5: HLA-DRB1 and DQB1 phenotype frequencies o f ATA positive and ATA
negative Black South African SSc patients.
Allele SAB ATA negative SAB ATA positive
HLA DRB1* (n=34) (%) (n=6) (%)
0101-0103 4 (11.76) 0 (0.0)
1501-1502 8 (23.53) 3 (50.0)
1601-1602 0 (0.0) 0 (0.0)
Sum DR2 8 (23.53) 0 (0.0)
0301-0303 12 (35.29) 1 (16.67)
0401-0411 3 (8.82) 0 (0.0)
1101-1104 9 (26.47) 1 (16.67)
1201-1202 4 (11.76) 1 (16.67)
Sum DR5 13 (38.24) 0 (0.0)
1301-1305 14 (41.18) 3 (50.0)
1401-1410 1 (2.94) 0 (0.0)
0701-0702 3 (8.82) 1 (16.67)
0801-0805 2 (5.88) 0 (0.0)
0901 0 (0.0) 0 (0.0)
1001 3 (8.82) 1 (16.67)
HLA DQB1* (n=34) (n=6)
0201-0203 7 (20.59) 0 (0.0)
0401-0402 8 (23.53) 2 (33.33)
0501-0504 11 (32.35) 2 (33.33)
0601 0 (0.0) 0 (0.0)
0602/9-12/14 21 (61.76) 5 (83.33)
0301-4/11-12 9 (26.47) 1 (16.67)
No significant differences in allele phenotype frequencies were observed between ATA positive and 
ATA negative Black South African SSc patients.
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Table 4.6: A  comparison o f HLA-DRB1 and DQB1 phenotype frequencies o f ACA positive and ACA negative SSc patients; in a Black South











0101-0103 1 (25.0) 3 (8.33) 291 (42.03) 261 (23.64)
1501-1502 1 (25.0) 10 (27.78) 13 (18.84) 25 (22.73)
1601-1602 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.82)
Sum DR2 1 (25.0) 10 (27.78) 13 (18.84) 25 (22.73)
0301-0303 0 (0.0) 13 (36.11) 142 (20.29) 502 (45.45)
0401-0411 0 (0.0) 3 (8.33) 32 (46.38) 32 (29.09)
1101-1104 0 (0.0) 10 (27.78) 7 (10.14) 17 (15.45)
1201-1202 0 (0.0) 5 (13.89) 1 (1.45) 2 (1.81)
Sum DR5 0 (0.0) 14 (38.89) 8 (11.59) 19 (17.27)
1301-1305 3 (75.0) 14 (38.89) 11 (15.94) 14 (12.73)
1401-1410 0 (0.0) 1 (2.78) 1 (1-45) 3 (2.73)
0701-0702 1 (25.0) 3 (8.33) 0 (14.49) 15 (21.82)
0801-0805 0 (0.0) 2 (1.20) 7 (10.14) 2 (3.64)
0901 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.73)
1001 0 (0.0) 4 (11.11) 1 (1-45) 1 (0.91)
HLA DQB1* (n=4) (n=36) (n=71) (n=l 12)
0201-0203 1 (25.0) 6 (16.67) 33 (46.48) 49 (43.75)
0401-0402 0 (0.0) 10 (27.78) 7 (9.86) 2 (1.79)
0501-0504 1 (25.0) 12 (33.33) 32 (45.07) 31 (27.68)
0601 0 (0.0) 0 (0.0) 1 (1.41) 0 (0.0)
0602/9-12/14 3 (75.0) 14 (38.89) 22 (30.99) 37 (33.04)
0301-4/11-12 0 (0.0) 4 (11.11) 41 (57.75) 59 (52.68)
Significant differences in allele phenotype frequencies were only observed between ACA positive and ACA negative British Caucasians (BC) SSc 
patients, and not in the South African Black (SAB)ACA positive vs. ACA negative population: 1 p =0.009, 2 p =0.013.
I l l
Table 4. 7: A comparison o f HLA-DRB1 and DQB1 phenotype frequencies o f anti-
U3RNPpositive and anti-U3RNP negative SSc patients; in a Black South African
SSc patient population and a British Caucasian SSc patient population
Allele SAB anti- SAB anti- BC anti- BC anti-
U3RNP U3RNP U3RNP U3RNP
negative positive positive negative
HLA DRB1* (n=35) (%) (n=5) (%) (n=2) (%) (n=177) (%)
0101-0103 4 (11.4) 0 (0.0) 0 (0.0) 55 (31.0)
1501-1502 11 (31.4) 0 (0.0) 0 (0.0) 38 (21.5)
1601-1602 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.1)
Sum DR2 11 (31.4) 0 (0.0) 0 (0.0) 38 (21.5)
0301-0303 13 (37.1) 0 (0.0) 2 (50.0) 62 (35.0)
0401-0411 2 (5.7) 1 (20.0) 0 (0.0) 64 (36.2)
1101-1104 7 (20.0) 3 (60.0) 0 (0.0) 24 (13.6)
1201-1202 3 (8.6) 2 (40.0) 0 (0.0) 3 (1.7)
Sum DR5 101 (28.6) 41 (80.0) 0 (0.0) 27 (15.3)
1301-1305 14 (40.0) 3 (60.0) 1 (50.0) 24 (13.6)
1401-1410 1 (2.9) 0 (0.0) 0 (0.0) 4 (2.3)
0701-0702 4 (11.4) 0 (0.0) 0 (0.0) 34 (19.2)
0801-0805 2 (5.7) 0 (0.0) 1 (50.0) 10 (5.6)
0901 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.7)
1001 4 (11.4) 0 (0.0) 0 (0.0) 2 (1.1)
HLA DQB1* (n=35) (n=5) (n=2) (n=181)
0201-0203 7 (20.0) 0 (0.0) 2 (100.0) 79 (43.7)
0401-0402 9 (25.7) 1 (20.0) 1 (50.0) 8 (4.5)
0501-0504 11 (31.4) 2 (40.0) 0 (0.0) 63 (34.8)
0601 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
0602/9-12/14 13 (37.1) 4 (80.0) 1 (50.0) 58 (32.0)
0301-4/11-12 2 (5.7) 2 (40.0) 0 (0.0) 100 (55.2)
A significant association of HLA DR5 with anti-U3RNP was observed in SAB patients; 1 
p=0.04, however, the number of individuals positive for anti-U3RNP were few for both 
populations, thus statistical analysis was considered inconclusive.
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Table 4.8: A comparison o f HLA-DRB1 and DQB1 phenotype frequencies o f anti-Ro positive and anti-Ro negative SSc patients; in a Black















0101-0103 4 (11.76) 0 (0.0) 2 (25.0) 53 (31.0)
1501-1502 9 (26.47) 2 (26.47) 1 (12.5) 37 (21.64)
1601-1602 0 (0.0) 0 (0.0) 1 (12.5) 1 (0.58)
Sum DR2 11 (32.35) 0 (0.0) 1 (12.5) 37 (21.56)
0301-0303 9 (26.47) 4 (66.67) 61 (75.0) 581 (38.80)
0401-0411 2 (5.88) 1 (16.67) 1 (12.5) 63 (36.72)
1101-1104 10 (29.41) 0 (0.0) 2 (25.0) 22 (12.82)
1201-1202 5 (14.71) 0 (0.0) 0 (0.0) 3 (1.75)
Sum DR5 14 (41.18) 0 (0.0) 0 (0.0) 27 (15.74)
1301-1305 16 (47.06) 1 (16.67) 1 (12.5) 24 (13.99)
1401-1410 1 (2.94) 0 (0.0) 0 (0.0) 4 (2.33)
0701-0702 3 (8.82) 1 (16.67) 0 (0.0) 34 (19.82)
0801-0805 1 (2.94) 1 (16.67) 1 (12.5) 10 (5.83)
0901 0 (0.0) 0 (0.0) 1 (12.5) 2 (1.17)
1001 2 (5.88) 2 (33.33) 0 (0.0) 2 (1.17)
HLA DQB1* (n=34) (n=6) (n=8) (n=179)
0201-0203 4 (11.76) 3 (50.0) 6 (75.0) 75 (41.90)
0401-0402 8 (23.53) 2 (33.33) 0 (0.0) 9 (5.03)
0501-0504 11 (32.35) 2 (33.33) 3 (37.5) 60 (33.52)
0601 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.56)
0602/9-12/14 14 (41.18) 3 (50.0) 1 (12.5) 58 (32.50)
0301-4/11-12 3 (8.82) 1 (16.67) 4 (50.0) 96 (53.63)
When allele phenotype frequencies were compared, a significant increase in HLA-DRB1 *0301-0303 was observed in the anti-Ro positive BC SSc 




A number of HLA alleles have previously been associated with an increased frequency 
of SSc and SSc subsets, and associations vary when different populations are examined, 
particularly when different racial groups are considered. (84;86). A variation in SSc 
autoantibody specificity is also recognised between different racial origins (24). 
However, HLA association with the disease is suggested to be independent of ethnic 
background. To support the hypothesis that HLA plays a significant role in SSc, one 
might expect that any differences in autoantibody profiles, between races, would be 
reflected in the purported associated HLA alleles. Thus despite the different frequencies 
of autoantibodies observed in the different races, HLA and ANA associations would be 
expected to remain the same. The work in this chapter has investigated autoantibody 
profiles, HLA and SSc disease subset of two, ethnically different, SSc patient 
populations, and considers this concept.
In concordance with reports, autoantibodies were present in more than 90% of patients 
in both populations (BC 92%, SAB 93%). However, the overall autoantibody profiles of 
the populations were very different. The majority of BC patients had an autoantibody to 
one of the major serologic groups (ACA, ATA or ARA III) (67%), which was not the 
case in the SAB population (26%). The majority of SAB sera had an autoantibody to 
either anti-U3RNP, anti-Ro or an unidentified autoantigen(s). The largest serological 
group in the SAB patient population was the positive unidentified autoantibody group 
(22%). Immunoprecipitation and immunodiffusion techniques used to identify 
autoantibodies, employed known protoype sera derived from a Caucasian SSc patient 
cohort. SAB patients demonstrated banding patterns on immunoprecipitation that were 
uncharacteristic to those seen in the BC population, and lines of identity could not be 
established, using any of the control sera, on immunodiffusion. Thirteen percent of SAB 
patients had anti-Ro autoantibodies, significantly more than those detected in BC 
(p=0.03), and more than has been previously reported (45). These results demonstrate 
that not only is the overall SSc autoimmune profile quite different in the two races, but 
certain autoantibody specificities are apparent in the SAB SSc population that have not 
been observed in the BC population.
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The greatest differences of autoantibody prevalence between the two races were in 
agreement with previous reports. The most striking difference was in the minor 
serologic group, anti-U3RNP (BC <1% vs. 18% SAB, p<0.0001), an observation that 
has been reported by a number of groups (24; 186; 187). Anti-U3RNP has previously 
been associated with severe SSc (186) although this was hot the case in this SAB 
population. The frequency of ACA also varied greatly. It has previously been reported 
that the occurrence of ACA is reduced in Blacks compared to Caucasians (23; 187). 
ACA was significantly reduced in the SAB patients compared to the BC SSc population 
in this study (BC 38.5% vs. 9% SAB, p=0.0002). Although absent entirely from one 
Black population (24), anti-PmScl was detected in one SAB patient, also with an 
unidentified specificity. Thus, it seems that autoantibodies directed against Pm-Scl are 
rare in Blacks.
It is evident in this study that the overall HLA background of each ethnic SSc 
population is quite different. Significant variences in allele frequencies were identified 
in both ethnic SSc patient populations, compared to their etnically matched control 
group. Of particular interest was that the observed differences in allele frequencies, 
were with contrasting alleles, in each of the populations. An increase in frequency of 
HLA DRB 1*0301-0303 and a decrease in HLA DQ6 and DQ3 were observed in the BC 
population compared with an increase in HLA-DR2, more specifically HLA 
DRB1*1501-1502, HLA DRB1*1301-1305 and an increase in HLA DQBl*0501-0504 
were identified in the SAB population.
HLA associations become more intriguing when autoantibody subgroups are 
considered. Typically in SSc, ACA has been associated with HLA DR1 and DR4 
(63;86;166;188). ACA was significantly associated with HLA-DRB1 *0101-0102 and 
HLA DR4 in the BC population. ACA is regarded as a marker of the limited form of 
SSc, and indeed ACA positive BC patients showed a significant increase in this form of 
the disease (p<0.0001). In concordance with this observation, pulmonary fibrosis, a 
clinical manifestation associated with more severe disease, was observed to be 
negatively associated with the BC ACA patients. As mentioned, HLA DR1 was 
increased 'in lcSSc BC patients, a type which has previously been reported as absent 
from a group of Japanese SSc patients with diffuse disease (189). Here, the SAB 
population, which included significantly more patients with dcSSc, showed a reduction
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in HLA DR1. In the anti-Ro serological group significant HLA associations with HLA- 
DRB 1*0301-0303 were identified in both the SAB and BC patient populations. 
Incidentally, these groups were of quite different sizes in each population (BC 4% and 
SAB 13.5%). Thus overall, the differences in the frequencies of HLA alleles, 
serological autoantibody and clinical profile, appear related and support the hypothesis 
that the HLA plays a significant role in SSc.
However, not all associations were equivalent in each population. Although this may 
seem to weaken the hypothesis, this could arise for a number of reasons. One 
contributory factor could be the small numbers occurring in some of the autoantibody 
groups. Also, discordance of associations with disease subtype between the populations 
could be partially due to differential assignation of disease subtype at different 
institutions, despite classification criteria, or maybe referral bias. Important data in this 
respect would be disease duration; A population including mostly patients with early 
disease, classed as lcSSc, may well be on course to develop dcSSc. In contrast to this a 
population may comprise patients who have suffered the disease for much longer. Thus 
those patients destined to develop dcSSc, would have done so. The two populations 
would, overall, give quite different profiles.
Associations identified in the ATA BC population were with HLA-DRB1*1101-1104 
alleles, a subtype of the broad HLA DR5 type, which has frequently been reported in 
Caucasian and Black races amongst others (83; 190). No HLA associations were 
observed in the SAB ATA positive population, however this group was rather small 
(n=6). ATA patients have regularly been reported to have the highest frequency of PF 
(86; 188) and indeed this was the case in the BC patients. However, SAB patients 
lacking any identifiable autoantibody were most likely to suffer PF. SAB ATA positive 
patients also showed no association with disease subtype, although conversely a weak 
association with dcSSc was identified in the BC ATA positive patients (p=0.08).
Studies by Kuwana et al (‘99) and Cram et a l (‘93) investigated immune reactivity to 
different portions of recombinant topo-I protein (190; 191). Both groups concluded that 
different races characteristically recognised different portions of the protein. The same 
portion, (adjacent to the carboxyl terminus), was recognised in White and Black SSc 
patients (190). It would be interesting to consider whether patients recognising different
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portions of this autoantigen could be further defined clinically and/or genetically. A 
study by Greidinger et al. suggested that autoantibodies to topoisomerase I but not ARA 
II were associated with lung function. (Although the report does not state whether ATA 
was found accompanying RNAP II or RNAP III or either) (192). When patients in the 
ATA serological group in this study were further divided according to other 
autoantibodies present in the serum, associations with pulmonary fibrosis or disease 
subtype could not be further defined. Although no HLA associations were identified in 
the ARA III group, in agreement with previous reports an association with dcSSc was 
observed (188; 193).
Although differences in the autoimmune response between races have not been defined, 
it is evident that HLA background, autoantibody profile and clinical course are 
ethnically variable. Exactly how genetic status, immunological and clinical processes 
relate to, or are independent of each other, is yet to be established, but results here 
suggest that associations between them are independent of ethnicity. Equivalent mutual 
exclusivity of autoantibodies was observed in both patient populations and was 
generally in concordance with reports, despite autoantibody multi-specificity in the 
majority of serum. This further suggests that the immune response is not only 
predetermined, but characterised by a factor or factors other than ethnicity, and implies 
a significant role of the HLA. Small populations with a high incidence of scleroderma, 
such as the Oklahoma Choctaw (31), provide valuable models for further investigating 
this notion. These populations have restricted gene pools, which not only support the 
idea of a genetic component to the disease, but also provide an exceptional opportunity 
for extensive genetic analysis.
HLA studies have revealed distinct evolutionary patterns for the HLA loci in ethnically 
diverse samples resulting in different predominant HLA haplotypes (87). It has been 
suggested that immunogenetic factors, including HLA class II molecules, probably 
mediate SSc-related autoantibody production (24). In this light, the variation in the 
prevalence of SSc disease subtype observed in different populations, coupled with 
variation in autoantibody frequencies, supports the hypothesis that the HLA plays a role 
in SSc. Observations here indicate that the production of SSc related serum ANA is 
related to immunogenetic background, as has also been recognised in other studies (24).
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CHAPTER 5
CLINICAL FEATURES AND MHC CLASS II 
ASSOCIATIONS IN INDIVIDUALS WITH 
ANTICENTROMERE ANTIBODIES
5.1: INTRODUCTION
Anticentromere antibodies (ACA) are most commonly identified in patients with SSc, 
but may also be present in a number of other autoimmune rheumatic conditions 
including rheumatoid arthritis (RA), SLE and primary Sjogren’s syndrome. In a study 
of patients with ACA, attending a rheumatology outpatient clinic, Vlachoyiannopoulos 
et a l found that 64% of patients with ACA had lcSSc, 17% with primary Sjogrens 
syndrome and 12% with idiopathic Raynaud's phenomenon (194). In a similar study, 
Chan et al. found that the majority of their patients with ACA had either the limited 
form of scleroderma (described in the report as CREST) (55%) or Raynaud’s 
phenomenon (29.6%) (195).
In scleroderma, the presence of ACA represents one of the three, recognised, major 
autoantibody groups. Approximately 26% of scleroderma patients are reported to have 
ACA (45), however this figure is lower in some non-Caucasian populations, including 
American Blacks (23), and Thai patients (196). SSc patients with ACA are most likely 
to have lcSSc. Of these patients most will have Raynaud’s phenomenon and an absence 
of renal involvement. Patients with lcSSc and ACA are also thought to have an 
increased risk of major peripheral vascular occlusive disease (60). As discussed earlier, 
Raynaud’s phenomenon may be the first manifestation of SSc and the presence of ACA 
in patients with Raynaud’s phenomenon identifies those patients at risk of going on and 
developing other features of lcSSc. The early identification of autoantibodies in these 
patients could bring attention to potential cases of SSc (47).
ACA are reported to be present in 10-20% patients with primary biliary cirrhosis (PBC), 
a condition often found in overlap with SSc (57). PBC patients who have ACA often 
have some features of SSc as well, such as Raynaud’s phenomenon and sclerodactyly 
(197). ACA has also been identified in patients not only with rheumatoid arthritis (RA), 
but in patients with RA concurrent with SSc (198). The latter study detailed three case 
reports of ACA positive RA patients who proceeded to develop lcSSc, 11-50 years after 
the onset of RA (198). It has been suggested that the presence of deforming arthritis, co­
occurring with SSc may represent a distinct, unique overlap condition (199). ACA has 
been identified as a significant risk factor for cancers in some patients with SSc (127). 
Some patients with SLE may have ACA. An increase in the age of disease onset and, an
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increased occurrence of Raynaud’s phenomenon, has been identified in ACA positive 
SLE patients compared with ACA negative SLE patients (200). The number of SLE 
patients with ACA has recently been suggested to be higher than first appreciated and 
may identify a distinct SLE group (200). Some Sjogren's syndrome patients may also 
have ACA. Analysis of a population of primary Sjogren’s patients, from an Italian 
institution, identified just over 16% of patients with ACA (201).
Genetic associations with ACA have previously been reported and mainly refer to those 
patients with SSc. Genth et al. reported that SSc patients with ACA were frequently 
positive for the broad phenotypes HLA DR1, DR4 or DRw8 (80). These observations 
were supported by Briggs et al., who reported a significant association of the presence 
of either DR1 or DR4 with the expression of ACA (107), and similarly by Reveille et 
al with regard, more specifically, to HLA DRB 1*0403 and 0407, and HLA DR5 (202). 
Association of ACA in SSc patients with the HLA DQB1 region have also been 
reported. Analyses has revealed a significant increase in frequency of HLA DQB1*0501 
(81 ;86), and a decrease in DQB 1*0201 in ACA positive SSc patients (81). Further 
analysis of HLA DQB1 has identified genotype sequences common to ACA positive 
SSc patients. A polar glycine or tyrosine residue at position 26 of the DQB1 first 
domain (HLA-DQB1: 26:L) was present in all ACA positive SSc patients in a study by 
Reveille et al., implying the necessity for a non-HLA-DQBl: 26:L allele for the 
generation of autoantibody (202). However this observation was not supported in study 
of Japanese, ACA positive, SSc patients (86).
Since the first description of autoantibodies directed toward the centromere region of 
cells in 1980, it has become recognised that a number of distinct protein components 
may be targeted, as described in the main introduction to this work (chapter 1). As 
mentioned, the three major centromere antigens CENP-A (19Kd), CENP-B (80Kd) and 
CENP-C (140Kd) are often targeted, whilst antibodies to CENP’s D, E, F and G occur 
less often. CENP-B is the most commonly recognised CENP antigen (203). CENP-A 
and CENP-B are recognised by IgG antibodies, and CENP-C by IgM antibodies (163). 
Various antigen regions (epitopes) on the CENPs have been identified. At least five 
epitopes have been identified on CENP-B, one of which is shared by CENP-A and 
CENP-C (57), and nine epitopes have been reported for CENP-C (204).
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There have been very few investigations into the characterisation of the ACA response, 
with regard to the presence of specific anti-CENPS and associations with particular 
clinical features or clinical profile. Some trends have been observed regarding the major 
autoantigens (CENP A, B and C), but not with the less frequently occurring anti-CENP 
autoantibodies. When a comparison between patients with anti-CENP-A, B, and C was 
made with anti-CENP-E positive patients, no unique clinical features in the anti-CENP- 
E positive group were identified (205). A study by Vazquez-Abad and colleagues 
investigated the autoantibody specificity of patients without Raynaud’s phenomenon or 
SSc (group A), compared to patients with these conditions (group B). It was concluded 
that the ACA specificity between the two groups was different. Most obviously, far 
fewer group A patients recognised CENP B, compared to group B patients. Moreover, 
group A patients who did recognise CENP B were thought to bind different epitopes to 
those recognised by patients in group B (206). Interestingly a study investigating 
reactivity’s toward CENP A and/or CENP B antigen revealed a significant difference in 
the distribution of the two autoantibody-specificities in SSc patients compared to an RA 
and SLE patient population. Ninety seven percent of SSc patients showed reactivity 
with both CENPs A and B, where as 83% of RA and SLE ACA positive samples 
showed mutually exclusive reactivity’s with antibodies directed against either CENP A 
or CENP B (207). Further, similar, comparisons between ACA positive patients with 




The objectives of the work in this chapter were; to characterise the clinical, 
immunogenetic and autoantigenic profile of ACA positive patients, and to assess the 
clinical course and disease evolution represented by an ACA positive population. This 
was investigated by means of the following aims:
I. To assess the clinical profile of ACA positive patients attending a rheumatology
clinic
II. To identify any genetic associations with disease, in patients with ACA
III. To identify any associations of HLA-DRB1 and/or DQB1 alleles, (at the allele
level or with previously reported amino acids at particular loci), with ACA 
positivity.
IV. To analyse disease outcome in a subgroup of ACA positive patients with a 
follow up of four years or more
V. To analyse specific polypeptide antigens (CENPs) recognised by ACA positive
sera and to identify associations with disease or HLA background
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5.3: MATERIALS AND METHODS
Patients .
Two populations of patients, selected from two institutions, were included in this part of 
the study:
Fifty-five patients attending the Royal National Hospital for Rheumatic Diseases 
(RNHRD), who tested positive for serum ACA, comprised the ‘first data set’. Of these 
patients, 43 had clinical data available and were included in the clinical profile study, 30 
in the HLA analysis and 25 in the longitudinal study.
A further 47 patients, attending a rheumatology clinic in Manchester were identified as 
ACA positive, and formed the ‘second data set’. Of these patients 41 were included in 
the HLA analysis section.
Detection o f  ACA autoantibody
The presence of ACA was established by indirect immunofluorescence of patient sera 
on Hep-2 cell substrate (method 2.4.2). ACA was assigned when the characteristic 
fluorescent pattern of discrete dots, (in interphase cells), and fluorescence of a 
metaphase plate (in dividing cells) was identified.
HLA-DRB1 and DQB1 typing
HLA-DRB1 and DQB1 alleles were identified by PCR-SSP genetic typing, according to 
method 2.2.2.
Identification o f  CENPs
Analysis of autoantigenic polypeptide recognition was performed on 44 ACA positive 
patients. Identification of CENPs recognised by ACA positive sera was investigated by 
immunoblotting, as described in method 2.4.5.
Clinical profile
Case notes of 43 patients, (all from the first data set), who had been found ACA positive 
during the period of July 1992 and June 1997, (five years), were reviewed and the 
precise clinical diagnosis at the time of first presentation was documented.
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Longitudinal disease profile
Follow up of at least 4 years was available on 25 ACA positive patients. Disease 
evolution, if any, over the total period of follow up available was documented. If a 
patient had missed an appointment, their GP was contacted and details on the latest 
follow up were obtained. This was carried out with, and under the guidance of, a 
rheumatology clinician.
Statistical analysis




5.4.1: Identification of ACA positive patients attending a connective tissue disease 
clinic at one of two selected institutions
Identification o f  A CA
Fifty-five patients attending the RNHRD were identified as ACA positive by indirect 
immunofluorescence and accepted into the study (data set one). Figure 4.2 is an 
example of a typical fluorescence pattern seen from ACA positive sera. Of a total 127 
patient sera, collected from patients attending the rheumatology clinic at the Hope 
hospital, Salford, 47 (36.5%) were found to have ACA present in their serum (data set 
two).
5.4.2: Assessment of the clinical profile represented by an ACA positive patient 
population attending a CTD clinic, subsequent identification of any genetic 
associations with disease
The following includes patients from the first data set only.
Patients
A total of 55 patients, who attended the RNHRD between July 1992 and June 1997 
were identified as ACA positive. Clinical information was available on 43 of these 
patients from which the overall ACA clinical profile was assessed. This included 41 
female: 2 male with a median age of 59 years (range 32-87 years).
Assessment o f  clinical profile represented by ACA patients received through a CTD 
clinic
Thirty-one, (72%) patients were diagnosed with lcSSc, of which 26 (60.5%) had lcSSc 
alone and six had a form of arthritis as well (table 5.1). Four patients were diagnosed 
with Sjogren’s syndrome, of which one patient also had an overlap with SLE and 
arthritis. Five patients had erosive RA, (3 seropositive, 2 seronegative). One of the 
patients with seronegative erosive RA also had fibromyalgia and Hashimoto’s 
thyroiditis. One patient was diagnosed with UCTD (table 5.1).
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Positive predictive value o f ACA fo r  lcSSc
The positive predictive value of ACA for lcSSc was 72% (table 5.2). The next most 
frequent association of ACA was with arthritis (28%).
5.4.3: Associations of ACA with HLA-DRB1 and/or DQB1 alleles
HLA-DRB1 and DQB1 phenotype frequencies were analysed and compared to the 
phenotype frequencies of 250 normal controls.
ACA associations with HLA: Data set one.
DNA was available from 30 ACA positive patients for HLA typing. HLA phenotype 
frequencies of these patients are shown in table 5.3 and are compared to 250 normal 
controls. HLA-DRB1*0101-0103 was significantly increased in the patients compared 
to controls (patients 40% vs. 21% controls, p=0.02). A decrease in HLA-DRB1*1301- 
1305 was also noted in patients however this did not reach significance (patients 7% vs. 
21.5% controls, p=0.09).
In the HLA-DQB1 alleles one significant difference was apparent between patients and 
controls. HLA-DQB1*0501 was significantly raised in patients (patients 41% vs. 30% 
controls, p=0.01) (table 5.3).
ACA associations with HLA: Data set two.
HLA typing was performed on 44 patients from the second data set and several 
significant differences in phenotype frequencies were observed when they were 
compared to normal controls. HLA-DRB 1*0101-0103 was significantly increased in 
ACA patients (patients 44% vs. 21% controls, p=0.001). HLA DR5 appeared decreased 
in patients (patients 5% vs. 19% controls, p=0.05), however when HLA-DR5 subtypes 
were analysed any significance was lost. A slight, notable, decrease remained in the 
DRB1*1101-1104 allele (patients 5% vs. 16% controls, p=0.09).
One significant difference was observed in the HLA-DQB1 alleles. HLA-DQB 1*0501 
was significantly increased in patients compared to normal controls (patients 43% vs. 
21% controls, p=0.001) (table 5.3).
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ACA associations with HLA: data sets one and two combined
To try and reduce the chance of false associations due to small numbers, the data sets 
were combined and the analysis repeated. Particular attention was paid to see if any 
previous associations were still apparent, or any trends had reached significance.
HLA-DRB1*0101-0103 was significantly raised in patients compared to controls 
(patients 42% vs. 21% controls, p=0.0003). A significant reduction in DR5 alleles was 
also observed (p=0.03). When this broad type was broken down HLA-DRB1*1101- 
1104 remained significantly decreased in patients compared to the controls (patients 
5.5% vs. 19% controls, p=0.03). HLA-DRB 1*0401-0411 was significantly raised in 
patients when compared to controls (patients 48% vs. 35% controls, p=0.050, and HLA- 
DRB 1*0701-0702 was significantly decreased (patients 14% vs. 25% controls, p=0.04). 
Of note, a significant number of ACA patients were found to be HLA-DRB 1*0101- 
0102 and/or HLA-DRB 1*0401-0411 positive when compared to controls (patients 73% 
vs. 51.5% controls, p=0.001; p=0.01 with B.Corr). (Table 5.4).
HLA-DQB1*0501 was significantly increased in patients compared to controls (42.5% 
vs. 29%  patients, p=0.0002).
Analysis o f  ACA and HLA-DQB1 position 26
The data was examined for the absence of the amino acid leucine at position 26 of the 
HLA-DQB1 third domain (HLA-DQB1: L: 26). The alleles HLA DQB1*0501, 0502, 
0503, 0402, 0601, 0301 all lack leucine at position 26 of the first domain.
Data set one
HLA-DQB1 position 26 was analysed in 29 patients in data set one. Five patients (17%) 
lacked leucine at position 26 from both alleles. Of the remaining patients 13 (45%) were 
heterozygous and 11 (38%) were homozygous for HLA-DQB1: L: 26. When these 
figures were compared to normal controls there were no significant differences.
Data set two
In the second data set, (n=41), ten (25%) patients lacked leucine from position 26 of 
both HLA-DQB1 alleles. Twenty-four (58.5%) of patients were HLA-DQB1: L: 26 
heterozygous, which was significantly less than the number of heterozygous normal
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controls (p=0.03). Seven (17%) patients were homozygous for leucine at this locus. This 
was also a significantly lower number of individuals compared to normal controls
(p=0.01).
Data sets one and two combined.
When the two data sets were combined 15 (21.5%) patients lacked leucine from 
position 26 of both HLA-DQB1 alleles. 37 (53%) were heterozygous for leucine at this 
position. Eighteen (25.5%) patients were homozygous for HLA-DQB1: L: 26, which 
was significantly lower when compared to normal controls (p=0.01). Significantly more 
ACA patients lacked at least one allele coding for leucine at this position compared to 
controls (patients 52/70 (74.2%) vs. 144/250 (57.6%) controls, p=0.01).
5.4.4: Analysis of the longitudinal profile of a subgroup of patients with a follow up 
of four years or more
Patients
ACA patients with a follow up of at least four years were evaluated to assess 
longitudinal profile. Twenty-five patients (24 female: 1 male) were included in this 
particular investigation with a mean follow up of 59 months (range: 48-144 months). 
The average age of initial diagnosis was 56 years.
Initial diagnosis and longitudinal profile
LcSSc
The initial diagnosis, associated or other conditions suffered, and details of follow up, 
can be seen in table 5.5. Sixty eight percent of patients, (17/25), had an initial major 
diagnosis of lcSSc of which four individuals initially presented with Sicca syndrome. 
Fourteen of these patients maintained an overall stable course. One showed slight skin 
progression, two had troublesome Raynaud’s, and one developed Sicca syndrome 
during the course of study. Of the remaining 3 patients in this group one showed 
significant disease progression and also developed osteoporosis (patient PP). One 
patient developed scleroderma renal crisis at 54/75 months of follow up. This occurred 
after a stable and mild course of about four years. The patient developed irreversible
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renal failure despite early and aggressive treatment, which included ACE inhibitors. The 
third patient died of a cause unrelated to SSc (myocardial infarction), at 134 months of 
follow up.
LcSSc and erosive rheumatoid arthritis
Three patients were initially diagnosed with lcSSc and erosive RA. Two of these 
patients were being treated with methotrexate (/required disease modifying therapy). 
There was no significant progression of scleroderma in these patients.
Seronegative/positive erosive rheumatoid arthritis
One patient presented initially with seronegative erosive RA and sicca syndrome, and 
one with seropositive erosive RA who also had mononeuritis multiplex, gangrene and 
Sicca syndrome. Neither patient showed signs of developing scleroderma over the 
duration studied (48 and 56 months respectively).
Other major initial diagnosis
One patient who was initially diagnosed with Raynaud’s phenomenon and oligoarthritis 
showed no disease progression. One patient with UCTD showed no change over the 54 
months studied.
5.4.5: Analysis of specific polypeptide antigens (CENPs) recognised by ACA 
positive sera and identification of associations with disease or HLA background
Forty-four ACA patients comprising data sets one and two were immunoblotted 
according to method 2.4.5. The aim of the work was to identify the specific CENP 
proteins recognised by an individuals’ serum. An analysis would then have been carried 
out to identify any associations of CENP proteins recognised with disease profile and/or 
HLA background. This was the last part of the laboratory research carried out for this 
project and unfortunately there were problems with the technique and thus there was not 
sufficient time to obtain the anticipated results. However some deductions can be made 
from the results that were achieved, although, it must be stressed that this is regarded as 
unfinished work. Immunoblotting work on some of the ACA positive patients had been 
previously carried out at Bath, as part of another study, and this work will be considered
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in the discussion of this chapter with regard to the HLA typing.
Immuno blotting o f  ACA positive patients
Forty-four ACA positive patients were immunoblotted. It was established that 41 (93%) 
of these patients possessed autoantibody recognising CENP A. No further conclusions 
with regard to the other CENPs could be made from this work due to reasons explained.
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Table 5.1: Disease affecting ACA positive patients
Disease Phenotype No. Patients
(n=43)
LcSSc 26
LcSSc/ Erosive RA 1
LcSSc/ Erosive polyarthritis 1
Lssc/ Polyarthritis 1
LcSSc/ Seropositive erosive RA 1
LcSSc/ RA 1
Primary Sjogren’s syndrome 2
RA, Sjogren’s syndrome 1
Raynaud’s Phenomenon/Arthritis 1
SLE 1
SLE/ Sjogren’s syndrome 1
Seronegative erosive RA 1
Seronegative erosive RA, Fibromyalgia, 
Hashimotos thyroiditis
1
Seropositive erosive RA 3
UCTD 1
Disease phenotypes encountered in an ACA positive patient population attending a 
connective tissue disease clinic.





Sjogren’s syndrome 4 (9)
Raynaud’s phenomenon 1 (2.5)
(In absence of SSc)
SLE 2 (5)
UCTD 1 (2.5)
The prevalence of each of the diseases affecting the ACA positive patients is shown.
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Table 5,3: HLA phenotype frequencies o f two ACA patient populations compared to
normal controls
Allele Data set 1 Controls Data set 2
HLA DRB1* (n=30) (%) (>7=250) (%) («=41) (%)
0101-0103 121 (40.0) 53 (21.2) 182 (44.0)
1501-1502 6 (20.0) 65 (26.0) 7 (17.1)
0101-1602 0 (0.0) 6 (2.4) 0 (0.0)
Sum DR2 6 (20.0) 71 (28.4) 7 (17.1)
0301-0303 8 (26.7) 53 (21.2) 6 (14.6)
0401-0411 14 (46.7) 88 (35.2) 20 (48.8)
1101-1104 2 (6.7) 41 (16.4) 2 (4-9)
1201-1202 1 (3.3) 7 (2.8) 0 (0.0)
Sum DR5 3 (10.0) 46 (19.2) 23 (4.9)
1301-1305 2 (6.7) 54 (21.5) 9 (22.0)
1401-1410 0 (0.0) 5 (2.0) 1 (2.4)
0701-0702 5 (16.7) 63 (25.2) 5 (12.2)
0801-0805 2 (6.7) 13 (5.2) 5 (12.2)
0901 0 (0.0) 4 (1.6) 0 (0.0)
1001 0 (0.0) 2 (0.8) 1 (2.4)
HLA DQB1* (n=29) (250) ii
0201 12 (41.0) 88 (35.2) 12 (27.3)
0401 0 (0.0) 0 (0.0) 0 (0.0)
0402 0 (0.0) 10 (4.0) 6 (13.6)
0501 12" (41.0) 52 (28.8) 195 (43.2)
0502 0 (0.0) 9 (3.6) 0 (0.0)
0503 0 (0.0) 5 (2.0) 2 (4.5)
0601 1 (3.4) 3 (1.2) 0 (0.0)
0602 6 (20.7) 60 (24.0) 7 (16.0)
0603/8 1 (3.4) 27 (10.8) 2 (4.5)
0604 1 (3.4) 28 (11.2) 4 (9.1)
0301 7 (24.1) 91 (36.4) 16 (36.4)
0302 9 (31.0) 51 (20.4) 13 (29.5)
0303 1 (3.4) 31 (12.4) 3 (6.8)
Significant differences in HLA allele frequencies were observed in both data sets when 
they were compared to normal controls, p values with OR(CI) are shown. HLA- 
DRB1*0101-0102 was raised in data set 1 and 2 (xp=0.02: 2.4(1.1-1.5) and 2p=0.0017: 
2.9(1.5-5.7), respectively). Other significant differences observed are as follows; 
3p=0.05: .22(0.05-0.97), 4p=0.01: 2.5(1.2-5.6), 5p=0.001: 3.3(1.7-6.5).
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0101-0103 301 (42.3) 53 (21.2)
1501-1502 13 (18.3) 65 (26.0)
101-1602 0 (0.0) 6 (2.4)
Sum DR2 13 (18.3) 71 (28.4)
0301-0303 14 (19.7) 53 (21.2)
0401-0411 342 (47.9) 88 (35.2)
1101-1104 43 (5.6) 41 (16.4)
1201-1202 1 (1.4) 7 (2.8)
Sum DR5 54 (7.0) 46 (18.4)
1301-1305 11 (15.5) 54 (21.5)
1401-1410 1 (1.4) 5 (2.0)
0701-0702 10s (14.1) 63 (25.2)
0801-0805 7 (9.9) 13 (5.2)
0901 0 (0.0) 4 (1.6)
1001 1 (1.4) 2 (0.8)
HLA DQB1* (n=73) (n=250)
0201 24 (32.9) 88 (35.2)
0401 0 (0.0) 0 (0.0)
0402 6 (8.2) 10 (4.0)
0501 316 (42.5) 52 (28.8)
0502 0 (0.0) 9 (3.6)
0503 2 (2.7) 5 (2.0)
0601 1 (1.4) 3 (1.2)
0602 13 (17.8) 60 (24.0)
0603/8 3 (4.1) 27 (10.8)
0604 5 (6.8) 28 (11.2)
0301 23 (31.5) 91 (36.4)
0302 22 (30.1) 51 (20.4)
0303 4 (5.5) 31 (12.4)
Several significant differences in phenotype frequencies were apparent when both data 
sets were combined and compared to normal controls; p-values with OR(CI) are as 
follows: ^=0.0003: 2.7(1.6-4.8), 2p=0.05: 1.7(1.0-2.9), 3-4p=0.03: 0.3(0.1-0.9), 5p=0.04: 
0.5(0.2-1.0), 6p=0.0002: 2.9(1.7-5.2).
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Table 5.5: Longitudinal clinical profile o f ACA positive patients with a follow up o f greater than four years
Patient Sex Age at Initial Diagnosis Consensus of follow up and comments Total follow- Associated/ other conditions
ID. diagnosis (Major clinical manifestation) up time
(months)
EC F 69 Seronegative erosive RA No SSc 048 Sicca Syndrome
SH F 62 LcSSc Slight skin progression 049
JL F 56 LcSSc No Progression 049 Sicca syndrome
BD F 36 LcSSc LcSSc 050
AL F 52 LcSSc No Progression 051
PP M 65 LcSSc Significant Progression, (developed 
osteoporosis)
053 Osteoporosis
BR F 59 LcSSc No Progression 054
JR F 35 UCTD UCTD 054
CD F 73 LcSSc No Progression 055
BM F 62 Raynauds/ oligoarthritis No Progression 056
PB F 46 Seropositive erosive RA One visit only. Still no SSc to date. 056 Mononeuritis multiplex, 
gangrene, sicca syndrome
RM F 59 LcSSc No Progression 059 Sicca syndrome
LO F 72 LcSSc, Erosive polyarthritis No Progression, feeling better. 063
DH F 48 LcSSc LcSSc. Troublesome Raynaud’s 074
PD F 45 LcSSc Developed SSc renal crisis at 66 months 
FU.
075 None
JM F 42 LcSSc LcSSc. Raynaud’s quite severe 079
LP F 42 LcSSc No Progression 082 None
HS F 61 LcSSc No Progression. Chest infections 082 Sicca Syndrome
Con’t.
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DH F 56 LcSSc No Progression 102
PaD F 33 Raynaud’s Ltd. SSc 113
10 F 61 LcSSc, Seropositive erosive RA Ltd. SSc -no progression. Aggressive RA -
MTX
113 SPERA
OA F 52 LcSSc Developed Sicca syndrome 130 PBC, Sicca syndrome
ML F 80 LcSSc Died '95 of MI and pneumonia 134
LD F 72 LcSSc, Erosive RA Severe Raynaud’s; digital ulcers. MTX for 
polyarthritis. LcSSc stable.
144 RA and Sicca syndrome
ACA patients with >4 years follow up (mean 59 months). Details of the initial diagnosis made are shown. Associated and/or other conditions 
regarded as significant have also been noted, and also comments with regard to disease progression or development over the follow up period. The 
majority of patients had an initial diagnosis of lcSSc (68%), and most maintained an overall stable course.
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5.5: DISCUSSION
Autoantibodies directed against the centromere have been reported in a number of 
rheumatic conditions, and the ACA positive population identified in this study 
encompasses many of them. A total of 102 patients, with a median age of 59 years, were 
found to be positive for ACA. All, except two patients, were female. ACA is 
infrequently detected in male patients (194;208). The majority, 72%, of ACA positive 
patients had lcSSc. Previous studies also report the preponderance of lcSSc in ACA 
positive individuals (194;209-211). With the exception of a few reported cases, ACA is 
extremely uncommon in dcSSc patients (194), and in concordance with such reports no 
dcSSc patients were identified in the present ACA patient population. ACA was also 
moderately predictive for arthritis and identified 28% of patients. Overall, ninety-one 
percent of ACA positive patients had a diagnosis of lcSSc and/or a form of arthritis. Of 
note, the arthritis in many of the patients was erosive. Of the remaining patients who did 
not fall into the SSc/arthritis category, two (7%) had Sjogren’s syndrome and one had 
UCTD. This observation lends support to the report by Tubach et al., who in a study of 
ACA positive individuals without Scleroderma or Raynaud’s phenomenon identified 
Sjogren’s syndrome as the most common diagnosis (209).
The results from the longitudinal study suggest that the prevailing impression of ACA 
delineating a subset of SSc patients, which have a stable and mild course, should be 
regarded with some caution. Signs of deterioration or disease progression were apparent 
in as many as seven (28%) patients in the longitudinal study. During the course of 
follow up, one patient (paD), developed lcSSc, following an initial diagnosis of 
Raynaud’s. This example demonstrates the significance of identifying ACA in 
Raynaud’s patients whose disease may be likely to evolve to lcSSc (47;212). The most 
extreme case of deterioration was a patient who developed scleroderma renal crisis, 
culminating irreversible renal failure. The complication occurred suddenly after a 
seemingly stable course of about four years. This observation suggests that even ACA 
positive SSc patients with mild disease should receive regular follow-up. Further, it 
must be appreciated that a minority of ACA positive patients may have unfavourable 
outcome: as is evident in this study, and as others have reported (210;213).
The co-occurrence of lcSSc and a form of arthritis, which was described in three
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patients by Zimmerman et al., was identified in five patients in this study (198). Misra 
et a l suggested that ACA positive patients with both lcSSc and arthritis might represent 
a distinct, unique overlap condition (199). Patients in this study support this hypothesis 
clinically however genetically there were no striking observations. Overall, HLA DR4 
and DR1 were significantly raised in the ACA patient population when compared to the 
normal control population. As mentioned in the main introduction to this thesis, specific 
DR4, and DR1, alleles carry the ‘shared epitope’ motif associated with rheumatoid 
arthritis (73). Only one lcSSc/arthritis patient was HLA DR4 positive, and sub-typing 
revealed an allele that does not bear the mentioned shared epitope (DRB 1*0407). 
However the two remaining patients, from which genetic material was available, both 
possessed alleles which bear the shared epitope, HLA DRB 1*0101-0102. Interestingly, 
in a report describing AT A positive scleroderma-rheumatoid arthritis patients, all 
patients were HLA-DR4 positive, however the study does not detail the precise HLA 
DR4 alleles concerned (214).
Several significant HLA associations were identified in the ACA positive patients. 
Significant differences in allele frequency were observed when the data sets were 
considered individually and some became stronger when the two sets were combined. 
Other significant frequency differences only became apparent when the larger group 
was considered. An increased frequency in HLA DRB 1*0101-0103 in the ACA positive 
patients compared to the controls was observed when the data sets were considered 
separately and when they were combined. HLA DR4 was raised in data sets one and 
two compared to controls, and the difference in frequency became significant when the 
data sets were combined. These observations are in agreement with previous reports, 
which have described an association of ACA with the presence of HLA DR1 or DR4 
(80; 107). A decrease in HLA DRB1 * 1101-1104 was noticed initially in data set 2, and a 
significant trend was seen when the two data sets were combined, and compared to 
controls. In accordance with a report by Morel et al, ACA positive patients 
demonstrated a significant increase in HLA-DQB 1*0501, (in data sets one, two and the 
combined set) (81).
The most striking observation was the prevalence of at least one HLA DRB1*0101- 
0102 and/or DRB 1*0401-0411 allele in the ACA patients. This was evident in nearly 
75% of patients, a significantly greater proportion compared to the control group. The
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increased frequencies of these alleles appeared to be reflected in the frequencies of HLA 
DR7 and DR5, which were significantly decreased in the patients compared to the 
controls. Thus, it may be interpreted from the results that HLA DR1 and/or DR4 may 
confer susceptibility for an ACA immune response in some individuals. HLA 
DQB 1*0501 is in linkage disequilibrium with HLA DR1, which may explain the 
significantly increased frequency observed in this allele.
The presence of at least one HLA DQB1 allele not coding for leucine at position 26 of 
the first domain has been suspected to be a key requirement for the generation of ACA 
(202). As position 26 is located in the floor of the antigen-binding cleft, it will directly 
affect which peptides bind to DQB1. Further, the polarity of the amino acids at this 
position will affect which peptides are preferentially bound. Reveille et al. and McHugh 
et al. reported the absence of leucine at position 26 from at least one allele in 100% of 
ACA positive individuals studied, implying that the presence of at least one polar amino 
acid at this locus is essential for an ACA immune response (122;202), respectively. 
Analysis of this locus in the present study revealed a significant increase in the number 
of patients who possessed at least one allele not coding for leucine (patients 74% vs. 
57.5% controls). However, 26% did not bear a polar residue at this locus and thus 
cannot ‘fully’ support the idea proposed by the aforesaid.
Some studies have been unable to identify such HLA associations (81 ;86), which has 
led them to investigate other loci (81). In accordance with the present study, Morel et al 
identified a positive association of ACA with HLA DQB1*0501, in SSc patients (81). 
This allele was present in 47% of individuals, a comparable figure to the number of 
ACA positive SSc patients positive for this allele in the present study (43%). However, 
as more than 50% of patients were negative for this allele they reasoned that this 
association was not strong, and thus analysed DQB 1*0501 negative patients in order to 
determine whether any other associations were playing a role in this form of the disease. 
Morel et a l went on to identify an increased frequency of the DQB1 amino acid 
sequence TRAELDT (amino acids 71-77) in DQB1*0501 negative, ACA positive SSc 
patients, which was independent of DQB 1*0501 (86). They suggest from their findings 
that SSc with ACA may be further subdivided into two forms, including those patients 
with DQB 1*0501 and those with DQB 1:TRAELDT:71-77 (86). The equivalent analysis 
of the patients included in this study could not support the associations identified by
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Morel et al.
The immunoblotting of ACA positive sera for the identification of CENP specificity 
was, as discussed earlier, incomplete work and therefore largely inconclusive. However 
analysis of immunoblotting data from 39 ACA positive patients, which had been 
generated previously by a final year project student at this institution (Loma Daly), 
showed reactivity to CENPS A, B and C in 28 patients. The remaining patients showed 
reactivity to 2 or less CENPs. HLA analysis did not reveal any associations with regard 
to the CENPs, or combination of CENPs, recognised.
The work in this chapter has identified ACA positive individuals, and investigated the 
clinical and immunogenetic aspects of the patient population. An association of ACA 
has been identified with lcSSc, which may show progression in a small number of 
patients. Identification of ACA also shows a degree of predictability for other rheumatic 
conditions especially arthritis, which has a tendency to be erosive in these individuals. 
The results confirm associations of ACA with HLA DR1 and DR4, however 
associations with specific loci remain modest. Further HLA analysis in larger groups of 
ACA positive SSc patients may reveal additional disease subtypes.
138
CHAPTER 6
INVESTIGATION OF GENES INVOLVED IN FIBROSIS: 
THEIR ASSOCIATION WITH SYSTEMIC SCLEROSIS 
AND SPECIFIC AUTOANTIBODIES
6.1: INTRODUCTION
As discussed in the main introduction to this thesis, the precise aetiology of SSc is 
unknown however there is mounting evidence from genetic studies of associations 
between SSc and polymorphisms in a number of genes that support the hypothesis of a 
genetic contribution to the disease.
Although SSc is a heterogeneous condition the recognised hallmark of the disease is 
fibrosis. As previously discussed in chapter 1, fibrotic lesions of scleroderma result 
from the excess deposition of normal components of connective tissue by a subset of 
activated fibroblasts. As the activated phenotype of the SSc-fibroblast is lost in vitro it 
is considered that local factors are responsible for their original activation (4).
The work in the chapter investigates the genes for proteins implicated in the SSc- 
fibrotic response. Five candidate genes, which are considered key in SSc-fibrosis have 
been investigated; TGFpl, TGFp2, TGFP3, B chain of platelet derived growth factor, 
PDGFB, tissue inhibitor of metalloproteinase-1, TIMP-1 and the a-2 subunit of 
collagen type V, Col5A2.
There is evidence indicating a role for TGFp in fibrosis. TGFp is the primary fibrogenic 
cytokine, activating and stimulating normal fibroblasts to produce connective tissue 
components. This cytokine has three structurally and functionally similar isoforms, 
TGFpl, TGFp2and TGFp3, which in mammals are each encoded for by separate 
genes. Once activated from its latent form, TGFp elicits multiple cellular responses in 
different cell types that are mediated through high affinity receptors. Activated TGFp 
can also associate with TGFp latency-associated peptide, which prevents its biologic 
activity (215). Recent studies have supported the role of TGFp in fibrosis. It has been 
shown that subcutaneous injection of TGFp into animals causes rapid fibrosis at the 
local site (216). An increase in fibroblast collagen synthesis is a recognised response to 
TGFp. Plasma TGFp levels have been reported to be elevated in patients with limited 
and diffuse SSc (217) and all three TGFp isotypes have been reported to be up regulated 
in the inflammatory stage of patients with SSc (218).
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TGFp can induce fibroblasts to produce their own TGFp, in an autocrine fashion, in 
addition to promoting the production of other pro-fibrotic cytokines such as platelet- 
derived growth factor (PDGF). TGFp can also affect the pathways for ECM 
degradation; the factors which degrade ECM (plasminogen activator and MMPs) are 
inhibited by TGFp, whilst those factors which inhibit the activity of degrading 
molecules (plasminogen activator inhibitor and TIMPS) are stimulated (215;219).
Platelet derived growth factor (PDGF) is a 30 KDa protein consisting of two related 
peptide chains, A and B. This potent fibroblast mitogen exists as three isoforms, PDGF 
AA, PDGF BB and PDGF AB, all of which are biologically active. PDGF is stored in 
the a  granules of platelets from which it is released after platelet activation. Other cells 
may also synthesise PDGF including macrophages and endothelial cells. At low 
concentrations PDGF is a chemoattractant for fibroblasts. It is chemotactic and an 
activator for monocytes and neutrophils and a potent modulator for T cell functions. 
(For review see http://www.copewithcytokines.de/cope.cgi7004931).
PDGF has been implicated in the pathogenesis of fibroproliferative disorders. A role for 
the factor in fibrosis is indicated by the impairment of wound healing in the presence of 
antibodies to PDGF (40). The production of collagens and other ECM components may 
be upregulated by PDGF (220). It also enhances the production of IL-6, a profibrotic 
cytokine, from SSc fibroblasts (221).
Tissue inhibitors of metalloproteinase (TIMP) are major regulators of extracellular 
matrix (ECM) synthesis and degradation. TIMP 1, a 28KDa protein, can inactivate 
stomelysin and collagenase activity (222). The mitogenic response of SSc fibroblasts to 
TIMP-1 has been reported as significantly greater than the response seen in normal 
fibroblasts, suggesting an important role for TIMP-1 as an autocrine growth factor in 
the fibrotic response in SSc (222).
The structural composition of the ECM is profoundly altered in affected SSc tissues. 
ECM components such as collagen type V regulate the organisation of ECM. 
Andrikopoulos et al demostrated that a homozygous deletion of the col5A2 gene in 
mice produced skin and eye abnormalities, resembling the typical changes seen in 
human connective tissue disease. They concluded that type V collagen is a key
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determinant in the assembly of tissue-specific matrices (223). In a fibrotic environment 
the balance between cells and the amount of surrounding ECM is disturbed and cellular 
interactions become altered. In comparison to normal fibroblasts scleroderma fibroblasts 
show enhanced adhesion to ECM components, possibly due to increased cellular 
receptors for ECM (224). Changes in the ECM environment of the fibroblast may 
contribute to the enhanced fibrotic response seen in SSc.
It is hypothesised that polymorphisms of genes involved in fibrosis may determine 
susceptibility to SSc. Gene polymorphisms may affect both the function and the level of 
protein production, and polymorphisms in genes involved in fibrosis could result in 
individuals with a predisposition to excessive fibrosis. Given the variation in the extent 
of skin fibrosis in different autoantibody subsets of disease, it is hypothesised that the 
genes involved in fibrosis may be associated with disease subtype. As functional 
polymorphisms for most of these candidate genes have not yet been mapped, 
investigation can only be done by association based analysis. Therefore, a strategy of 
using microsatellite markers that map either within the candidate gene or within a 
distance of one centimorgan (cM) of the gene has been used as described in chapter 2. 
The genes for six proteins involved in the fibrotic response (TGFB1, TGFB2, TGFB3, 
TIMP1, PDGFB and Col5A2) have been investigated in a case-control study using 
microsatellite markers.
A similar investigation, using the same group of patients, was carried out by Susol et al. 
in which, an association of microsatellite markers for TGFp3, TGFp2 and TIMP1 with 
SSc when compared to controls was identified (225). In this study patients were then 
stratified according to limited or diffuse disease. Analysis, by global chi-square with 
Monte-Carlo simulation, revealed a significant difference in allele frequency of the 
TGFP2 marker in lcSSc patients compared to normal controls. The allele frequency 
distribution for the TGFp3 marker was significantly different when dcSSc patients were 
compared to controls and lcSSc patients (110). In the present study patients are 
stratified according to autoantibody positivity. A comparison will be made with the data 
from Susol et al. (stratified according lcSSc/dcSSc) to investigate whether associations 
appear stronger or to be weakened with autoantibody stratification.
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6.2: CHAPTER AIMS
The work in this chapter details an investigation of the polymorphisms of five candidate 
genes for proteins considered key in the SSc-fibrotic response, and their association 
with SSc and SSc autoantibody subgroups, by the use of microsatellite markers. The 
investigation was carried out by means of the following aims:
I. To screen a panel of microsatellite marker for candidate genes that encode 
proteins involved in fibrosis
II. To identify any microsatellite marker allele associations with SSc
III. To identify any microsatellite marker allele associations with specific 
autoantibody in SSc patients
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6.3: MATERIALS AND METHODS
Patients and controls
One hundred and ninety-one, Caucasian, systemic sclerosis patients, from two centres 
were included in the investigation detailed in this chapter. Fifty-one individuals were 
patients of the Royal National Hospital for Rheumatic Diseases in Bath and the 
remaining 140 were enrolled from the Hope Hospital, Salford.
One hundred and ninety-six healthy individuals comprised the control group. Control 
samples were obtained from the Norfolk Family Health Service Authority Register, 
which comprises individuals who had registered with a general practitioner, and from 
blood donors in the Oxford area.
DNA extraction
DNA was extracted from EDTA treated blood samples as described in method 2.2.1. 
Genotyping o f  microsatellite markers fo r  candidate genes
The genes for five proteins involved in the fibrotic response (TGFpi, TGFp2, TGFP3,
PDGFB and COL5A2) were investigated by the use of microsatellite markers according
%
to method 2.2.3. (Details of the microsatellite markers can be seen in table 2.1). 
Autoantibody identification
Immunofluorescence, Ouchterlony double immunodiffusion and immunoprecipitation 
techniques were used to identify serological autoantibodies in all SSc patients, 
according to methods 2.4.2, 2.4.3 and 2.4.4 respectively.
Statistical analysis
Statistical analysis was carried out as previously described (section 2.5). All values have 
been corrected, (Bonferroni correction), to reduce the chance of false positive results 
due to multiple testing of the data.
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6.4: RESULTS
6.4.1: Allele frequency analysis of microsatellite markers in SSc patients
For each microsatellite marker, associations with SSc were investigated by comparing 
allele frequencies of patients with those observed in the normal control population. 
Further analysis was carried out with stratification of patients according to the presence 
of specific autoantibodies. Observed allele frequencies for the microsatellite markers 
corresponding to the candidate genes investigated are shown in tables 6.1 to 6.7. The 
allele frequencies for all SSc cases, SSc cases stratified with regard to specific 
autoantibody and control subjects are detailed.
Microsatellite marker allele frequency comparisons between SSc patients and normal 
controls
The microsatellite marker dlS419, which maps within one cM of TGFp2, was used to 
investigate association of this gene with SSc and TGFp2. A significant increase in the 
frequency of allele 109 was observed in SSc patients compared to controls (p=0.05). 
D14S277, the microsatellite marker associated with the candidate gene TGFP3 was 
significantly decreased in patients compared to controls (p=0.05). Allele 102 of the 
microsatellite marker that maps within PDGFB gene was raised in the SSc population 
when compared to normal controls, however this did not reach significance (p=0.06). 
No significant differences in allele frequencies for the microsatellite markers mapping 
for the other candidate genes investigated showed any significant differences in allele 
frequencies when compared to normal controls.
6.4.2: Allele frequency analysis of microsatellite markers in SSc patients stratified 
according to the presence of specific autoantibodies
Stratification according to the presence o f  specific autoantibodies
The microsatellite markers for the SSc candidate genes of interest have been 
investigated further to identify any association with specific autoantibody. 
Autoantibody specificities for centromere, topoisomerase-I, RNAP III, Jo-1, Pm-Scl, 
Ro, La and U1RNP proteins have been investigated. Anti-U3RNP autoantibody has not
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been considered, as there were not a sufficient number of patients positive for this 
autoantibody for analysis (n=2).
Investigation o f  association o f  the microsatellite marker fo r  PDGFB, (d22S284), with 
specific autoantibody
A significant increase in the frequency of allele 108 was observed in anti-Ro positive 
SSc patients when compared with normal controls (p=0.0065). In the ACA positive 
patients allele 108 was also raised in patients compared to controls, although this did not 
reach significance (p=0.065) (table 6.1).
Investigation o f  the association o f  the microsatellite marker fo r  TGF/32, (dlS419% 
with specific autoantibody
There were no significant differences in allele frequencies observed in any of the SSc 
autoantibody groups compared to normal controls. Allele 114 was raised in ATA 
positive patients and allele 115 was raised in anti-La patients, however these differences 
did not reach significance (p=0.09) (Table 6.2).
Investigation o f  the association o f  the microsatellite marker fo r  COL5A2, (d2S389), 
with specific autoantibody
One significant difference in allele phenotype frequency was identified when marker 
d2S389, which maps to Col5A2 gene, was investigated. Allele 108 was significantly 
raised in ATA positive patients compared to controls (p=0.003) (Table 6.3).
Investigation o f  the association o f  microsatellite marker fo r  PDGFB, (PDGFB), with 
specific autoantibody
The frequency of allele 102 was significantly raised in anti-Pm-Scl positive patients 
compared to controls (p=0.01) (Table 6.4).
Investigation o f  the association o f  microsatellite marker fo r  TGF/33, (dl4S277) with 
specific autoantibody
Anti-La positive patients showed a significant increase in the frequency of allele 107 
compared to controls (p=0.042). No other significant differences were observed in any 
of the other autoantibody groups. However, a slight decrease in allele 106 and increase
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in allele 109 were identified in ARA III positive individuals compared to controls 
(p=0.07, without correction for the number of variables tested) (Table 6.5).
Investigation o f  the association o f  microsatellite marker fo r  TGF/31, (dl9S400) with 
specific autoantibody
The frequency of allele 101 was significantly increased in anti-Ro positive patients 
compared to normal controls (p=0.001). No other alleles, in any of the other 
autoantibody groups showed any significant variation in frequency compared to normal 
controls for this marker (Table 6.6).
Investigation o f  the association o f  microsatellite marker fo r  TIMP1, (dxS426) with 
specific autoantibody, in fem ale patients
The microsatellite marker dxS426 was used to investigate association between SSc and 
TIMP1. This gene maps to the X chromosome and thus the data have been stratified 
according to gender. One hundred and sixty eight patients genotyped for this locus were 
female and 29 were male. Only the female patients have been considered here, as the 
number of men included in the study was too few (Table 6.7). No significant differences 
in allele frequencies of patients compared to controls were observed.
6.4.3: Comparison of previously reported associations of microsatellite marker 
alleles in patients stratified according to cutaneous involvement with patients 
stratified in the present study according to autoantibody status.
In the study by Susol et al., which considered the same group of patients detailed in the 
present study, associations with microsatellite markers TGFP3 and TIMP 1 with SSc 
patients were identified. It was hypothesised that if TGFp3 and TIMP genes were 
involved in determining the degree of fibrosis, then a difference in the frequency of 
allele distribution between lcSSc and dcSSc patients would be expected.
When patients were analysed according to cutaneous involvement, a significant 
difference in the frequency of allele distribution for the microsatellite marker TGFp3 
was identified (p=0.03). Allele 106 was increased in lcSSc patients (lcSSc 18.7% vs. 
8.8% dcSSc). Allele 109 was significantly increased in dcSSc patients (dcSSc 7.5% vs.
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1.7% lcSSc). The results indicate that a gene polymorphism in linkage disequilibrium 
with TGFp3 marker may have a role in determining the disease subtype.
Analysis of the microsatellite marker for TIMP 1 required stratification according to 
gender, as this gene maps to the sex chromosomes. Analysis did not show any 
significant differences in the distribution of allele frequency in female SSc patients. A 
significant difference in allele frequency distribution was identified between male SSc 
cases and controls (p=0.Q3). Allele 108 was found to be positively associated, and allele 
114 negatively associated, with male SSc. It was concluded thus that a gene 
polymorphism within TIMP, which is in linkage disequilibrium with the marker 
DXS426 may exist that predisposes individuals to SSc. Stratification according to lcSSc 
and dcSSc did not show any significant differences in the distribution of allele 
frequency.
It is hypothesised that stratification according to autoantibody positivity may support 
gene associations and possibly define patient groups further. Tables 6.8 and 6.9 are 
direct comparisons of the data from Susol et al, stratified according to dcSSc or lcSSc 
with data from the present study. (Specific alleles of interest, identified from earlier 
analysis have been considered).
It can be seen from table 6.8 that there are similarities in the data from the two studies. 
ACA, as discussed earlier, is associated with lcSSc. The frequency of allele 106 is 
comparable in ACA positive and lcSSc patients (20.4% and 18.7%, respectively 
(controls 25.0%)), despite differences in the size of each population. A similar trend can 
be seen for allele 106 between ARA III positive patients and dcSSc patients (9.4% and 
8.8%, respectively, (controls 25.0%)).
ARA III is often associated with dcSSc. The frequency of allele 109 for the 
microsatellite marker for TGF03 is raised in ARA III positive patients and dcSSc 
patients (9.4% and 7.5%, respectively) compared to controls. Conversely, the frequency 
of this allele in ACA positive patients and lcSSc patients is comparable to the control 
population (2.1% and 1.7%, respectively, compared to 2.3%).
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The results from both studies are supportive of each other. They suggest that allele 106 
for microsatellite marker for TGFp is not associated with dcSSc or ARA III positive 
patients and allele 109 for this marker may render some individuals susceptible to the 
progressive form of SSc. The association with ARA III may also indicate an association 
of the allele with renal disease, a manifestation often associated with this autoantibody.
Table 6.9 shows a similar analysis of three alleles of interest for the microsatellite 
marker for TIMP 1. Significant allele frequency differences identified in the male SSc 
patients were lost on stratification for Ic/dcSSc. Allele 108 was found to be positively 
associated, and allele 114 negatively associated, in the total male SSc group analysed by 
Susol et al.. Allele associations of this kind were not supported when patients were 
stratified according to autoantibody status.
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ATA (n=20) ARA III (n=16) 





Anti-Ro (n=9) Anti-La (n=9) 







101 4(1.0) 3(2.1) 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4(1.0)
102 59 (15.4) 23 (16.0) 9 (22.5) 3 (9.4) 0 (0.0) 3 (16.7) 1 (5.6) 3 (16.7) 1 (6.3) 50(13.0)
103 2(0.5) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5)
104 23 (6.0) 8 (5.6) 3 (7.5) 0 (0.0) 1 (8.3) 2(11.1) 0 (0.0) 1 (5.6) 0 (0.0) 28 (7.2)
105 16 (4.2) 4(2.8) 1 (2.5) 3 (9.4) 1 (8-3) 0 (0.0) 1 (5.6) 1 (5.6) 1 (6.3) 19(5.0)
106 63 (16.4) 19(13.2) 7(17.5) 9(28.1) 4 (33.3) 1 (5.6) 3 (16.7) 4 (22.2) 3(18.8) 52 (13.4)
107 132 (34.6) 45 (31.3) 16(40.0) 13 (40.6) 4 (33.3) 6 (33.3) 7 (38.9) 5 (27.8) 9 (56.3) 164 (42.3)
108 46(12.0) 22(15.3) 2(5.0) 1 (3.1) 0 (0.0) 3 (16.7) ‘6 (33.3) 3 (16.7) 2(12.5) 28 (7.2)
109 27 (7.1) 14 (9.7) 2(5.0) 1 (3.1) 1 (8-3) 3 (16.7) 0 (0.0) 1 (5-6) 0 (0.0) 29 (7.4)
110 4(1.0) 2(1.4) 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 8(2.1)
111 1 (0.3) 1 (0.7) 0 (0.0) • 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
112 5(1.3) 2(1.4) 0 (0.0) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5)
140 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Investigation of association between SSc and PDGFB, using microsatellite marker D22S284 which maps within lcM of PDGFB. Allele 108 was 
significantly raised in anti-Ro positive SSc patients compared to normal controls: p1 =0.0065, with Bonferroni correction, OR=6.4(2.2-18.4).
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Anti-Ro (n=9) Anti-La (n=9) 







102 9(2.4) 5 (3.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 2(12.5) 13 (3.4)
103 1 (0.3) 0 (0.0) 1 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 1 (0.3)
104 10 (2.7) 6(4.2) 0 (0.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 11 (2.8)
105 4(1.1) 0 (0.0) 1 (2.5) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4(1.0)
106 54 (14.3) 15(10.6) 5 (12.5) 2(6.7) 1 (8.3) 7 (38.9) 3 (16.7) 6 (33.3) 3 (18.8) 58(15.0)
107 32 (8.5) 16(11.3) 3 (7.5) 3 (10.0) 0 (0.0) 3 (16.7) 2(11.1) 1 (5.6) 1 (6.3) 20 (5.2)
108 18(4.8) 6(4.2) 1 (2.5) 0 (0.0) 0 (0.0) 1 (5.6) 1 (5.6) 1 (5.6) 1 (6.3) 21(5.4)
109 *11 (3.0) 3(2.1) 0 (0.0) 2 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 1 (0.3)
110 26 (6.9) 8 (5.6) 3 (7.5) 4(13.3) 2(16.7) 0 (0.0) 4 (22.2) 3 (16.7) 2(12.5) 31 (8.0)
111 104 (27.5) 50 (35.2) 10 (25.0) 6 (20.0) 5(41.7) 3 (16.7) 1 (5.6) 1 (5.6) 5(31.3) 129 (33.2)
112 34 (9.0) 14 (9.9) 3 (7.5) 4(13.3) 0 (0.0) 1 (5.6) 3 (16.7) 2(11.1) 0 (0.0) 50(12.8)
113 33 (8.7) 11 (7.8) 6(15.0) 3 (10.0) 1 (8.3) 2(11.1) 2(11.1) 1 (5.6) 0 (0.0) 24 (6.2)
114 19 (5.0) 4(2.8) 5(12.5) 2 (6.7) 1 (8-3) 0 (0.0.) 0 (0.0) 0 (0.0) 0 (0.0) 10 (2.6)
115 12(3.1) 3(2.1) 1 (2.5) 1 (3.3) 2(16.7) 0 (0.0) 2(11.1) 3 (16.7) 0 (0.0) 9 (2.3)
116 8(2.1) 1 (0.7) 1 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4(1.0)
118 1 (0.3) 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
119 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
117 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Investigation of TGFp2 by microsatellite marker D1S419, which maps within 1 cM of this candidate gene. A significant increase in the frequency 
of allele 109 was observed in SSc patients: 1=0.05 with Bonferonni correction.’OR=l 1.6(1.5-90.3).
150







ATA (n=20) ARAIII(n=16) 














101 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 0(0) 0 (0.0) 0 (0.0) 4(1.0)
103 26 (7.0) 11 (7.9) 5 (12.5) 2 (6.3) 0 (0.0) 0 (0.0) 3 (16.7) 3 (16.7) 2(12.5) 26 (6.7)
105 6(1.6) 3(2.1) 0 (0.0) 1(3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 7(1.8)
106 68(18.1) 19(13.6) 7(17.5) 5 (15.6) 3 (25.0) 5 (27.8) 5 (27.8) 6 (33.3) 1 (6.3) 69(17.8)
107 121 (32.2) 48 (34.3) 13 (32.5) 10(31.3) 2 (16.7) 7 (38.9) 5 (27.8) 4 (22.2) 5(31.3) 106 (27.3)
108 5 (0.3) 0 (0.0) *3 (7.5) 0 (0.0) 1 (8.3) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 1 (0.3)
109 2(0.5) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8)
110 4(1.1) 1 (0.7) 1 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 0(0)
111 27 (7.2) 11 (7.9) 2 (5.0) 3 (9.4) 2 (16.7) 0 (0.0) 1 (5.6) 2(11-1) 0 (0.0) 28 (7.2)
112 37 (9.8) 15(10.7) 4(10.0) 2(6.3) 0 (0.0) 1(5.6) 1 (5.6) 1 (5.6) 4 (25.0) 38 (9.8)
113 14 (3.7) 10(7.1) 0 (0.0) 2(6.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 12(3.1)
114 18 (4.8) 6(4.3) 2(5.0) 1 (3.1) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 32 (8.2)
115 43(11.4) 15(10.7) 2 (5.0) 5 (15.6) 1 (8.3) 5 (27.8) 2(11.1) 2(11.1) 1 (6.3) 55 (14.2)
116 4(1.1) 0 (0.0) 1 (2.5) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 7(1.8)
119 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Investigation of candidate gene Col5A2 by the use of microsatellite marker D2S389 which maps wihin lcM of the gene. A significant increase in 
the frequency of allele 108 was observed in ATA positive patients when compared to controls: 1=0.003 with Bonnferoni correction, OR=31.7(3.1- 
309).
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ACA (n=68) ATA (n=20) ARA III (n=16) 
(A=T36) (%) (A=40) (%) (A=32) (%)
Anti-Jo-1 (n=6) 
(A=12) (%)
Anti-Pm-Scl (n=8) Anti-Ro (n=9) Anti-La (n=9) 







101 239(61.3) 93 (68.4) 21 (52.5) 21 (65.6) 7 (58.3) 10 (62.5) 17 (94.4) 13 (72.2) 13 (81.3) 254 (65.1)
102 24 (6.2) 8 (5.9) 2 (5.0) 2(6.3) 0 (0.0) f3 (18.8) 0 (0.0) 0 (0.0) 0 (0.0) 9 (2.3)
103 12(3.1) 4(2.9) 3 (7.5) 1 (3.1) 1 (8-3) 0 (0.0) 1 (5.6) 1 (5.6) 0 (0.0) 13 (3.3)
105 3 (0.8) 1 (0.7) 0 (0.0) 2(6.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8)
106 9 (2.3) 2(1.5) 4(10.0) 1 (3.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (12.5) 12(3.1)
107 65 (16.7) 19(14.0) 7(17.5) 1 (3.1) 2 (16.7) 1 (6.3) 0 (0.0) 4 (22.2) 1 (6.3) 68 (17.4)
108 28 (7.2) 9 (6.6) 2 (5.0) 4(12.5) 2 (16.7) 2(12.5) 0 (0.0) 0 (0.0) 0 (0.0) 30 (7.7)
109 2 (0.5) 0 (0.0) 1 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
120 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0(0)
Investigation of PDGFB using the microsatellite marker pdgfb, which maps with the PDGFB gene. The frequency of allele 102 was significantly 
increased in Pm-Scl: 1=0.01 with Bonfferoni correction, OR=9.8(2.4-40.4).
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AC A (n=71) 
(A=142) (%)
ATA (n=20) ARAIII(n=16) 





Anti-Ro (n=9) Anti-La (n=9) 







102 23 (6.1) 11 (7.7) 3 (7.5) 1 (3.1) 1 (10.0) 1 (5.6) 0 (0.0) 0 (0.0) 1 (6-3) 19 (4.9)
103 19 (5.0) 8 (5.6) 3 (7.5) 1 (3.1) 0 (0.0) 1 (5.5) 1 (5.6) 0 (0.0) 0 (0.0) 23 (5.9)
104 5(1.3) 1 (0.7) 0 (0.0) 2 (6.3) 0 (0.0) 1 (5.6) 1 (5.6) 0 (0.0) 0 (0.0) 4(1.0)
105 19 (5.0) 4(2.8) 1 (5.0) 4(12.5) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 10 (2.6)
106 *63 (16.7) 29 (20.4) 3 (7.5) 3 (9.4) 1 (10.0) 5 (27.8) 1 (5.6) 1 (5.6) 3 (18.8) 98(25.1)
107 165 (43.7) 60 (42.3) 17 (42.5) 13 (40.6) 5 (50.0) 5 (27.8) 10 (55.6) 214 (77.8) 8 (50.0) 158 (40.4)
108 62 (16.4) 23 (16.2) 8 (20.0) 4(12.5) 2 (20.0) 3 (16.7) 4 (22.2) 2(11.1) 2 (12.5) 54(13.8)
109 12 (3.2) 3 (2.1) 3 (7.5) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 9 (2.3)
110 3 (0.8) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 9 (2.3)
111 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0(0)
114 1 (0.3) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5)
115 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
117 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0) 0(0)
120 3 (0.8) 0 (0.0) 1 (5.0) 1 (3.1) 0 (0.0) 0 (0.0) 1 (5.6) 1 (5.6) 0 (0.0) 1 (0.3)
Investigation of TGFp3 by the use of microsatellite marker D14S277 which maps within lcM of the candidate gene. A significant decrease in allele 
frequency was observed in allele 106 in the SSc patient group and a significant increase in allele 107 in anti-La positive patients: p1=0.05 
(OR=0.6(0.4-0.8), p2=0.04 (OR=5.1(1.7-16.0) respectively, with Bonferroni correction.
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ATA (n=20) ARAIII(n=16) 





Anti-Ro (n=9) Anti-La (n=9) 







101 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) *2(11.1) 0 (0.0) 0 (0.0) 1 (0.3)
102 45 (12.0) 21 (14.6) 2 (5.0) 3 (9.4) 3 (25.0) 3 (16.7) 0 (0.0) 1 (5.6) 3 (18.8) 39 (10.2)
103 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
104 13 (3.5) 6(4.2) 1 (2.5) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 11 (2.9)
105 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2(0.5)
106 16 (4.3) 6(4.2) 1 (2.5) 1 (3.1) 0 (0.0) 1 (5.6) 1 (5.6) 1 (5.6) 0 (0.0) 20 (5.2)
108 99 (26.3) 30 (20.8) 14 (35.0) 8 (25.0) 4 (33.3) 4 (22.2) 7 (38.9) 7 (38.9) 3 (18.8) 101 (26.3)
110 56 (14.9) 24 (14.9) 8 (20.0) 5(15.6) 2 (16.7) 4 (22.2) 2(11.1) 2(11.1) 1 (6.3) 48 (12.5)
111 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
112 46 (12.2) 17(10.6) 5 (12.5) 5(15.6) 2(16.7) 0 (0.0) 1 (5.6) 2(11.1) 5(31.3) 60(15.6)
114 62 (16.5) 23 (14.3) 6(15.0) 5 (15.6) 0 (0.0) 3 (16.7) 4 (22.2) 4 (22.2) 2(12.5) 65 (16.9)
115 1 (0.3) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
116 29 (7.7) 11 (6.8) 1 (2.5) 1 (3.1) 1 (8.3) 2(11.1) 0 (0.0) 1 (5.6) 1 (6-3) 28 (7.3)
118 5(1-3) 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0) 1 (5.6) 1 (5.6) 0 (0.0) 0 (0.0) 6(1.5)
120 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2(0.5)
Investigation of association of TGFpl with SSc by the use of microsatellite marker dl9S400. A significant increase in the frequency of allele 101 
was observed in anti-Ro positive patients when compared to controls: 1=0.0015 with Bonferroni correction, OR=47.6(4.1-553.0).
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ACA (n=67) ATA (n=13) ARA III (n=13) Anti-Jo-1 (n=5) 
(A=134) (%) (A=26) (%) (A=26) (%) (A=10)(%)
Pm-Scl (n=8) 
(A=16) (%)
Anti-Ro (n=6) Anti-La (n=7) 







103 1 (0.3) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
104 22 (6.5) 11 (8.2) 3(11.5) 2 (7.7) 0 (0.0) 0 (0.0) 1 (8.3) 1 (7.1) 0 (0.0) 23 (11.5)
105 164 (48.8) 69 (51.5) 12 (46.2) 16(61.5) 7 (70.0) 11 (68.8) 6 (50.0) 8(57.1) 7 (58.3) 109 (54.5)
106 33 (9.8) *13 (9.7) 3 (11.5) 0 (0.0) 1 (10.0) 3(18.8) 2 (16.7) 1 (7.1) 1 (8.3) 15 (7.5)
107 2 (0.6) 0 (0.0) 2 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
108 3 (0.9) 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
109 3 (0.9) 2(1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
110 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
111 2 (0.6) 1 (0.7) 1 (3.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
113 3 (0.9) 0 (0.0) 0 (0.0) 1 (3.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
114 49 (14.6) 21 (15.7) 3(11.5) 2 (7.7) 1 (10.0) 2(12.5) 3 (25.0) 3 (21.4) 2(16.7) 35 (17.5)
115 15 (4.5) 6 (4.5) 1 (3.9) 2 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.1) 0 (0.0) 4(2.0)
116 8 (2.4) 2(1.5) 1 (3.9) 2 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2(16.7) 5 (2.5)
117 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.0)
118 1 (0.3) 0 (0.0) 0 (0.0) 1 (3.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0-5)
119 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
132 0 (0.0) 0 (0.0) 0(0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2(1.0)
Investigation of association between TIMP 1 and SSc by use of the microsatellite marker DXS426, which maps within lcM of this candidate gene. 
TEMP 1 maps to the X chromosome, thus patients and controls have been stratified according to gender and only data from females is shown. No 
significant differences in the allele frequencies of patients compared to controls were identified.
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Table 6,8: A direct comparison o f  the frequencies o f  two alleles o f  the microsatellite 
marker fo r  TGF/33; between patients stratified according to cutaneous classification 
o f  disease, or, A C  A or ARA III positivity.
Allele Data from Susol et al. Data from present study Controls
















106 56(18.7) 7 (8.8) 29 (20.4) 3 (9.4) 98 (25.0)
109 5(1.7) 6 (7.5) 3 (2.1) 3 (9.4) 9 (2.3)
The frequencies of the alleles shown are comparative between ACA positive patients 
and lcSSc patients, and ARA III and dcSSc SSc patients. This supports associations of 
autoantibody with disease subtype, and the association of specific polymorphisms with 
disease subgroups.
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Table 6.9: A direct comparison o f  the frequencies o f  three alleles o f  the microsatellite 
marker fo r  TIM P1; between male and female patients stratified according to 
cutaneous classification o f disease and those who were ACA or ARA III positive
Allele Data from Susol et al. Data from present study Controls
lcSSc dcSSc ACA ARA III
Male [n=16] [ii=ll] [n=5] [n=2] [n=51]
[A-32] [A=22] [A=10] [A=4] [A=102]
(%) (%) (%) (%) (%)
108 3 (9.4) 2(9.1) 1 (10.0) 0 (0.0) 2 (2.0)
114 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0) 24 (23.8)
115 1 (3.1) 0 (0.0) 1 (10.0) 0 (0.0) 6 (5.9)
Female [n=127] [n=29] [n=67] [ii=13] [n= 100]
[A=254] [A=58] [A=l 34] [A=26] [A=200]
(%) (%) (%) (%) (%)
108 3 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
114 47(18.5) 2 (3.4) 21 (15.7) 2 (7.7) 35 (17.5)
115 4(1.6) 5 (8.6) 6(4.5) 2 (7.7) 4 (2.0)
Significant differences in distribution of allele frequency were lost on stratification of 
patients according to limited or diffuse disease. No significant differences in allele 




In this study a range of microsatellite markers have been used to investigate candidate 
genes for SSc. The markers map very close to (<1 cM), (or within), the gene of interest 
and it is anticipated that strong linkage disequilibrium will exist between markers and 
genes, thus association with a microsatellite marker is likely to reflect association with a 
disease polymorphism within the gene sequence. Gene polymorphisms may affect 
protein production and function, thus specific polymorphisms of genes involved in 
fibrosis may leave an individual susceptible to excessive fibrosis. Awad et al 
demonstrated a variation in TGFpi production with genetic polymorphism and 
identified a specific allele associated with increased TGFpl production and pre­
transplant fibrotic pathology (226).
The effects of TGFp are widespread. Although all three isoforms of TGFp can induce 
ECM production, studies have suggested that each isoform may not equally contribute 
to this process. It has been proposed that TGFpl and TGFp2 may have a more central 
role in excess ECM production, causing fibrosis and scar formation, whilst TGFP3 may 
be more involved in the subsequent down-regulation of ECM matrix production, 
possibly by down-regulating TGFpi production (227;228). Thus it has been suggested 
that the high levels of TGFpl, TGFp2 and TGFp3 in SSc skin may indicate that either 
insufficient TGFP3 is being produced or that TGFP3 is not functionally able to down- 
regulate the production/action of TGFpi (110). It is suggested that if the levels or 
functionality of TGFp2 and TGFP3 are altered, due to a particular gene polymorphism, 
leading to excess TGFP2 and reduced TGFbp3 activity, an individual may be 
predisposed to fibrosis (110). The ratio of TGFp isoforms, particularly that of TGFpl 
relative to TGFP3, has been suggested to be a significant factor in reducing scarring and 
fibrosis (227), thus it may be that a particular combination of genetic polymorphisms 
may create an environment that makes individuals susceptible to fibrosis.
A difference in distribution of TGFP3 microsatellite marker alleles between lcSSc and 
dcSSc patients was identified in the study by Susol et al. indicating a possible role for 
TGFP3 in determining the degree of cutaneous fibrosis the patient develops (110). In 
the present study a significant increase in the allele 107, for this marker, was identified
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in anti-La positive SSc patients compared to controls. Susol et a l identified a significant 
increase in the frequency of allele 106 in lcSSc patients compared to dcSSc patients, 
and a significant decrease in the frequency of allele 109 in lcSSc patients compared to 
dcSSc patients, for the microsatellite marker for TGFp3. Interestingly an increase in 
frequency of allele 109, and a decrease in allele 106, was observed in ARA III positive 
patients in this study (although after correction the values no longer reached 
significance). Patients with ARA III have the greatest risk of dcSSc (45), thus an 
increase of allele 109 in ARA III positive patients supports the observation by Susol et 
al of this allele being raised in dcSSc patients. The significant increase of allele 106 in 
lcSSc patients reported by Susol et a l is also supported by the observation of a 
decreased frequency of this allele in patients with ARA III in the present study. 
Defining patients by autoantibody may allow those at risk of developing diffuse 
cutaneous disease to be identified more easily.
The marker for TGFp2 had a significantly different allele frequency distribution in 
lcSSc patients compared with controls in the study by Susol et al. An association with 
this allele was also identified in the present study when SSc patients were compared to 
controls, but not when patients were stratified according to autoantibody. These results 
indicate that the marker for TGFP2 may not be associated with clinical or autoantibody 
subset of disease.
Significant differences in allele frequencies were observed in anti-Ro and anti-Pm-Scl 
positive patients for the markers for PDGFB: D22S284 and pdgfb respectively, in ATA 
patients for Col5A2 and in anti-Ro positive patients for TGFpi. However the numbers 
of individuals in each of these groups were very small and thus their true significance 
remains doubtful, particularly in the absence of any comparative published data.
This study has identified associations of microsatellite markers for TGFp2 and TGFp3, 
which are generally supported by the one published report considering this area (110). 
The results indicate that polymorphisms within TGFp2, TGFp3 may exist that
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predispose individuals to SSc. Increased numbers of patients positive for specific 





The aim of the work detailed in this thesis was to further understanding of the aetio- 
pathogenesis of SSc by; investigating the significance, and pattern, of autoantibody 
production, identifying possible genetic predetermination or restriction of autoantibody 
generation and exploring the relationship of these two factors with disease profile, 
course and outcome.
The pathogenesis of SSc is unknown. However, the presence of particular 
autoantibodies, which are often indicative of clinical expression, disease course, and 
overall severity, are unlikely to play a directly pathogenic role, but are certainly reliable 
markers of, and an invaluable aid to, the diagnosis and prognosis of individual patients. 
The mechanism underlying autoantibody production and the pattern of autoantibodies 
seen in SSc, the occurrence of distinct clinical subgroups, and the apparent associations 
between the two, may be held in an underlying genetic predeterminant. It is this concept 
that has formed the basis of this research.
This study began with an investigation and comparison of the HLA background of a 
group of Caucasian SSc patients, who had been positively identified for either of the 
major serological SSc autoantibodies: ATA or ARA III. ATA, ARA III and ACA (the 
latter autoantibody was considered separately) are regarded as mutually exclusive, a 
phenomenon which has been supported in this study. It was hypothesised that HLA 
associations would become stronger when autoantibody subgroups were considered. 
Results from this study confirm the previously reported association of HLA DR5 with 
ATA. More specifically this association was identified with the HLA DRB1*1101-1104 
alleles, and not HLA DRB1* 1201-1202, which also comprises DR5. An association of 
HLA DQB 1*0301 with ATA was confirmed and an association with HLA-DQB 1*0602 
was identified. Within the ARA III autoantibody group no significant HLA associations 
were found. Fanning et a l also failed to identify any HLA associations in ARA III 
positive SSc patients. Previously reported associations of specific amino acid loci (HLA 
DQB1: Y: 30, DQB1:71TRAELDT77 and DQB1: Y: 26) with ATA were also supported. 
Again such associations were not present in the ARA III positive SSc population.
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T cell proliferative responses of ATA positive SSc patients and normal individuals, to 
topoisomerase I supported those observations reported by Kuwana et a l (85), and also 
the association of HLA DR11 in these individuals. This suggests that HLA DR11 
related alleles might facilitate a T cell driven ATA response. When a genetic model, 
regarding the presence of HLA DQB1: Y: 30 homozygosity in individuals able to 
mount a T cell proliferative responses to topoisomerase I, and an absence or 
heterozygosity for HLA DR4 in those who did not, was applied to the data from this 
study and from Kuwana et als study, it could account for 88% of patients.
In conclusion, work from this part of the study has supported previous HLA DR and 
DQ allele and amino acid loci associations in patients with ATA. These associations are 
not apparent in ARA III positive patients and, thus, it may be concluded that these two 
groups of patients, defined by mutually exclusive autoantibodies, are genetically 
distinct. However, mutual exclusivity of these autoantibody groups could not be 
explained by the genetic analysis carried out. That is not to say that a genetic component 
is not responsible.
Overall, this part of the investigation has identified HLA associations in patients with 
regard to their autoantibody status. These autoantibody associations become stronger 
when particular amino acid loci are considered. The consideration of other loci and 
possibly a combination of loci may strengthen or define associations further. The 
proliferative response of T cells from normal individuals provides evidence that; 
autoreactive T cells are part of the normal immune system repertoire, the response is 
genetically restricted, and also suggests that there is an unidentified factor initiating 
disease.
As discussed in the main introduction to this thesis in order for tolerance to be broken at 
the level of T cells, a general requirement is the presentation of cryptic epitopes of an 
autoantigen. A requirement for this is the provision of a self antigen in an altered 
context, as described by Rosen et al. (44). Topoisomerase I appears to be susceptible to 
cleavage by reactive oxygen species in a metal cation-dependent manner (43). Such 
modification of this protein, which may perhaps be driven by the generation of reactive 
oxygen species as a result of ischaemia reperfusion injury, may result in uniquely
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expressed cryptic epitopes becoming exposed to the immune system initiating a T cell 
driven immune response.
The second part of the study considered ethnic variation in the autoimmune response 
and clinical expression of SSc. It was hypothesised that if HLA is a determinant of 
autoantibody profile, and is associated with disease course and/or outcome, then 
associations would be expected to remain the same independent of race. Of particular 
consideration was whether different HLA frequencies existed in the different ethnic 
groups, and if they did then could these differences explain the variance in autoantibody 
incidence and disease subtype in alternative races. Differences in SSc/HLA associations 
in alternative ethnic populations have previously been acknowledged. In the present 
study overall autoantibody profiles were indeed different between the races and 
supported previous reports. HLA frequencies were also different in each population. 
When HLA associations with autoantibody were investigated, associations were 
identified, and were in accordance with the literature, regardless of racial group. Thus 
overall the difference in the frequency of HLA alleles, serological autoantibody and 
clinical profile were relative within each racial group, and were quite different between 
the two populations. The proposed relationship between these three factors is thus 
supported, as is the hypothesis that HLA plays a significant role in SSc. This study 
provides evidence that HLA background, autoantibody profile and clinical course are 
ethnically variable however associations between these three factors are independent of 
ethnicity. Further, autoantibody mutual exclusivity, which was observed in both races, 
implies that specific processes give rise to a particular autoimmune response that may 
be, at least in part, genetically restricted. Overall, results from this part of the study 
indicate that the autoimmune response is predetermined -  partially genetically and by 
other predisposing factors such as environmental exposure.
This study then went on to consider the autoimmune response directed against the 
centromere proteins. ACA form the third major autoantibody group in SSc, however 
ACA are not specific to SSc. To characterise the autoimmune response to ACA this part 
of the study considered all ACA positive patients identified through a rheumatology 
clinic. In concordance with previous reports ACA was identified in a spectrum of 
rheumatological conditions, where the majority of patients had lcSSc. The dcSSc 
variant was not associated with ACA, and in this particular population was not
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encountered, which also supports current literature. Results from this study found that 
more than 91% of ACA patients, identified through a rheumatological setting, had 
lcSSc and/or a form of arthritis. ACA is generally regarded as a marker for a relatively 
benign disease course, though there is evidence from this study to suggest that for a 
minority of patients this is not the case. Previous associations of ACA with HLA DR1 
and DR4 have been supported and an association with HLA DQB 1*0501 has also been 
identified. In fact HLA DRB 1*0101-0104 and/ or HLA DRB 1*0401-0411 was present 
in 75% of patients suggesting that possession of at least one of these alleles predisposes 
individuals to, but is not an absolute requirement for, the ACA immune response, and 
further that HLA DR1 and/ or DR4 confers susceptibility in some individuals to lcSSc 
and/or RA in particular. Previous associations of amino acids at specific HLA DQB1 
loci could not be supported in this study. It would be interesting to consider amino acid 
loci when patients are stratified according to their reactivity toward the CENP antigens.
Evidence has been provided in this study for an association between polymorphisms of 
genes involved in fibrosis, identified through linkage disequilibrium with a 
polymorphism of the microsatellite marker for die gene of interest. Such associations 
have been identified with markers for TGFP3 and TIMP 1. This implies that 
polymorphisms within these genes may exist that predispose individuals to SSc. An 
association with TGFP3 was supported by the results from the comparative study by 
Susol et al. where the same group of patients were considered, but stratified according 
to disease subtype. Results from the present study support the hypothesis that a 
polymorphism of TGFP3, may have a role in determining whether a patient will have 
limited or diffuse disease. Identifying the association of this polymorphism within the 
ARA III autoantibody group may allow a more precise sub-grouping of patients; thus 
not only allowing determination of the degree of skin involvement but may also indicate 
the risk of internal manifestations and overall disease course. Thus stratification 
according to autoantibody status can support associations observed when patients are 
subgrouped according to disease subtype and may offer a potentially more sensitive tool 
for diagnosis and prognosis.
The present study has identified genetic characteristics, which distinguish autoantibody 
groups identified in SSc. Differences have been identified between the ACA 
autoantibody response, and genetic and clinical characteristics of ATA SSc patients, and
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normal individuals who posses topoisomerase I specific autoreactive T cells. 
Autoantibody and HLA associations are independent of ethnicity; where autoantibody 
frequency alters in each race, according to HLA background.
To define associations of this nature further, more sensitive HLA techniques, which are 
now available, need to be employed. Since the work for this thesis began there have 
been substantial developments in genetic technology. Speed, automation and high 
throughput were not phrases associated with the PCR work carried out at the beginning 
of this project. With the availability of sophisticated genetic technologies there is great 
potential for extensive analysis of the gentetic contribution to SSc. An initial next step 
for this work would be to carry out HLA DPB1 typing. Associations with alleles at this 
locus have recently been emerging with SSc, and further, with SSc autoantibody groups 
(229). Any future work should also undertake the identification of additional candidate 
genes in SSc. Gene expression analysis by subtractive hybridisation techniques could be 
used to identify genes that are specifically expressed in disease tissue compared to 
normal tissue. Comparisons of the expression levels of genes, in different samples could 
be made, using differential display analyses. cDNA microarray technology allows 
simultaneous monitoring of differential expression of many genes at one time. 
Comparisons of gene expression profiles of healthy controls compared to SSc patients 
may reveal genes associated with SSc. Complex disease gene localisation has 
accelerated with single nucleotide polymorphism (SNP) mapping. Identification of 
SNPs occurring within the MHC could further elucidate genetic contribution to the 
disease. Identification of susceptibility genes will enhance understanding of the 
mechanisms of the disease process culminating SSc.
Only when clinical, genetic typing and autoantibody specificities are considered in their 
smallest components will any precise associations existing between them become 
defined. However, it is acknowledged that what these subgroups are exactly is not 
known. Larger patient numbers would increase the statistical power of the analysis 
carried out here. When more intricate autoantibody patterns are considered however, 
with the rarity of SSc, this is indeed a problem. Nevertheless: existing relationships of 
HLA-autoantibody-clinical profile have been supported, further associations defined 
and new ones identified and proposed.
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It is possible that ‘HLA and Autoantibody’ association and ‘clinical profile’ are 
independent consequences of an inciting event such as an environmental trigger of some 
kind, (which, may differ in different cases of SSc). Fanning et a l proposed two 
possibilities regarding the pathogenesis of SSc and trying to explain the mutual 
exclusivity of autoantibodies observed in this disease. Firstly it was suggested that the 
three mutually exclusive autoantibody groups represent three distinct disease entities, 
and second the possibility that these groups have a common origin, which is modified 
by HLA specificity into the serologically defined disease subgroups. Their extensive 
HLA-autoantibody analysis failed to show associations that were strong enough to be 
wholly responsible for the observed mutual exclusivity. Therefore the separate disease 
hypothesis was supported. Along these lines one may consider that in fact both theories 
are important as is represented in figure 7.1.
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A hypothesis for the mechanism of disease pathogenesis in SSc, by which distinct 
disease subgroups are given rise to, where by: Clinical and serological expression of 
disease is dictated primarily by the inciting event and then by genetic restriction; 
potentially giving rise to a number of disease variants. Disease variants may be distinct 
or overlap with those derived from an alternative inciting event and genetic background 
(e.g. A or B, or B:E respectively). Thus variants may be identified by clinical and 
serological expression and genetic background, as described in figure 1.3, and 
represented by the red triangle. The red triangle is representative of the triad hypothesis 




Primers used in the identification of HLA-DRB1 and HLA-DQB1 typing by PCR-SSP 
Primers fo r  amplification o f  HLA-DQB1 alleles
ler Mix 5’-primer 5 sequence3 3’-primer 5 sequence3 Amplified specificities
1 B-5’01 CGGAGCGCGTGCGGGG B-3’01 GCTGTTCCAGTACTCGGCAA DQB1*0501
2 B-5’02 T GCGGGGT GT GACC AGAC B-3’02 TGTTCCAGTACTCGGCGCT DQB1*0502
3 B-5’02 TGCGGGGTGTGACCAGAC B-3’03 GCGGCGTCACCGCCCGA DQB 1*0503
4 B-5’03 GCCATGTGCTACTTCACCAAT B-3’04 CACCGTGTCCAACTCCGCT DQB 1*0601
5 B-5’04 CGTGCGTCTTGTGACCAGAT B-3’05 GCTGTTCCAGTACTCGGCAT DQB 1*0602
6 B-5’05 GGAGCGCGTGCGTCTTGTA B-3’05 GCTGTTCCAGTACTCGGCAT DQB1*0603, DQB1*0608
7 B-5’06 CGT GT ACC AGTTT AAGGGC A B-3’06 GCAGGATCCCGCGGTACC DQB 1*0604
8 B-5’07 GTGCGTCTTGTGAGCAGAAG B-3’07 GCAAGGTCGTGCGGAGGCT DQB 1*0201/0202
9 B-5’08 GACGGAGCGCGTGCGTCT B-3’08 CTGTTCCAGTACTCGGCGG DQB1*0201, DQB1*0302
10 B-5’09 GACGGAGCGCGTGCGTTA B-3’09 AGTACTCGGCGTCAGGCG DQB1*0301, DQB1*0304
11 B-5’08 GACGGAGCGCGTGCGTTA B-3’09 AGTACTCGGCGTCAGGCG DQB 1*0302, DQB1*0303
12 B-5’08 GACGGAGCGCGTGCGTTA B-3’10 CTGTTCCAGTACTCGGCGT DQB 1*0303
13 B-5’10 CACCAACGGGACCGAGCT B-3’11 GGTAGTTGTGTCTGCATACG DQB 1*0401
14 B-5’11 CACCAACGGGACCGAGCG B-3’11 GGTAGTTGTGTCTGCATACG DQB 1*0402
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APPENDIX II
Primers fo r  amplification o f HLA-DRB1 alleles
Primer Mix 5’-primer 5 sequence3 3’-primer
1.1 5,01 TTGTGGCAGCTTAAGTTTGAAT 3’ 15
1.2 5’01 TTGTGGCAGCTTAAGTTTGAAT 3’ 10
15 5’02 TCCTGTGGCAGCCTAAGAG 3’01
16 5’02 TCCTGTGGCAGCCTAAGAG 3’02
03 5’03 TACTTCCATAACCAGGAGGAGA 3’03
17 5’06 GACGGAGCGGGTGCGGTA 3’048
18 5’03 TACTTCCATAACCAGGAGGAGA 3’047
4 5’04 GTTTCTTGGAGCAGGTTAAACA 3’047
3’048
7 5’07 CCTGTGGCAGGGTAAGTATA 3,079
8mod 5’08 AGTACTCTACGGGTGAGTGTT 3’045
3’ 18
09 5’09 GTTTCTTGAAGCAGGATAAGTTT 3’079
10 5’10 CGGTTGCTGGAAAGACGCG 3’047
11 5’05 GTTTCTTGGAGTACTCTACGTC 3’06
12 5’08 AGTACTCTACGGGTGAGTGTT 3’08
13.1 5’03 TACTTCCATAACCAGGAGGAGA 3’ 10
13.2 5’05 GTTTCTTGGAGTACTCTACGTC 3’045
13.3 5’03 TACTTCCATAACCAGGAGGAGA 3’ 17
14.1 5’05 GTTTCTTGGAGTACTCTACGTC 3’ 11
+5’08 AGTACTCTACGGGTGAGTGTT
14.2 5’03 TACTTCCATAACCAGGAGGAGA 3’ 12
















































For 1 lower gel.
Double distilled, filter purified water 12.4ml
Lower gel buffer (1.5M Tris/HCl pH8.8, 0.4%w/v SDS) 7.5ml
Acrylamide (30% (w/v) acrylamide 937.5:1) bisacrylamide) 10.0ml
10% aqueous ammonium persulphate 150.0ul
TEMED 22.5pl
5% acrylamide gel
For 1 upper gel
Double distilled, filter purified water 5.9ml
Upper gel buffer (0.5M Tris/HCl pH6.8, 0.4 w/v SDS) 2.5ml
Acrylamide (30% (w/v) acrylamide (37.5:1) Bisacrylamide) 1.6ml




Clinical, serological and HLA typing data fo r Bath Caucasian patients included in this study.
Scleroderma
Patient ID Diagnosis
skin type (l- 
3) (l+2=Ltd.) Autoantibodies Sex HLA-DRB1* HLA-DQB1* 71 77TRAELDT DQB1:Y:30 DQB1:Y:26 D.O.B
1 SSc, PBC L(2) ACA F 0302,0401 0604,0301/4 N,Y N,Y N,Y 29/09/1933
2 SSc L(l) ACA/ AMA F 05/01/2016
3 SSc D(3) RNAP I, IIO, IIA, III F 21/03/1958
4 SSc L(l) ACA M 27/08/1943
5 SSc L(2) Ro, La, Jo-I, U1RNP +/-sm F 17/07/2014
6 SSc 1(2) Pm-Scl F 1501-1502, 0301 0602, 0201 Y,N Y,N N,N 27/06/2027
7 SSc L(l) Topo-I, RNAP IIO, Jo-I F 0101, 1301-1302 0501,0603/8 N,Y N,N N,N 14/04/2027
8 SSc L(l) ACA F 0101 0501 N,N N,N N,N 06/05/1961
9 SSc L(l) ACA F 25/08/2025
10 SSc L(l) RNAP I, IIO, IIA, III F 0301,0701-0702 0201(H) N,N N,N N,N 22/11/1933
11 SSc L(l) ACA F 1501-1502, 1101-1104 0602, 0301 Y,Y Y,Y N,Y 07/05/2005
12 SSc D(3) RNAP I, IIO, IIA, UI F 27/03/2017
13 SSc L(l) ACA F 24/04/1937
14 SSc L(l) RNAP III F 17/11/2019
15 SSc Topo-I F 1501-1502, 0801-0805 0602, 0301/4 Y,Y Y,Y N,Y 01/09/1944
16 SSc D(3) RNAP I, III
17 SSc, SLE L(l) U1RNP +/-sm F 14/03/1939
18 SSc L(2) Topo-I, Ro 09/01/1925
19 SSc L(l) ACA F 0301,0701-0702 0201,0201 N,N N,N N,N 19/01/1961
20 SSc L Topo-I F 0101-0102,0701-0702 0501,0303 N,Y N,Y N,N 09/01/1934
21 SSc,RA L(l) ACA F 0101,0701-0702 0501,0201 N,N N,N N,N 20/04/1934
22 SSc L(l) ACA F 08/06/2027
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23 SSc D(3) Topo-I F
24 SSc L(l) ACA F
25 SSc, RA L(2) Topo-I F
26 SSc D(3) Jo-I F
27 SSc L(l) ACA F
28 SSc L ACA F
29 SSc L(l) ACA F
30 SSc L(2) U1RNP +/-sm F




33 (Hypothyroidism) L(l) U1RNP +sm F
34 SSc L ACA F
35 SSc L(l) Pos. Unid. F
36 SSc L(l) DCNS, ENA Neg. M
37 SSc L(l) Topo-I, Ro, La
38 SSc, RA L(l) Ro, La, Pm-Scl F
39 SSc L(l) Topo-I F
40 SSc L(l) ACA F
41 SSc L(l) Jo-I F
42 SSc L(l) ACA F
43 SSc, SLE L(l) Jo-I, UlRNP+Sm F
44 SSc L(l) ACA F
45 SSc L(l) Topo-I M
46 SSc L(l) ACA F
47 SSc D(3) Topo-I, RNAP IIO M
48 SSc L(l) ACA F
49 SSc L(i) ACA F
50 SSc L(l) ThRNP F
51 SSc ACA F
52 SSc L(2) Jo-I F
1501-1502,0301 0602,0201 Y,N N,Y N,N 13/11/1935
21/02/1935
0401, ? 0302,0301 Y,Y Y,Y N,Y 12/04/2019
0101-0102, 0301 0501,0201 N,N N,N N,N 15/01/1954
01/07/1936
1302, 0401 0201,0302 N,Y N,Y N,N 19/11/1954
0101,0101 0501,0201 N,N N,N N,N 06/12/2022
0401, 1301 0603/8, 0301 Y,Y N,Y N,Y 05/12/1953
20/02/1949
0101 0501 N,N N,N N,N 03/10/1957
0401-0411, 1301-1302 0603/8, 0301 Y,Y N,Y N,Y
18/03/1947
22/10/2019
0401,0403 0302, 0302 Y,Y Y,Y N,N 23/07/2027




0101, 1201-1202 0501,0301 N,Y N,Y N,Y
22/03/2012
28/12/1943
0404, 1201-1202 0302,0301/4 Y,Y Y,Y N,Y 08/19/25
0401-0411,0101-0102 0501,0302 N,Y N,Y N,N 30/01/1946
0301(H) 0201(H) N,N N,N N,N 19/03/2029
0801-0805,1501-1502 0602 Y,Y Y,Y N,N 02/19/15
0301,0404 0201,0302 N,Y N,Y N,N 26/01/2027
0101,0404 0501,0302 N,Y N,Y N,N 09/04/1931
0301,0301





1501-1502,0701-0702 0602, 0201 Y,N Y,N N,N 16/10/1940
0301,0901 0201,0303 N,Y N,Y N,N 26/12/1951
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53 SSc L(2) La, Pm-Scl F 0301, 1101-1104 0201, 0301/4 N,Y N,Y N,Y 14/04/1956
54 SSc D(3) Topo-I, RNAP IIO 
Nucleolar, ENA Neg, IP-
F 0301,0701-0702 0201,0303 N,Y N,Y N,N 26/08/2022
55 SSc L(2) nothing ID F 0301,0701-0702 0201 N,N N,N N,N 17/11/1951
56 SSc D(3) Topo-I, RNAP IIO, IIA M 0401-0411, 1101-1104 0302, 0301 N,Y Y,Y N,Y 07/08/1961
57 D(3) RNAP I, III
58 SSc L(l) ACA F 0701-0702 0201 N,N N,N N,N 29/10/1940
59 SSc L(l) ACA F 28/01/1937
60 SSc L(2) ACA F 0404,0701-0702 0201,0303 N,Y N,Y N,N 27/05/2013
61 SSc L(l) ACA F 0301,0401-0411 0201,0302/3 N,Y N,Y N,N 12/09/2022
62 SSc L(2) RNAP I, IIO, IIA, III F 13/04/1937
63 Raynauds Raynauds! ACA F 12/01/1931
64 SSc L(l) ACA F 0101-0102,0301 0501,0201 N,N N,N N,N 25/01/1952
65 SSc L( 1) ACA F 0101,0101 0501(H) N,N N,N N,N 23/05/1933
66 SSc L(l) Topo-I, Ro, Jo-I F 1101-1104, 1301-1302 0603/8,0301 Y,Y N,Y N,Y 17/11/2019
67 SSc/ diverticulitis L(l) ACA F 1501-1502, 0401-0411 0602, 0302 Y,Y Y,Y N,N 22/08/2024
68 SSc L(l) Scl-70 by ENA F 0103,0301 0501,0201 N,N N,N N,N 20/06/2010
69 SSc L(2) ACA F 1501, 1502 0601,0602 Y,Y Y,Y Y,N 22/01/2026
70 SSc L(l) ACA F 09/01/2020
71 SSc L(2) Topo-I F 08/05/2020
72 SSc D(3) RNAP I, IIO, IIA, III M 21/12/2020
73 SSc L(l) ACA M 0301, 1101-1104 0201,0301/4 N,Y N,Y N,Y 04/19/27
74 SSc L(2) Topo-I, RNAP IIO F 0901, 1101-1104 0301,030 Y,Y Y,Y Y,Y 02/03/1951
75 SSc L(l) ACA F 1501-1502,0407 0602, 0301/4 Y,Y Y,Y N,Y 02/01/1943
76 SSc L(l) Topo-I, RNAP IIO F 1501-1502,0701-0702 0602, 0201 Y,N Y,N N,N 23/10/2019
77 SSc L(l) ACA F 15/03/1949
78 SSc D(3) RNAP I, IIO, IIA, III
79 SSc L(l) ACA F 23/03/1957
80 SSc L(l) Ro, La F 0101,0301 0501,0201 N,N N,N N,N 28/04/1934
81 SSc, RA L(l) Neg. F 13/11/2026
82 SSc L(l) Topo-I 25/03/2018
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83 SSc L(l) ACA F 0101,0401-0411 0501,0301 N,Y N,Y N,Y 15/01/1933
84 SSc D(3) RNAP I, IIO, IIA, III F 0301,0408 0201,0302 N,Y N,Y N,N 18/03/2019
85 SSc L(l) Ro M 0101,0301 0501,0201 N,N N,N N,N 04/10/2021
86 SSc L(l) ACA F 0403 0302 Y,Y Y,Y N,N 20/02/1931
87 SSc L Topo-I M 31/08/1934
88 SSc L(2) Topo-I, RNAP IIO, nA F 10/01/1938
89 SSc L(2) Pos. Unid. F 0301,0701-0702 0201 N,N N,N N,N 17/09/2020
90 SSc L(2) Ro, La, U3RNP M 0301, 1301 0603/8, 0201 Y,N N,N N,N 22/04/1942
91 SSc D(3) Topo-I, U1RNP+/-Sm F 1501-1502, 1101-1104 0602, 0301 Y,Y Y,Y N,Y 27/06/1942
92 SSc L(l) ACA F 0101,0301 0501,0201 N,N N,N N,N 10/12/2027
93 SSc L(2) Various ANA F 0101,0404 0501,0302 N,Y N,Y N,N 19/02/2024
94 SSc L(l) ACA F 0401-0411,0801-0805 0302,0302 Y,Y Y,Y N,N 08/12/1935
95 SSc D(3) RNAP IIO, Topo-I, Ro F 1101-1104, 1302 0604, 0301/4 Y,Y N,Y N,Y 27/10/1940
96 SSc L(2) Ro, U1RNP Z F 1501-1502,1601-1602 0501,0502 N,N N,N N,N 26/05/1949
97 SSc D(3) RNAP I, IIO, IIA, III F 22/07/1939
98 SSc D(3) RNAP I, III F 0701-0702 0201,0303 N,Y N,Y N,N 21/08/1949
99 Topo-I 0401-0411,0701-0702 0302,0201 Y,N Y,N N,N
100 Topo-I 1501-1502, 1101-1104 0602, 0602 Y,Y Y,Y N,N
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APPENDIX V:
Clinical, serological and HLA typing data fo r  Manchester Caucasian patients included in this study.
Patient ID Aab. Result Consensus. ANA Pattern Sex Disease Subtype HLA-DRB1* HLA-DQB1*
SO-112 RNAP I, II, III F. Sp. NS F dcSSc 0301,04 0302,0301
SO-230 ACA ACA F lcSSc 0101, 13 0301,05031
TO-181 ACA ACA M lcSSc 0701, 1301-1302 0301,0201/0202
MP-6 La F. Sp. NS F dcSSc 0701, 13 0201/2, 0604
MP-245 Jo-1 Wk. F. Sp. M lcSSc 0401,0402 0301,0302
MP-191 ACA ACA F lcSSc 0101,0301 0201/2, 0501
BP-210 RoLa DCNS F lcSSc 0901, 13 0604, 03032
BS-141 Positive Unid. DCNS F lcSSc 01, 1201 0301,0501
BS-232 Pm-Scl Nucleolar, F. Sp. M lcSSc 0301, 04 0201/2, 0302
PP-162 Neg. C. Sp. Nucleolar F lcSSc 1001, 11 0301,0501
VP-106 Jo-1 Discrete cytoplasmic sp. F lcSSc 0301, 15 0201/2, 0603
RR-203 Pm-Scl F. Sp. Nucleolar F lcSSc NT NT
JR-85 Topo-I F. Sp. Nuclolar Sp. F dcSSc 15, 15 0602, 0602
JR-5 ACA ACA F lcSSc ND ND
JR-61 ACA ACA F lcSSc 0401, 13 0604, 0301
GR-183 Neg. 2-3 bright nuclear dots F lcSSc 01,03 0501,0603
WS-221 ACA & Positive Unid. ACA & discrete cytoplasmic speckle F lcSSc 0801, 13 0402, 0604
LS-186 Ro, La DCNS F lcSSc 0301, 1102 0201/2, 0301
PR-143 RNAP I,III F. Sp. NS F dcSSc 04, 15 0302, 0602
MS-231 ACA ACA F lcSSc 04, 15 0402, 0602
GT-219 Neg. C. Sp. Nucleolar M lcSSc 13, 15 0602, 0603
IW-52 Positive Unid. Cytoplasmic Sp. Discrete C. Sp. In nucleolus F lcSSc 15,0101/02/04 0602, 0501





























AH-188 RNAP I, II, III
AB-26 ACA









F. Sp. NS 
ACA
3-4 patches of tiny dots. 
Cytoplasmic Sp.
DCNS 
C. Sp. NS 
Wk. F. Sp. (Neg)
A mess, failed.
ACA 
F. Sp. NS 
DCNS 
ACA









F lcSSc 0301,04 0201/2, 0302
F lcSSc 0101,04 0301,0501
F lcSSc 04, 11 0301,0302
F lcSSc 0310, 0801 0201/2, 0402
F lcSSc 0301, 14 0201/2, 05013
F lcSSc 0701,04 0201/0202, 03032/0302
F dcSSc ND ND
F lcSSc 0701, 1301/1302 0201/0202, 0201/0202
M dcSSc 0101/0102/0104, 0301 0501,0201/0202
F lcSSc 15, 0301 0602, 0201/0202
F lcSSc 04, 14 05031,03
F lcSSc 0402, 0404 0302,0302




F lcSSc 09/1413/1417 0301,0201/0202
M dcSSc 0101, 15 0501, 0602
F lcSSc 0301,0701 0201/2, 03032
F lcSSc 0101,0701 0501, 0201/2
F lcSSc NT 0301,0302
F dcSSc 0301,0701 0201/2, 0201/2
F lcSSc 0301,0401 0201/2, 0301
F lcSSc 1001, 1101 0301,0501
M lcSSc 0101, 11 0301,0501
F lcSSc 15, 04 0302,0602
F lcSSc 15, 11 0301,0602
F dcSSc 0701,0701 0201/2, 03032
F dcSSc 0103,15 0301,0602
F lcSSc 0101,0301 0201/2, 0501
M dcSSc 0403, 0404 0302, 0304
F lcSSc NT NT
MC-27 ACA ACA
BD-272 RNAP I, Ilwk, III Clumpy Nucleolar, discrete cytoplasmic dots.
JF-87 Pm-Scl F. Sp. Nucleolar
MG-267 Positive Unid. Homogeneous.
FC-204 ACA ACA
KM-220 U1RNP DCNS
JM-177 ACA ACA (wk)
AC-137 ACA ACA







SM-70 RNAP II, Topo-I F. Sp. Nucleolar
Failed sample (Hint of Pm-scl
AF-202 but not confirmed) F. Sp
SB-25 ACA ACA
JC-268 ACA ACA
MD-43 RNAP I, II, III F. Sp. Nucleolar
PF-263 Neg. (wk) F. Sp. Nucleolar
GG-265 ACA ACA
Failed sample (Hint of Pm-scl
GH-247 but not confirmed) Neg
CK-129 RNAP I, Ilwk, III F. Sp.
MM-217 RNAP I, III F. Sp.
AG-179 Positve Unid. Clumpy Nucleolar & C. Cytoplasmic Sp.




F lcSSc 15, 0301 0602, 0201/0202
F dcSSc 0101,0301 0501,0201/2
F lcSSc 0301,13 0201/2, 0604
F lcSSc 0701,04 0302, 03032
F lcSSc 11, 13 0301,0604
M lcSSc 0301,0401 0201/2, 0301
F dcSSc NT 0301,0301
F lcSSc 0101,04 0302,0501
M dcSSc 0301, 11 0201/2, 0301
F lcSSc 0102,0401 0501,0302
F lcSSc 0301,0401 0201/2, 0302
M lcSSc 0101,0301 0201/2, 0501
F lcSSc 0801,1101 0301,0402
F lcSSc 0101,0101 0501,0501
F dcSSc 0801, 13 0402, 0604
F lcSSc 0101, 1104 0301,0501
F lcSSc NT NT
F lcSSc 04,04 0301,0301
F lcSSc 0701, 15 0201/2, 0602
F dcSSc 0101, 1301 0501,0603
F lcSSc 15,0701 0602, 0201/0202
F lcSSc 0101,0801 0402, 0501
F lcSSc 15, 0301 0201/2, 0602
F dcSSc 0103,0103 0501,0501
F lcSSc 0101,0701 0201/2, 0501
F lcSSc 15,0401 0302, 0602
M lcSSc 04, 04 0301,0302
F lcSSc 0301,0701 0201/2, 0201/2
F lcSSc 0101/0102/0104, 0501,0302/03031/03032
KG-145 Topo-I Homozygous
JH-28 Multiple Unid. Bands F. Sp. Wk Nucleolar
BK-110 Neg. Neg.
LM-97 Neg. Neg.
JB-78 Topo-I F. Sp. Nucleolar
CB-89 ACA ACA
DC-196 ACA ACA
VE-36 RNAP I,II,in C. Sp. NS
HF-269 wkUlRNP DCNS
PH-46 Positive Unid. C. Cytoplasmic Sp.
JH-136 ACA ACA, F. Sp.
ML-211 Positive Unid. Neg.
AM-86 wk. Unidentified Neg.
BB-132 RNAP I, II, III Clumpy Nucleolar
BC-256 Ro, La, U3RNP Clumpy Nucleolar
JB-233 U1RNP DCNS
ME-190 Topo-I Strong F. Sp.
SF-74 ACA ACA
GH-228 U1RNP DCNS
PH-240 ACA (wk) Wk ACA
BL-21 " ACA ACA
JM-175 RNAP I, Ilwk, III Wk DCNS











M dcSSc 11, 1103 0301,0301
M dcSSc NT NT
F lcSSc 13, 14 05031,0604
M dcSSc 04, 1301/1302 0301,0301
F lcSSc 0102, 0401 0302,0501
F lcSSc 0101, 15 0501,0602
F dcSSc 11, 14 0301,05031
F lcSSc 0301,0401 0201/2, 0302
F lcSSc 04, 03
0201/0202,
0302/03031/03032
F lcSSc 0103,13 0501,0605
F dcSSc 0301,0701 0201/2, 03032
M lcSSc 04, 04 0301,0302
F lcSSc 0301,071 0201/2, 0201/2
F lcSSc 0301,0801 0402, 0201
F lcSSc 0101,0401 0302, 0501
F dcSSc 0101,0701 0501,03032
F lcSSc 01011/0102/0104, 04 0501,0301
M lcSSc 0301-0302, 0303 0201/0202, 0201/0202
F lcSSc 0103,0701 0501,0201/0202
M lcSSc 04,0301 0301,0201/0202
F dcSSc 0103, 15 0602, 0301
F lcSSc 0301, 15 0201/2, 0603
F dcSSc 0301, 13 0201/2, 0604
F lcSSc NT 0302, 0501
F lcSSc 0101, 13 0501,0603
F dcSSc 04, 1103 0301, 0302



























































F dcSSc 0103, 11 0301,0301
F SSc 0301, 04 0201/2, 0302
F lcSSc nt 0301,0302
F lcSSc 0301,04 0201/2, 0302
M lcSSc NT 0603,0604
M dcSSc 15,0101/0102/0104 0602, 0501
F lcSSc 0101/0102/0104, 03 0501,0201/0202
F lcSSc 0701,0301 0201/2, 0201/2
F lcSSc 0701,01 0501,0201/0202
F lcSSc 04, 13 0302,0603
M dcSSc 04, 08 0402, 03
F dcSSc 0301,0301 0201/0202, 0201/0202
F dcSSc 2(DR15), 2(DR16) 0602, 06011/06012
M dcSSc 0101, 15 0501,0602
F lcSSc 0301, 04 0201/2, 0302




F lcSSc 18 0602, 0302/03032
F lcSSc 15, 0301 0602, 0201/0202
F lcSSc 0301,0701 0201/2, 0201/2
APPENDIX VI:
Clinical, serological and genetic data fo r  South African Black SSc patients included in this study
Patient Disease Indirect
ID Sex Age Subtype PF Aab Result Consensus Ouchterlony Im munofluorescence HLA DRB1* HLA DQBl*
D2 F 49 dcSSc N Positive Unidentified No Line Homozygous 1102, 1302 0311/12/04
D3 F 47 lcSSc N Positive Unidentified 
Wk. Positive unidentified,
Not Ro or La F.Sp. V.Wk 1/40 1101, 1301 0604-9/12, 0603/14
D4 M 38 lcSSc Y (possible V. Wk.UlRNP) 
Wk. Positive unidentified,
No Line DCNS 1001, 1501 0501-0504,0602/10/11
D5 F 54 lcSSc N (possible V. Wk.UlRNP) No Line DCNS 0301, 1102 0201-0203,0201-0203
D8 F 50 lcSSc N U3RNP F. Sp. & Sp. Nucleolar 1101,1101 0602/10/11,0602/10/11
D9 F 17 dcSSc N Negative Wk. Homozygous 0302, 0302 0401-0402, 0401-0402
D ll F 26 lcSSc N Ro F. Sp. 1/40 0301, 1001 0201-0203,0501-0504
D13 F ACA ACA 07, 1301 0201-0203, 0603/4
D14 F 40 dcSSc N ACA ACA 1302, 1501 0602-4/ 9-12/ 14 (H)
D15 F 43 dcSSc N U3RNP & Positive Unidentified No Line Nucleolar Clumpy 1101,1201 03011/12/04, 0501-0504
D16 F U3RNP Nucleolar Clumpy 1101, 1301 03011/12/04, 0603/4
D17 F 42 dcSSc N RNAP I, III & Ro Ro F. Sp. & Nucleolar Clumpy 0302, 1501 0401-0402, 0602/10/11
D18 F 48 lcSSc N ACA ACA 1301, 1301 0602-4/ 9-12/ 14(H)
D19 F 38 dcSSc Y Topo-I Topo-I F. Sp 1101, 1101 03011/12/04, 0602/10/11
D21 F 47 lcSSc N Positive Unidentified F. Sp. NS 0302,1301 0401-0402,0604-9/12
D22 Ro, La DCNS 08, 1501 0311/12/04,0602/10/11
D23 F 28 dcSSc Y Ro Ro
U1RNP, Ro,
DCNS 0302,1501 0401-0402, 0602/10/11
D25 F 37 lcSSc N Ro, La, U1RNP (Blot: La, U1RNP) DCNS 0301, 1001 0201-0203,0501-0504
D26 F 42 lcSSc N Positive Unidentified No Line DCNS 0301,07 0201-0203,0201-0203
D28 F 50 dcSSc Y Topo-I Topo-I F. Sp & Nucleolar 0302, 1201 0401-0402, 0501-0504
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D29 F 47 dcSSc N ACA & Positive Unidentified
D31 F 37 dcSSc N Weak Positive Unidentified
D32 M 40 dcSSc N Ro, La, U1RNP, Topo-I
D33 F 66 lcSSc N U1RNP +/-sm U1RNP
D34 M 44 lcSSc N Ro, U1RNP +/-sm Ro
D35 F 40 dcSSc N U3RNP & Positive Unidentified Pos. unid
D37 F 31 lcSSc N Negative
D38 F 59 dcSSc Y Positive unidentified Pm-Scl
D39 F 54 dcSSc N Ro, La Not Jo-1
D40 F 33 dcSSc N Positive Unidentified No Line
D41 M 47 dcSSc N Positive Unidentified
D42 F 58 lcSSc N U3RNP
D43 F 33 lcSSc N Topo-I V. Wk pos. (unid
D44 F 18 dcSSc N Topo-I Topo-I
D45 F 39 dcSSc N Negative
D47 F 46 dcSSc N RNAP Ho, Topo-I
D48 F 63 dcSSc N RNAP I, III
D49 F 32 dcSSc N Weak Positive Unidentified No Line
V. Wk. U1RNP +/-sm & V. Wk. U1RNP&
D51 F 41 dcSSc Strong Unidentified postitive. strong unid.
D52 F 40 dcSSc N U1RNP +/-sm U1RNP
D53 F 37 dcSSc N U1RNP +/-sm U1RNP
D54 F 36 lcSSc U3RNP
D56 F 55 dcSSc N U3RNP
D57 F 54 dcSSc N U1RNP +/-sm Possible U1RNP
D58 M 38 dcSSc U3RNP
181
ACA & F. Sp. 0102/4, 0102/4 0501-0504, 0501-0504
Wk. F. Sp. NS 1102, 1301 0311/12/04, 0602/10/11
DCNS 07, 1301 0401-0402, 0602/10/11
DCNS 0302,1501 0401-0402, 0602/10/11
F. Sp. & Cytoplasmic Sp. &
Cytoskeletal & Nuclear Rim 0301,07 0201-0203, 0201-0203
Nucleolar Clumpy 04, 1301 0401-0402, 0603/4
Wk. F. Sp. & Wk.
Cytoplasmic 0102/4, 1501 0501-0504, 0602/10/11
Nucleolar Clumpy 1201,0302 0401-0402, 0501-0504
F. Sp. NS 04, 1302 0401-0402, 0604-9/12
Nucleolar Clumpy 08, 1301 0311/12/04, 0501-0504
F. Sp. 0102/4, 1301 0501-0504, 0604-9/12
F. Sp. 1201, 1301 0501-0504, 0603/14
Nucleolar & Discrete
Nuclear Sp. 1001, 1501 0501-0504, 0602/10/11
F. Sp. 1301, 1501 0602-4/ 9-12/ 14 (H)
Nucleolar & Discrete Sp. 1102,1501 03011/12/04, 0602/10/11
F. Sp. 1301, 1501 0602-4/ 9-12/ 14
F. Sp Nucleolar & F. Sp. 1101, 1301 03011/12/04 0604-9/12
Nucleolar.
Cytoplasmic & Nucleolar. 0301,0301 0201-0203, 0201-0203
F. Sp. & Nucleolar 0102/4 1201 0501-0504, 0501-0504






HLA-DKB1 * and HLA-DQB1 * typing data fo r  250 British Caucasian normal controls, with reference o f  amino acids at specific loci considered 
in this work.
ID Number HLA-DRB1* HLA-DQB1* HLA-DQB1:71TRAEDLT77 HLA-DQB1:30: Y? HLA-DQB1:26 HLA-DQB1:26: Y?
1 0101,0701-0702 0201,0501 N, N N/N L,G N,N
2 0301, 1401/1404-1405 0503, 0201 N, N N/N G,L N,N
3 0401, 1301-1302 0603/8, 0302 Y,Y N/Y L,L N,N
4 0301,1501-1502 0602, 0201 Y, N Y/N L,L N,N
5 1501-1502,1101-1104 0602, 0301/4 Y,Y Y/Y L,T N,Y
6 0301,0701-0702 0201(H) N,N N/N L,L N,N
7 0102 (H) 0501 (H) N, N N/N G,G N,N
8 0101,0901 0501,0303 N, Y N/Y G,L N,N
9 1501-1502, 0301 0602,0201 Y, N Y/N L,L N,N
10 0301,0401 0201,0301/4 N, Y N/Y L,T N,Y
11 1501-1502, 0401 0602, 0301/4 Y,Y Y/Y L,T N,Y
12 0401,0407 0301/4 (H) Y,Y Y/Y T,T Y,Y
13 0301,0403 0201,0301/4 N, Y N/Y L,T N,Y
14 1501-1502, 0701-0702 0602,0201 Y,N Y/N L,L N,N
15 0801-0805, 1101-1104 0301/4 (H) Y, Y Y/Y T,T Y,Y
16 0301,0701-0702 0201 (H) N, N N/N L,L N,N
17 0401, 1302 0604, 0301/4 Y,Y N/Y L,T N,Y
18 1501-1502,0401 0602, 0301/4 Y,Y Y/Y L,T N,Y
19 0401,0701-0702 0302,0303 Y,Y Y/Y L,L N,N
20 0801-0805,0901 0601,0303 Y,Y Y/Y T,L Y,Y
21 1601-1602, 0701-0702 0502, 0201 N, N N/N G,L N,N
22 1501-1502, 0701-0702 0602,0201 Y, N Y/N L,L N,N
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23 0401,0701-0702 0201, 0301/4 N, Y
24 0102,1501-1502 0501,0502 N, N
25 1601-1602, 0401 0502, 0301/4 N, Y
26 1302,0404 0602, 0302 Y,Y
27 1501-1502 (H) 0602(H) Y,Y
28 1501-1502, 0401 0602,0302 Y, Y
29 0101, 1101-1104 0501,0301/4 N, Y
30 1501-1502, 0701-0702 0601,0303 Y, Y
31 0701-0702, 1302 0604,0303 Y, Y
32 1302 (H) 0604(H) Y,Y
33 1101-1104 (H) 0601,0301/4 Y, Y
34 0407, 0301 0201, 0301/4 N, Y
35 1601-1602, 0801-0805 0502, 0402 N, N
36 0404, 1301-1302 0603/8, 0302 Y,Y
37 0301(H) 0201 (H) N, N
38 0101, 1302 0501, 0604 N, Y
39 0404, 1302 0604, 0302 Y,Y
40 1501-1502, 1101-1104 0602, 0301/4 Y,Y
41 1501-1502, 1301-1302 0602,0603/8 Y,Y
42 1401/4/5, 0701-0702 0201,0503 N, N
43 1501-1502, 1303-1304 0602,0301/4 Y,Y
44 0801-0805 (H) 0402 (H) N, N
45 0101,0701-0702 0501,0303 N, Y
46 0101,0301 0501,0201 N, N
47 0701-0702,0404 0201,0302 N, Y
48 0701-0702 (H) 0303(H) Y,Y
49 1501-1502, 0301 0602, 0201 Y, N
50 0701-0702, 1301-1302 0303, 0603/8 Y,Y
51 1501-1502, 1302 0602, 0604 Y,Y
52 1501-1502, 1302 0602, 0604 Y,Y

































54 1501-1502, 1302 0602 (H) Y,Y
55 0401,0901 0301/4, 0303 Y, Y
56 0301, 1101-1104 0201,0301/4 N, Y
57 1501-1502,0301 0602, 0201 Y, N
58 0701-0702, 1001 0501,0201 N, N
59 1501-1502, 0301 0602 (H) Y,Y
60 0301, 1302 0201,0302 N, Y
61 0301,0801-0805 0201,0402 N, N
62 0101,1101-1104 0501,0301/4 N, Y
63 0301,0101 0502,0201 N, N
64 0301 (H) 0201(H) N, N
65 1501-1502, 1302 0602,0604 Y,Y
66 0701-0702, 1302 0604, 0201 Y, N
67 1302, 0801 0604, 0402 Y, N
68 0701-0702, 1302 0303,0604 Y, Y
69 1501-1502, 0407 0602, 0301/4 Y, Y
70 1501-1502,0405 0602,0201 Y, N
71 0401,0701-0702 0303,0302 Y,Y
72 0401,0801-0805 0301/4, 0402 Y, N
73 0101,0701-0702 0501,0201 N, N
74 0404, 1101-1104 0301/4, 0302 Y,Y
75 0101, 1301 0501,0603/8 N, Y
76 0701-0702 (H) 0603/8, 0303 Y, Y
77 0101 (H) 0501(H) N, N
78 0401,0301 0201,0302 N, Y
79 0401, 1101-1104 0301/4 (H) Y, Y
80 1101-1104, 1302 0604, 0301/4 Y, Y
81 1301 (H) 0603/8 (H) Y,Y
82 0301 (H) 0201(H) N, N
83 1501-1502, 1101-1104 0602,0301/4 Y, Y

































85 0408, 1101-1104 0301/4 (H) Y,Y
86 0101,0301 0501,0201 N, N
87 0101,0401 0501,0301/4 N, Y
88 0701-0702, 0301 0201(H) N, N
89 0401,1302 0604, 0302 Y,Y
90 0407, 0701-0702 0201,0301/4 N, Y
91 0401,0701-0702 0302, 0201 Y, N
92 0401(H) 0302 (H) Y, Y
93 0101, 1101-1104 0501,0301/4 N, Y
94 0101, 1101-1104 0501,0301/4 N, Y
95 1501-1502, 0301 0602, 0201 Y, N
96 0404 (H) 0302 (H) Y, Y
97 0101, 1201-1202 0501, 0301/4 N, Y
98 0401, 1302 0604, 0302 Y,Y
99 1501-1502 (H) 0602 (H) Y, Y
100 0301, 1101-1104 0201,0301/4 N, Y
101 0401 (H) 0301/4 (H) Y, Y
102 0701-0702 (H) 0602, 0302 Y, Y
103 0404, 1302 0604, 0302 Y,Y
104 1501-1502, 0701-0702 0602,0303 Y, Y
105 0101, 1301-1302 0501,0603/8 N, Y
106 0701-0702, 0401 0301/4, 0303 Y,Y
107 0101,0301 0201,0501 N, N
108 0408, 1501-1502 0602, 0301/4 Y,Y
109 0701-0702 (H) 0201(H) N, N
110 0404, 1101-1104 0301/4, 0302 Y, Y
111 0101, 1101-1104 0501,0301/4 N, Y
112 0101, 1301-1302 0603/8, 0501 Y, N
113 1501-1502, 0701-0702 0602, 0201 Y, N
114 1501-1502, 0301 0602, 0201 Y, N

































116 0801-0805,1201-1202 0602,0301/4 Y, Y
117 1501-1502, 1301 0602, 0603/8 Y, Y
118 1501-1502, 0701-0702 0303,0602 Y, Y
119 1501-1502,1101-1104 0602, 0303 Y, Y
120 0701-0702 (H) 0302,0201 Y, N
121 0701-0702 (H) 0201(H) N, N
122 1501-1502, 1301 0602, 0603/8 Y,Y
123 1101-1104, 1303-1304 0301/4 (H) Y, Y
124 0101 (H) 0501(H) N, N
125 1501-1502, 0301 0602, 0201 Y, N
126 1501-1502, 0301 0603/8, 0201 Y, N
127 0101, 1301-1302 0201,0302 N, Y
128 0404(H) 0302, 0301/4 Y, Y
129 0301, 1101-1104 0201,0301/4 N, Y
130 0701-0702, 1101-1104 0301/4, 0303 Y, Y
131 0701-0702, 0401 0303,0302 Y,Y
132 0101,0401 0501,0302 N, Y
133 0101,0401 0501,0301/4 N, Y
134 1301,0404 0603/8, 0302 Y,Y
135 0404(H) 0301/4, 0302 Y, Y
136 1501-1502, 0301-0302 0602,0201 Y, N
137 1501-1502 (H) 0602(H) Y, Y
138 0401, 1501-1502 0604, 0301/4 Y, Y
139 0401,0404 0302, 0301/4 Y,Y
140 0701-0702, 1101-1104 0301/4, 0303 Y, Y
141 1101-1104, 1201-1202 0301/4 (H) Y,Y
142 0101, 1302 0501,0604 N, Y
143 0101,0701-0702 0501,0201 N, N
144 0301,0402 0201, 0302 N, Y
145 1302,1101-1104 0604, 0301/4 Y,Y
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178 1101-1104, 0401 0301/4 (H) Y,Y
179 0701-0702 (H) 0201(H) N, N
180 0301, 1101-1104 0201,0301/4 N, Y
181 1501-1502, 1101-1104 0602, 0301/4 Y,Y
182 1101-1102, 0701-0702 0301/4, 0303 Y, Y
183 1101-1104, 0404 0302, 0301/4 Y, Y
184 0404, 0301 0201,0302 N, Y
185 1101-1104, 1201-1202 0301/4 (H) Y, Y
186 0301(H) 0201 (H) N, N
187 0103,1501-1502 0501,0602 N, Y
188 0301(H) 0201 (H) N, N
189 0401, 1501-1502 0602, 0302 Y, Y
190 1501-1502, 0301 0201,0602 N, Y
191 0701-0702, 1101-1104 0201,0301/4 N, Y
192 0401,0801-0805 0301/4, 0402 Y, N
193 0301,0402 0302, 0201 Y, N
194 1501-1502, 1001 0501,0602 N, Y
195 0401,0701-0702 0303,0301/4 Y,Y
196 0401, 1301-1302 0603/8, 0301/4 Y, Y
197 0701-0702, 1101-1104 0303,0301/4 Y, Y
198 0401,0701-0702 0201,0301/4 N, Y
199 1501-1502, 1101-1104 0602, 0301/4 Y,Y
200 0701-0702, 0408 0301/4, 0303 Y,Y
201 0101,0301 0201,0501 N, N
202 0407, 0401 0302, 0301/4 Y,Y
203 0101, 1401/4/5 0503,0501 N, N
204 0401,1401/4/5 0301/4, 0503 Y,N
205 1501-1502, 0801-0805 0402, 0602 N, Y
206 1501-1502 (H) 0603/8, 0602 Y,Y
207 0407, 1601-1602 0502, 0301/4 N, Y

































209 0103,1501-1502 0602, 0301/4 Y,Y
210 0301, 1302 0201, 0603/8 N, Y
211 0401,0101 0501,0301/4 N, Y
212 0701-0702, 1201-1202 0301/4, 0303 Y,Y
213 1501-1502, 1101-1104 0602, 0301/4 Y,Y
214 0404,0101 0501,0302 N, Y
215 0102, 1201-1202 0501,0301/4 N, Y
216 0301, 1302 0604, 0201 Y, N
217 0401(H) 0301/4 (H) Y,Y
218 1501-1502, 0404 0302, 0602 Y,Y
219 0404, 1101-1104 0302, 0301/4 Y,Y
220 0101, 1101-1104 0501, 0301/4 N, Y
221 1501-1502 (H) 0602 (H) Y,Y
222 0404(H) 0302 (H) Y,Y
223 0701-0702 (H) 0201 (H) N, N
224 1501-1502, 0701-0702 0201, 0602 N, Y
225 0401, 1301 0603/8, 0301/4 Y,Y
226 1501-1502 (H) 0602 (H) Y,Y
227 0101,0701-0702 0501,0303 N, Y
228 1302, 1101-1104 0604,0301/4 Y,Y
229 0101,0404 0501, 0302 N, Y
230 0101,0401 0501, 0302 N, Y
231 0404, 1101-1104 0301/4, 0302 Y,Y
232 1501-1502 (H) 0602 (H) Y,Y
233 0101,0401 0501,0301/4 N, Y
234 0701-0702 0201,0303 N, Y
235 0404, 0701-0702 0201,0302 N, Y
236 0301,1303-1304 0201,0301/4 N, Y
237 0701-0702, 1301 0603/8, 0201 Y, N
238 0404, 0301 0201,0302 N, Y

































240 0301 (H) 0201(H) N, N
241 0401, 1201-1202 0302, 0301/4 Y, Y
242 0801-0805, 1101-1104 0301/4, 0402 Y, N
243 0701-0702, 0801-0805 0201,0402 N, N
244 0101, 1301 0501,0603/8 N, Y
245 1501-1502,0401 0602,0302 Y, Y
246 0401,0301 0201,0301/4 N, Y
247 0701-0702, 0404 0201, 0302 N, Y
248 0701-0702 0603, 0303 Y,Y
249 0301,1302 0604, 0201 Y,N














Disease subtype, autoantibody and microsatellite marker allele data fo r  patients from  RNHRD, Bath and Hope hospital, Salford.
Patient Disease d22s284 d22s284 dls419 dls419 d2s389 d2s389 Pdgfb Pdgfb d!4s277 d!4s277 d!9s400 d!9s400 dxs426 dxs426
ID Subtype Autoantibodies Sex 1 2 1 2 1 2 1 2 1 2 1 2 1 2
188 dcSSc RNAP I, II, III m 106 107 112 113 106 107 108 108 107 108 110 112 105
137 lcSSc ACA f 102 107 104 113 107 107 101 107 107 108 102 106 104 114
179 lcSSc Positive Unidentified f 104 109 111 111 105 107 101 101 103 106 112 108 105 106
78 dcSSc Topo-I m 102 107 111 114 103 110 101 101 107 107 108 114 105
251 dcSSc Negative f 107 112 111 111 106 114 101 101 105 107 108 116 105 105
26 lcSSc ACA f 102 108 106 110 103 107 101 101 107 108 108 108 105 114
224 dcSSc Ro, La m 102 107 106 110 107 112 101 101 107 108 108 112 105
25 lcSSc ACA f 107 109 111 111 107 112 101 107 105 108 110 110 114 114
270 dcSSc RNAP I, II, III m 107 107 109 115 107 111 105 107 105 105 106 118 105
27 lcSSc ACA f 108 109 107 112 107 112 101 101 106 107 102 108 105 105
256 lcSSc Ro, La, U3RNP f 105 107 110 112 107 107 101 101 107 107 102 108 104 105
66 dcSSc RNAP I, II, III f 105 106 109 110 107 107 101 101 108 109 108 108 105 105
280 lcSSc Negative f 106 107 111 113 106 107 101 101 103 106 102 118 106 114
272 dcSSc RNAP, I, II wk, III f 106 107 110 112 112 113 101 105 107 109 104 114 105 105
43 dcSSc RNAP I, II, III f 108 102 106 114 106 107 101 101 107 107 108 110 105 115
4 lcSSc Wk. Topo-I m 102 107 114 116 111 112 101 108 103 105 108 114 105 105
36 dcSSc RNAP I, II, III f 106 112 111 114 105 107 101 101 108 109 104 108 105 105
209 dcSSc Topo-I m 107 107 106 112 103 107 101 101 107 109 108 110 105
263 lcSSc Negative f 106 108 106 111 107 111 101 101 105 108 102 110 105 105
264 lcSSc ACA f 108 108 112 114 111 114 101 108 107 107 104 108 105 106
269 lcSSc WkUlRNP f 102 107 111 111 110 115 101 101 106 107 112 112 105 105
74 lcSSc ACA f 107 107 111 113 112 115 101 106 107 108 108 112 104 105
206 lcSSc ACA f 106 107 108 114 107 113 101 101 102 106 108 112 105 114
191
267 lcSSc Positive Unidentified f  105 107 104 106
46 lcSSc Positive Unidentified f  108 109 108 113
228 lcSSc U1RNP m 106 107 106 108
107 lcSSc Negative f  108 108 112 113
212 lcSSc Pm-Scl f  106 108 106 113
146 lcSSc ACA f 102 106 106 111
71 lcSSc ACA f 108 108 111 111
Failed Sample (Hint of
247 lcSSc Pm-Scl but not confirmed) f 102 107 110 115
28 dcSSc Multiple unidentified bands m 102 105 106 108
240 lcSSc ACA Wk. f 102 112 111 111
31 lcSSc ACA m 108 109 111 111
69 lcSSc ACA f 107 108 111 112
253 lcSSc ACA f 109 109 106 107
244 dcSSc ACA f 106 108 111 111
21 lcSSc ACA m 105 107 107 111
34 dcSSc RNAP I, II, III f 105 107 110 111
167 lcSSc ACA f 104 107 111 111
177 dcSSc ACA f 106 108 108 111
70 lcSSc RNAP II, Topo-I 104 109 107 114
86 lcSSc Weak Unidentified m 108 108 106 108
175 dcSSc RNAP I, Ilwk, III f 107 109 104 105
149 lcSSc Negative f 104 107 109 110
230 lcSSc ACA f 106 110 108 115
181 lcSSc ACA m 101 106 112 113
6 dcSSc La f 106 107 106 115
210 lcSSc Ro, La f 106 108 106 106
85 dcSSc Topo-I f 106 107 107 111
61 lcSSc ACA f 107 107 106 110
255 lcSSc U1RNP f 107 107 110 111
187 lcSSc ACA f 106 107 106 106
192
106 107 101 107 107 108 102 108 105 114
106 116 101 101 107 108 110 114 106 106
107 112 101 101 105 107 108 116 105 106
107 107 101 101 107 108 110 116 106 114
106 107 102 108 106 106 106 114 105 105
107 112 101 101 103 106 110 114 106 114
106 107 107 107 107 108 102 104 105 105
101 114 101 101 103 106 112 114 105 106
107 111 101 107 105 107 108 116 105
106 114 101 108 107 107 104 112 105 105
107 114 101 101 108 108 105
107 107 101 108 106 106 110 112 105 114
107 107 103 108 106 107 102 116 104 106
103 115 101 101 107 108 102 108 103 105
107 107 101 101 102 107 110 114 115
111 115 102 102 103 107 102 112 105 116
107 107 101 108 105 107 108 116 105 114
103 115 107 101 103 107 114 114 105 105
107 107 107 108 103 120 102 106 105 114
106 111 101 101 107 107 110 110 114
111 116 108 108 102 107 112 114 105 116
106 113 107 107 106 111 102 112 105 105
112 114 101 101 107 107 108 114 104 105
103 107 101 108 103 110 112 114
106 111 107 107 107 107 108 108 105 115
103 111 101 101 107 120 114 114 106 114
107 107 101 106 107 109 110 116 105 105
107 115 101 101 103 107 102 114 105 106
106 112 107 106 106 107 102 102 105 116
112 115 101 101 107 107 108 112 104 108
144 lcSSc Pm-Scl f  107 108 106 107
72 lcSSc ACA f 102 112 106 111
22 lcSSc Jo-I f  104 106 111 111
18 lcSSc Negative f  102 106 106 111
79 lcSSc ACA f  102 107 110 112
52 lcSSc Positive Unidentified f 107 109 106 116
213 dcSSc Topo-I m 102 105 111 113
180 lcSSc ACA f 103 107 106 112
53 lcSSc f  105 106 106 106
95 dcSSc Negative f 104 107 106 112
87 lcSSc Pm-Scl f  104 107 106 113
89 lcSSc ACA f 102 105 107 113
Failed Sample (Hint of
202 lcSSc Pm-Scl but not confirmed) f 102 110 109 113
162 lcSSc Negative f 102 108 111 114
54 dcSSc f  104 106 111 114
55 lcSSc f 107 109 105 111
205 lcSSc Positive Unidentified f  106 107 102 107
17 SSc Positive Unidentified f  106 107 107 112
132 lcSSc RNAP I, II, III f  106 107 113 118
139 lcSSc Pm-Scl f  107 109 108 111
56 lcSSc f 104 107 111 119
118 dcSSc Topo-I f  102 107 106 114
133 lcSSc Ro, Pm-Scl f  107 108 107 112
268 lcSSc ACA f 105 107 107 111
222 lcSSc ACA f 102 107 104 111
56 lcSSc f 102 107 104 111
229 lcSSc ACA f 104 107 104 113
140 lcSSc ACA f 107 107 107 111
136 lcSSc ACA f 104 106 111 113
129 dcSSc RNAP I, II wk, III f  106 107 106 111
193
106 115 101 101 115 117 102 114 105 105
106 114 101 107 106 107 114 114 105 105
107 119 108 108 102 102 112 106 117
109 112 101 107 103 106 108 114 105 105
106 111 101 101 106 108 106 108 105 105
107 111 101 101 106 107 114 114 108 115
103 115 101 107 107 107 108 114 104
113 115 101 101 107 107 108 108 105 115
106 112 101 107 106 108 114 116 105 114
106 112 108 108 107 107 110 118 114 115
112 115 101 108 106 106 102 110 105 105
107 107 101 101 103 106 106 114 104 104
111 115 101 101 106 107 108 114 105 115
103 114 101 101 105 107 108 114 105 114
103 107 101 101 108 110 112 116 105 115
107 107 107 107 102 107 102 116 131 113
106 107 101 101 106 106 106 108 105 105
106 112 101 101 106 107 108 112 105 105
103 114 101 101 106 107 110 112 105 115
107 115 101 101 107 107 108 110 105 105
107 115 101 101 106 107 104 106 105 105
106 112 101 101 102 108 108 110 105 106
107 107 101 101 103 104 108 108 105 106
107 113 101 106 107 107 108 112 105 114
107 111 108 101 103 108 108 116 105 108
106 114 101 101 107 107 102 114 106 114
105 107 101 107 106 106 110 112 105 106
107 115 101 101 107 114 106 106
107 113 101 107 102 107 105 105
103 107 101 101 107 107 108 114 104 105
110 dcSSc Negative m 102 107 111 112
211 dcSSc Positive Unidentified f 102 108 113 113
97 lcSSc Negative f 102 107 106 113
112 dcSSc RNAP I, II, III f 101 107 107 110
143 dcSSc RNAP I, III f 102 106 112 113
141 lcSSc Positive Unidentified f 102 106 113 116
57 lcSSc f 102 107 109 114
199 lcSSc U1RNP f 106 107 102 111
135 lcSSc Positive Unidentified f 105 106 104 109
138 lcSSc ACA f 106 108 111 111
58 lcSSc f 105 107 110 110
246 dcSSc La f 102 104 108 110
231 lcSSc ACA f 107 109 102 111
145 dcSSc Topo-I f 102 107 107 114
106 lcSSc Jo-I f 106 107 106 114
249 lcSSc U1RNP f 107 107 107 109
241 lcSSc Positive Unidentified f 102 107 108 112
186 lcSSc Ro, La f 106 108 111 113
274 dcSSc Topo-I f 104 106 111 112
190 dcSSc Topo-I f 106 107 108 111
183 lcSSc Negative f 102 107 106 107
221 lcSSc ACA & Positive unidentified f 106 107 111 113
197 lcSSc ACA f 104 107 111 113
200 lcSSc Negative f 103 108 114 114
217 lcSSc RNAP I, III f 106 107 107 111
232 lcSSc Pm-Scl m 104 107 102 107
203 lcSSc Pm-Scl f 102 109 106 111
196 lcSSc ACA f 102 108 106 109
195 lcSSc ACA f 107 107 102 112
227 lcSSc Positive Unidentified m 107 107 106 108
218 dcSSc Topo-I f 102 107 106 113
194
114 115 101 102 102 109 108 108 115 115
114 115 101 101 103 105 106 114 105 105
107 112 102 107 107 107 108 114 106 114
115 115 101 103 104 107 108 112 105 105
106 107 101 101 105 107 102 114 105 113
107 116 101 102 102 108 102 108 X X
107 112 101 101 107 107 108 110 104 114
105 107 101 101 107 108 102 114 105 105
107 107 101 101 107 108 ’ 108 116 113 114
103 106 107 108 107 107 110 112 105 106
107 114 102 107 108 109 110 112 105 105
106 107 101 107 107 107 108 112 105 105
103 106 101 107 102 109 106 110 105 105
106 116 102 107 103 107 104 114 104 105
107 111 101 101 102 107 112 116 105 105
107 112 101 101 102 107 108 112 114 116
106 110 101 101 106 107 104 114 105 105
103 115 101 101 107 107 108 110 105 105
103 107 101 107 106 108 107 115
107 106 107 107 107 108 108 108 105 105
106 107 102 108 107 107 108 110 105 109
107 111 101 103 106 107 102 112 105 114
107 113 103 107 107 107 110 116 105 116
103 107 102 108 107 107 108 114 105 114
106 115 101 101 105 120 108 114 105 118
107 107 101 101 102 108 114 118 106 106
106 115 102 102 106 108 108 110 106 114
103 106 101 102 103 106 108 116 105 105
106 112 102 107 106 106 102 102 X X
115 115 101 120 103 107 112 112 105 105
111 114 101 103 105 106 110 112 104 111
192 lcSSc U1RNP m 107 108 106 111
194 lcSSc ACA f 107 108 110 110
193 lcSSc ACA Wk. f 102 106 109 113
233 lcSSc Negative f 104 107 111 112
257 lcSSc ACA Wk. m 104 107 X X
191 lcSSc ACA f 104 108 104 111
219 lcSSc Negative m 106 107 106 113
265 lcSSc ACA f 109 109 102 107
216 dcSSc V. Wk. Topo-I m 104 109 111 113
245 lcSSc Jo-I m 106 107 111 115
59 dcSSc m 107 112 106 111
60 lcSSc f 104 107 111 114
239 lcSSc ACA f 102 107 108 113
220 lcSSc m 107 109 108 116
248/261 dcSSc Negative m 102 108 111 119
266 lcSSc ACA f 108 109 107 110
262 lcSSc U1RNP f 105 108 102 106
61 dcSSc f 106 107 111 113
260 lcSSc ACA f 107 108 111 111
204 lcSSc ACA f 106 107 107 111
62 lcSSc f 102 107 106 111
63 lcSSc f 104 106 111 114
64 lcSSc f 107 106 112 112
65 lcSSc f 102 106 116 116
66 lcSSc f 102 106 107 111
223 lcSSc f 106 107 111 111
(Bath Patients)
1 SSc ACA f 106 107 . 104 106
2 SSc ACA/ AMA f 102 107 106 111
3 SSc Pm-Scl f 102 107 106 111
4 SSc ACA f 105 106 104 111
195
107 112 101 101 107 109 108 114 105 105
111 112 101 105 107 108 114 116 105 114
106 107 101 102 106 107 102 102 105 105
107 115 101 107 108 110 106 116 106 106
107 115 101 101 107 107 110 110 105 105
107 106 101 101 103 106 110 110 105 105
107 112 102 107 106 108 102 108 108 108
107 107 102 108 107 108 108 114 106 111
107 111 101 109 102 107 108 108 105 105
106 111 101 107 105 106 108 108 105 105
107 113 101 102 107 108 112 112 108 108
107 107 101 108 104 105 106 110 104 105
107 115 101 101 102 106 102 108 105 116
106 112 101 101 107 107 108 112 104 104
106 106 107 107 106 107 103 108 106 106
114 115 102 102 106 107 108 112 105 114
103 107 101 101 107 108 104 112 105 114
103 106 102 108 107 107 106 108 105 105
105 106 101 107 106 107 102 110 105 105
107 112 101 107 106 107 112 114 105 115
107 115 107 108 106 107 108 110 105 106
106 107 101 101 105 108 114 116 104 114
107 107 101 106 107 108 103 108 105 114
114 115 101 103 102 106 108 114 105 105
106 107 107 109 107 107 108 110 106 114
106 112 101 101 106 107 101 114 105 116
X X X X 107 109 104 108 X X
107 115 101 107 102 107 106 110 105 105
107 115 X X 107 108 102 116 105 106
105 107 101 101 102 106 102 114 105 114
5 SSc RNAP I, IIO, IIA, III f 106 107 111
6 SSc ACA f 107 108 109
7 SSc ACA f 106 109 111
8 SSc Topo-I f 102 107 111
9 SSc ACA f 102 107 111
10 SSc Topo-I f 106 108 105
11 SSc ACA f 106 107 106
12 SSc ACA f 104 107 111
13 SSc ACA f 106 107 107
14 SSc ACA f 102 109 111
15 SSc Pos. Unid. f 107 107 106
16 SSc DCNS, ENA Neg. m 102 107 109
17 SSc ACA f 107 107 108
18 SSc Jo-I f 109 110 111
19 SSc ACA f 102 107 106
20 SSc ACA f 107 108 107
21 SSc ACA f 102 106 107
22 SSc ACA f 102 107 106
23 SSc ThRNP f 106 107 106
24 SSc ACA f 102 107 106
25 SSc Jo-I f 105 106 110
26 SSc La, Pm-Scl f 102 109 106
27 SSc Topo-I, RNAP IIO, IIA m 102 106 110
28 SSc ACA f 102 104 102
29 SSc ACA f 108 109 107
30 SSc ACA f 102 111 111
31 SSc ACA f 108 110 111
32 SSc ACA f 102 102 107
33 SSc Topo-I, Ro, Jo-I f 107 107 110
































106 113 101 106 106 107 108 116 105 114
106 107 101 101 107 108 112 116 105 105
113 115 102 107 107 107 102 114 105 114
107 107 101 103 107 107 108 114 104 105
111 113 101 101 107 108 110 112 105 106
106 115 102 107 108 108 108 114 X X
107 107 X X 106 108 102 102 X X
106 113 101 101 107 107 104 110 105 115
111 115 101 101 104 106 114 114 105 106
103 111 101 107 107 108 110 114 104 115
106 115 101 108 107 107 108 110 104 114
106 112 101 101 107 108 102 108 105
106 106 101 101 102 107 108 116 105 106
106 115 103 107 107 107 108 108 105 105
107 107 101 101 108 108 108 108 104 115
107 107 101 101 107 108 108 110 105 106
106 115 101 103 107 107 108 114 104 105
107 107 101 101 107 108 110 112 114 114
106 115 101 101 102 107 114 116 114 115
X X 101 101 106 107 102 114 105 114
101 114 101 101 107 108 102 110 105 105
106 106 101 107 107 107 110 116 105 114
107 112 101 101 107 109 110 112 130
103 112 101 101 102 108 112 116 105 109
106 115 101 107 106 108 108 X 105 105
103 112 101 101 105 107 104 108 105 114
103 107 101 101 102 106 102 114 105 114
109 112 101 102 106 107 102 106 105 105
106 108 101 101 107 108 102 110 105 114
107 115 107 108 107 108 114 116 104 114
35 SSc ACA f 106 108
36 SSc ACA m 102 109
37 SSc Topo-I, RNAP IIO f 106 107
38 SSc ACA f 101 107
39 SSc Topo-I, RNAP IIO f 107 108
40 SSc Ro, La f 106 107
41 SSc ACA f 101 107
42 SSc RNAP I, IIO, IIA, III f 105 107
43 SSc Ro m 108 108
44 SSc ACA f 107 108
45 SSc Pos. Unid. f 107 107
46 SSc Ro, La, U3RNP m 107 108
47 SSc Topo-I, U1RNP+/-Sm f 106 107
48 SSc ACA f 107 109
49 SSc Various ANA f 107 107
50 SSc Topo-I, RNAP IIO f 102 107


















112 107 111 101 107 105 108 110 110 105 109
112 112 113 101 101 107 107 110 114 108
111 107 112 101 106 107 107 108 108 105 114
111 106 111 101 101 106 109 102 116 104 105
113 106 107 101 103 102 108 110 112 106 107
115 103 106 101 101 107 108 114 114 105 114
111 112 113 X X 102 108 114 116 114 115
X 112 115 101 101 104 107 110 110 X X
110 106 106 101 101 107 108 108 118 105
115 110 111 X X 107 108 112 115 105 105
111 X X 103 107 106 108 102 116 X X
115 106 115 101 103 106 107 106 108 105
110 103 114 101 106 106 107 110 112 105 106
111 106 112 101 101 107 108 108 110 105 114
112 X X X X 107 107 108 114 X X
112 106 111 101 106 107 108 108 112 105 116




Susol E, Rands AL, Herrick A, McHugh N, Barrett JH, Oilier WE, Worthington J. 
Association of markers for TGFb3, TGFb2 and TIMP1 with systemic sclerosis. 
Rheumatology, 2000: 39, 1332-1336
A.L.Rands, G.R.Harvey, E.Susol, A.Herrick, N.J.McHugh. Immunogenetics and 
clinical features in scleroderma patients with either anti-topoisomerase-I or anti-RNA 
polymerase III antibodies. The 6th International workshop for scleroderma research. 
2000. Abstract. Awarded: The symposium prize for outstanding work.
AL Rands, J Whyte, B Cox, ND Hall, NJ McHugh. MHC class II associations with 
autoantibody and T cell immune responses to the scleroderma autoantigen 
topoisomerase-I. Journal of Autoimmunity. 2000: 15,451-458.
J.Dunphy, M. Oliver, A.L.Rands, C.R.Lovell and N.J.McHugh. Antineutrophil 
cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like 
syndrome. British Journal of Dermatology. 2000: 142 (3): 461-468.
E Susol, AL Rands, A Herrick, N McHugh, JH Barrett, WER Oilier, J Worthington. 
Association of markers for TGFp2, TGFP3 and TIMP1 with systemic sclerosis. 
Rheumatology, 2000; 39:139
Harvey, G.R., Butts, S., Rands, A.L., Patel, Y. McHugh, N.J. Clinical and serological 
associations with anti-RNA polymerase antibodies in systemic sclerosis. Clinical and 
Experimental Immunology. 1999: 117: 395-402.
A. L. Rands, A. Kumar, J. Dunphy, P. Owen, B. Cox, L. Daly, N. J. McHugh. Clinical 
features, immunogenetics and outcome in individuals with anti-centromere antibodies. 
Annals of the Rheumatic Diseases. XIV European League Against Rheumatism 
Congress. 1999. Abstract.
J. Dunphy, A Rands, B. Cox, N. J. McHugh. ANCA positivity and HLA Class II 
antigen in minocycline-associated lupus-like illness. Annals of the Rheumatic 
Diseases. XIV European League Against Rheumatism Congress. 1999. Abstract.
P.A.Owen, B. Cox, A. Rands, A. Al-Saidi, N.J.McHugh. The serological profile of 
autoantibody reactivity to the UlsnRNP particle and its relationship to HLA DRB1 and 
DQB1 alleles. Annals of the Rheumatic Diseases. XIV European League Against 
Rheumatism Congress. 1999. Abstract.
Alison Rands, Jean Whyte, Nicolas Hall, Neil McHugh. MHC Class II associations 
with B and T cell immune responses to topoisomerase-I. British Society for 
Rheumatology XlVth AGM. 1997. Abstract.
Juliet Dunphy, Alison Rands, and Neil J McHugh. Anti-myeloperoxidase antibodies 
in minocycline lupus syndrome. British Society for Rheumatology XlVth AGM. 1997. 
Abstract.
198
GR Harvey, A Rands, PJ Maddison, NJ McHugh. Antibodies to RNA polymerases in 
systemic sclerosis: clinical and serological associations. British Society for 
Rheumatology XlVth AGM 1996 Abstract.
GR Harvey, A Rands, NJ McHugh. Anti-RNA polymerase antibodies in systemic 
sclerosis: association with anti-topoisomerase I antibodies and identification of 
autoreactive subunits of RNA polymerase II. Clinical and Experimental Immunology. 
1996,105 (3): 468-474.
Georgina R. Harvey, Alison Rands, Yusuf I. Patel, Peter J. Maddison, and Neil J. 
McHugh. Antibodies to RNA Polymerases in Systemic Sclerosis: Clinical and 
Serological Associations. American College of Rheumatology. 60th AGM. 1996. 
Abstract.
Neil J. McHugh, Juliet Dunphy, Alison Rands, and Colin Hill.
Anti-Myeloperoxidase Antibodies in Minocycline-Induced Lupus Syndrome And 
Myeloperoxidase Dependent Drug Cytotoxicity. American College of Rheumatology. 




(1) Perez MI, Kohn SR. Systemic sclerosis. J Am Acad Dermatol 1993; 28:525-547.
(2) LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr. et 
al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J 
Rheumatol 1988; 15:202-204.
(3) Silver RM. Clinical problems: The lungs. Rheum Dis. Clin North Am 1996; 
22:825-840.
(4) Fagundus DM, LeRoy EC. Systemic sclerosis (scleroderma). In: Belch JJF, 
Zurier RB, editors. Connectice tissue diseases. London: Chapman & Hall, 1995: 
51-64.
(5) Silver RM, Miller KS. Lung involvement in systemic sclerosis. Rheum Dis Clin 
North Am 1990; 16:199-216.
(6) Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996; 22:861- 
878.
(7) Medsger TA, Jr. Systemic sclerosis (scleroderma), Localized scleroderma, 
eosinophilic fasciitis, and calcinosis. In: McCarty DJ, editor. Arthritis and allied 
conditions. A textbook of rheumatology. Philadelphia. London.: Lea & Febiger, 
1989:1119-1165.
(8) Young MA, Rose S, Reynolds JC. Gastrointestinal manifestations of 
scleroderma. Rheum Dis Clin North Am 1996; 22:797-823.
(9) Black CM, Stephens C. Systemic sclerosis (scleroderma) and related disorders. 
Oxford textbook of rhuematology. Oxford University Press, 1993: 771-789.
(10) Cerinic MM, Generini S, Pignone A, Casale R. The nervous system in systemic 
sclerosis (scleroderma): Clinical features and pathogenetic mechanisms. Rheum 
Dis Clin North Am 1996; 22:879-892.
(11) Wigley FM. Clinical aspects of systemic and localized scleroderma. Curr Opin 
Rheumatol 1994; 6:628-636.
(12) Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr. Systemic sclerosis sine 
scleroderma: Demographic, clinical, and serologic features and survival in forty- 
eight patients. Arthritis Rheum 2000; 43:444-451.
(13) Venables PJW. Miscellaneous Disorders: Overlap syndromes. In: Klippel JH, 
Dieppe PA, editors. Rheumatology. London: Mosby International, 1998: 28.1- 
28.7.
(14) Jablonska S, Blaszczyk M. Scleroderma overlap syndromes. Adv Exp Med Biol 
1999; 455:85-92.
(15) Medsger TA, Jr., Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al. 
A disease severity scale for systemic sclerosis: Development and testing. J 
Rheumatol 1999; 26:2159-2167.
200
(16) Barnett AJ. Scleroderma (progressive systemic sclerosis): progress and course 
based on a personal series of 118 cases. Med J Aust 1978; 12:129-134.
(17) Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody 
patterns and different prognoses in patients with scleroderma with various extent 
of skin sclerosis. J Rheumatol 1986; 113:911-916.
(18) Silman AJ. Scleroderma - Demographics and survival. J Rheumatol 1997; 
24:58-61.
(19) Silman AJ. Scleroderma and survival. Ann Rheum Dis 1991; 50:267-269.
(20) Mayes M. Scleroderma Epidemiology. Rheum Dis Clin North Am 1996; 
22:751-764.
(21) Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RHJr, Bums CJ et al. 
Racial differences in scleroderma among women in Michigan. Arthritis Rheum 
1997; 40:734-742.
(22) Steen VD, Medsger TA, Jr. Epidemiology and natural history of systemic 
sclerosis. Rheum Dis Clin North Am 1990; 16:1-9.
(23) Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in 
the freqencies of scleroderma-related autoantibodies. Arthritis Rheum 1992; 
35:216-218.
(24) Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA, Jr. Racial differences in 
the distribution of systemic sclerosis-related serum antinuclear antibodies. 
Arthritis Rheum 1994; 37:902-906.
(25) Arnett F. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev 
Immunol 1995; 12:107-128.
(26) Briggs D, Welsh KI. Major histocompatibility complex class II genes and 
systemic sclerosis. Ann Rheum Dis 1991; 50 Suppl. 4:862-865.
(27) Mayes MD. Classification and epidemiology of scleroderma. Seminars in Cutan 
Med Surg 1998; 17:22-26.
(28) Silman AJ, Howard Y, Hicklin AJ, Black C. Geographical clustering of 
scleroderma in south and west London. Brit J Rheumatol 1990; 29:92-96.
(29) Silman AJ, Jannini S, Synnons D, Bacon P. An epidemiological study of 
scleroderma in the West Midlands. BritJ.Rheumatol. 27, 286-290. 1988.
(30) Harley JB, Neas BR. Oklahoma Choctaw and systemic sclerosis: The Founder 
effect and genetic susceptibility. Arthritis Rheum 1998; 41:1725-1728.
(31) Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E et al. Increased 
prevalence of systemic sclerosis in a native American tribe in Oklahoma. 
Association with an Amerindiam HLA haplotype. Arthritis Rheum 1996; 
39:1362-1370.
201
(32) Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular 
hypothesis. Semin Arthritis Rheum 1975; 4:351-368.
(33) Hunt BJ, Jurd KM. Endothelial cell activation: A central pathophysiological 
process. BMJ 1998; 316:1328-1329.
(34) Smith EA, LeRoy EC. Systemic sclerosis: Etiology and pathogenesis. In: 
Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby International, 
1998:9.1-9.10.
(35) Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J 
Rheumatol 1997; 24:53-57.
(36) Seibold JR. Systemic sclerosis: Clinical features. In: Klippel JH, Dieppe PA, 
editors. Rheumatology. London: Mosby International, 1998: 8.1-8.14.
(37) White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 
1996; 22:695-708.
(38) LeRoy EC. A brief overview of the pathogenesis of scleroderma (systemic 
sclerosis). Ann Rheum Dis 1992; 51:286-288.
(39) Varga J, Rudnicka L, Vitto J. Connective tissue alterations in systemic sclerosis 
(SSc). Clin Dermatol 1994; 12:387-396.
(40) LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for 
determining the pathogenesis of systemic sclerosis. Is transforming growth 
factor p the answer? Arthritis Rheum 1989; 7:817-825.
(41) Postlethwaite AE. Connective tissue metabolism including cytokines in 
scleroderma. Curr Opin Rheumatol 1993; 5:766-772.
(42) ota H, Kumagai S, morinobu A, Nakao K. Enhanced production of transforming 
growth factor-beta (TGF-P) during autologous mixed lymphocyte reaction in 
SSc patients. Clin Exp Immunol 1995; 100:99-103.
(43) Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely 
fragmented by metal-catalyzed oxidation reactions: Implications for 
pathogenesis. J Exp Med 1997; 185:71-79.
(44) Rosen A, Casciola-Rosen L, Wigley F. Role of metal-catalyzed oxidation 
reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 1997; 
9:538-543.
(45) Harvey GR, McHugh NJ. Serological abnormalities in systemic sclerosis. Curr 
Opin Rheumatol 1999; 11:495-502.
(46) Kuwana M, Medsger TA, Jr., Wright TM. T and B cell collaboration is essential 
for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J 
Immunol 1995; 155:2703-2714.
202
(47) Sarkozi J, Bookman AAM, Lee P, Keystone EC, Fritzler MJ. Significance of 
anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 1987; 
83:893-898.
(48) Youinou P, Revelen R, Bordron A. Is antiendothelial cell antibody the murder 
weapon in systemic sclerosis? Clinical & Experimental Rheumatology 1999; 
17:35-36.
(49) Carvalho D, Savage COS, Black CM, Pearson JD. IgG antiendothelial cell 
autoantibodies from scleroderma patients induce leukocyte adhesion to human 
vascular endothelial cells in vitro. J Clin Invest 1996; 97:111-119.
(50) Osborne BA. Apoptosis and the maintenance of homoeostasis in the immune 
system. Curr Opin Immunol 1996; 8:245-254.
(51) Bordron A, Dueymes M, Levy Y, Jamin C, LeRoy J-C, Shoenfeld Y et al. The 
binding of some human antiendothelial cell antibodies induces endothelial cell 
apoptosis. J Clin Invest 1998; 101:2029-2035.
(52) Sgonc R. The vascular perspective of systemic sclerosis: of Chickens, mice and 
men. Int Arch Allergy Immunol 1999; 120:169-176.
(53) Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis 
Clin North Am 1996; 22:709-735.
(54) Hsieh T. DNA topoisomerases. Curr Opin Cell Biol 1992; 4:396-400.
(55) Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM. Autoantibody to 
centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980; 
77:1627-1631.
(56) Eamshaw WC, Tomkiel JE. Centromere and kinetochore structure. Curr Opin 
Cell Biol 1992; 4:86-93.
(57) McHugh.N.J. Centromere Autoantibodies. In: Peter.J.B., Shoenfeld.Y, editors. 
Autoantibodies. Elsevier Science B.V., 1996: 161-167.
(58) Steen VD, Ziegler GL, Rodnan GP, Medsger TA, Jr. Clinical and laboratory 
associations of anticentromere antibody in patients with progressive systemic 
sclerosis. Arthritis Rheum 1984; 27:125-131.
(59) Pollard KM, Reimer G, Tan EM. Autoantibodies in scleroderma. Clin Exp 
Rheumatol 1989; 7/S-3:57-62.
(60) Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere 
antibody as a predictor of digital ischemic loss in patients with systemic 
sclerosis. Arthritis Rheum 1992; 35:688-693.
(61) Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA, Jr. 
Serum autoantibody to the nucleolar antigen PM-Scl: Clinical and
immunogenetic associations. Arthritis Rheum 1992; 35:1211-1217.
203
(62) Okano Y, Medsger TA, Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 
RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990; 
33:1822-1828.
(63) Steen VD, Powell VD, Medsger TA, Jr. Clinical correlations and prognosis 
based on serum autoantibodies in patients with systemic sclerosis. Arthritis 
Rheum 1988; 31:196-203.
(64) Fanning GC, Welsh KI, Bunn C, Du Bois R, Black CM. HLA associations in 
three mutually exclusive autoantibody subgroups in UK systemic sclerosis 
patients. Brit J Rheumatol 1998; 37:201-207.
(65) Nelson CA, Fremont DH. Structural principles of MHC class II antigen 
presentation. Reviews in immunogenetics 1999; 1:47-59.
(66) McCluskey J. The human leukocyte antigens and clinical medicine: an 
overview. Reviews in immunogenetics 1999; 1:3-20.
(67) Garca KM, Chan VSF, Ohashi PS. T Cell tolerance and autoimmunity. Reviews 
in immunogenetics 2000; 2:2-17.
(68) Schiffenbauer J, Schwartz BD. The HLA comlex and its relationship to 
rheumatic diseases. Rheum Dis Clin North Am 1987; 13:463-485.
(69) Wicker LS. Major Histocompatibility Complex-linked control of autoimmunity. 
J Exp Med 1997; 186:973-975.
(70) Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev 
Immunol 1991; 9:493-525.
(71) Steinman L. Escape from "Horror Autotoxicus": pathogenesis and treatment of 
autoimmune disease. Cell 1995; 80:7-10.
(72) Pisetsky DS. Rheumatic disease etiology: Immune-mediated inflammation. In: 
Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby International, 
1998: 13.1-13.6.
(73) Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An 
approach to understanding the molecular genetics of susceptibility to rheumatoid 
arthritis. Arthritis Rheum 1987; 30:1205-1213.
(74) Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO et al. A 
molecular basis for MHC Class II - associated autoimmunity. Science 1988; 
240:1003-1009.
(75) Das P, Abraham R, David C. HLA transgenic mice as models of human 
autoimmune diseases. Reviews in immunogenetics 2[1], 105-114. 2000.
(76) Seglias J, Li EK, Cohen MG, Wong RWS, Potter PK, So AK. Linkage between 
rheumatoid arthritis susceptibility and the presence of HLA-DR4 and DRp 
allelic third hypervariable region seqences in Southern Chinese persons. 
Arthritis Rheum 1992; 35:163-167.
204
(77) Nepom GT, Byers P, Seyfried C, Healey LA, Wilske K, Stage D et al. HLA 
genes associated with rheumatoid arthritis. Identification of susceptibility alleles 
using specific oligonucleotide probes. Arthritis Rheum 1989; 32:15-21.
(78) Reveille JD. Molecular genetics of systemic sclerosis. Curr Opin Rheumatol 
1995; 7:522-528.
(79) Gladman DD, Keystone EC, Baron M, Lee P, Cane D, Mervert H. Increased 
frequency of HLA-DR5 in scleroderma. Arthritis Rheum 1981; 24:854-856.
(80) Genth E, Mierau R, Genetzky P, von Muhlen CA, Kaufinann S, von Wilmowsky 
H et al. Immunogenetic associations of scleroderma-related antinuclear 
antibodies. Arthritis Rheum 1990; 33:657-665.
(81) Morel PA, Chang HJ, Wilson JW, Conte C, Falkner D, Tweardy DJ et al. HLA 
and ethnic associations among systemic sclerosis patients with anticentromere 
antibodies. Hum Immunol 1995; 42:35-42.
(82) Vlachoyiannopoulos PG, Dafni UG, Pakas I, Spyropoulou-Vlachou M, 
Stavropoulos-Giokas C, Moutsopoulos HM. Systemic scleroderma in Greece: 
low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 
2000; 59:359-367.
(83) Vargas-Alarcon G, Granados J, Ibanez De Kasep G, Alcocer-Varela J, Alarcon- 
Segovia D. Association of HLA-DR5 (DR11) with systemic sclerosis 
(scleroderma) in Mexican patients. Clinical & Experimental Rheumatology 
1995;13:11-16.
(84) Reveille JD, Durban E, MacLeod-St.Clair MJ, Goldstein R, Moreda R, Altman 
RD et al. Association of amino acid sequences in the HLA-DQB1 first domain 
with the antitopoisomerase 1 autoantibody response in scleroderma (progressive 
systemic sclerosis). J Clin Invest 1992; 90:973-980.
(85) Kuwana M, Kaburaki J, Okano Y, Inoko H, Tsuji K. The HLA-DR and DQ 
genes control the autoimmune response to DNA topoisomerase I in systemic 
sclerosis (scleroderma). J Clin Invest 1993; 92:1296-1301.
(86) Kuwana M, Okano Y, Kaburaki J, Inoko H. HLA class II genes associated with 
anticentromere antibody in Japanese patients with systemic sclerosis 
(scleroderma). Ann Rheum Dis 1995; 54:983-987.
(87) Salamon H, Klitz W, Easteal S, Gao X, Erlich HA, Femandez-Vina M et al. 
Evolution of HLA class II molecules: alleleic and amino acid site variability 
across populations. Genetics 1999; 152:393-400.
(88) Masi AT, Feigenbaum RT, Chatterton RT, Cutolo M. Integrated hormonal- 
immunological-vascular (H-I-V triad) systems interactions in the rheumatic 
diseases. Clin Exp Rheumatol 1995; 13:203-216.
(89) Cutolo M, Sulli A, Seriolo B, Accardo S, Masi AT. Estrogens, the immune 
response and autoimmunity. Clin Exp Rheumatol 1995; 13:217-226.
205
(90) Nelson JL. Microchimerism and the pathogenesis of systemic sclerosis. Curr 
Opin Rheumatol 1998; 10:564-571.
(91) Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal 
progenitor cells persist in maternal blood for as long as 27 years postpartum. 
Proc Natl Acad Sci USA 1996; 93:705-708.
(92) Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A et al. 
Microchimerism and HLA-compatible relationships of pregnancy in 
scleroderma. Lancet 1998; 351:559-622.
(93) Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin 
lesions from women with systemic sclerosis. N Eng J Med 1998; 338:1186- 
1191.
(94) Bell SA, Faust H, Mittermuller J, Kolb HJ, Meurer M. Specificity of antinuclear 
antibodies in scleroderma-like chronic graft-versus-host disease: Clinical 
correlation and histocompatibility locus antigen association. Br J Dermatol 
1996; 134:848-854.
(95) Seibold J. Scleroderma. In: Kelly WN, Harris ED, Ruddy S, Sledge CB, editors. 
Arthritis and allied conditions. Philadelphia: Saunders,W.B., 1996: 1133-1162.
(96) Nelson JL. Maternal-fetal immuology and autoimmune disease. Is some 
autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 
1996; 39:191-194.
(97) Green MC, Sweet HO, Bunker LE. Tight skin, a new mutation of the mouse 
causing excessive growth of connective tissue and skeleton. Am.J.Pathol. 82, 
493-512. 1976.
(98) Everett ET, Pablos JC, Harris SE, LeRoy EC, Norris JS. The tight skin (TSK) 
mutation is closely linked to B2M on mouse chromosome 2. Mammalian 
Genome 1994; 5:55-57.
(99) Siracusa LD, Christner P, Mcgrath R, Mowers SD, Nelson KK, Jimenez SA. 
The tight skin (Tsk) mutation in the mouse, a model for human fibrotic diseases, 
is tightly linked to the beta 2-microglobulin (B2m) gene on chromosome 2. 
Genomics 1993; 17:748-751.
(100) Siracusa LD, Mcgrath R, Ma Q, Moskow JJ, Manne J, Christner PJ et al. A 
tandem duplcation within the fibrillin 1 gene is associated with the mouse tight 
skin mutation. Genome Research 1996; 6:300-313.
(101) Christner PJ, Peters J, Hawkins D, Siracusa LD, Jimenez SA. The tight skin 2 
mouse. An animal model of scleroderma displaying cutaneous fibrosis and 
mononuclear cell infiltration. Arthritis Rheum 1995; 38:1791-1798.
(102) Christner PJ, Siracusa LD, Hawkins DF, Mcgrath R, Betz JK, Peters J et al. A 
high resolution linkage map of the tight skin 2 (Tsk2) locus: a mouse model for 




(103) Gershwin ME, Abplanalp H, Castles JJ, Ikeda RM, Van Der Water J, Eklund J 
et al. Characterization of a spontaneous disease of white leghorn chickens 
resembling progressive systemic sclerosis (scleroderma). J Exp Med 153, 1640- 
1659. 1981. Abstract
(104) Abplanalp H, Gershwin ME, Johnston E, Reid J. Genetic contol of avian 
scleroderma. Immunogenetics 1990; 31:291-295.
(105) Atkinson JP. Some thoughts on autoimmunity. Arthritis Rheum 1995; 38:301- 
305.
(106) Briggs DC, Welsh K, Pereira RS, Black CM. A strong association between null 
alleles at the C4A locus in the Major Histocompatibility Compex and systemic 
sclerosis. Arthritis Rheum 1986; 29:1274-1277.
(107) Briggs D, Stephens C, Vaughan R, Welsh K, Black C. A molecular and 
serological analysis of the major histocompatibility complex and complement 
component C4 in systemic sclerosis. Arthritis Rheum 1993; 36:943-957.
(108) Takeuchi F, Nabeta H, Hong GH, Matsuta K, Tokunaga K, Tanimoto K et al. 
C4A and C4B null alleles are genetic markers of different types of systemic 
sclerosis in Japanese patients. Clin Exp Rheumatol 1998; 16:55-60.
(109) Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996; 85:311- 
318.
(110) Susol E, Rands AL, Herrick A, McHugh N, Barrett JH, Oilier WER et al. 
Association of markers for TGFp3, TGFp2 and TIMP1 with systemic sclerosis. 
Rheumatology (Formerly B J Rheum) 2000; 39:1332-1336.
(111) Susol E, Herrick A, Oilier WER, Worthington J. Candidate gene analysis in 
systemic sclerosis using microsatellite markers. Brit.J.Rheumatol. 37, 87. 1998.
(112) Susol E, Rands AL, Herrick A, McHugh N, Barrett JH, Oilier WER et al. 
Association of markers for TGFP2, TGFp3 and TIMP1 with systemic sclerosis. 
Rheumatology (Formerly B.J.Rheum.) 39, 139. 2000. Abstract.
(113) Zetterquist H, Olerup O. Identification of the HLA-DRB1*04, -DRB1*07, and - 
DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR- 
SSP) in 2 hours. Human Immunol 1992; 34:64-74.
(114) Takeuchi F, Nabeta H, Frank K-H, Conrad K. Association of the TNFal3 
microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 
2000; 59:293-296.
(115) Fanning GC, Black CM, Welsh K. TNF, LTa and TNF-RII polymorphisms in 
systemic sclerosis. Associations with clinical subgroup, pulmonary fibrosis and 
raised creatinine kinase levels. Arthritis Rheum Suppl. 9, 1735. 1998. Abstract.
(116) Tan FK, John TL, Milewicz D, Arnett FC, Sequencing of hte fibrillin 1 gene in 





(117) Tan FK, Stivers DN, Foster MW, Chakraborty R, Howard RF, Milewicz DM et 
al. Association of microsatellite markers near the fibrillin 1 gene on human 
chromosome 15q with scleroderma in a native American population. Arthritis 
Rheum 1998;41:1729-1737.
(118) Tan FK, Stivers DN, Arnett FC, Chakraborty R, Howard R, Reveille JD. HLA 
Haplotypes and microsatellite polymorphisms in and around the major 
histocompatibility complex region in a Native American population with a high 
prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999; 53:74-80.
(119) Feghali CA, Wright TM. Epidemiologic and clinical study of twins with 
scleroderma. Arthritis Rheum 1995; 38:S308.
(120) McHugh NJ, Harvey GR, Whyte J, Dorsey JK. Segragation of autoantibodies 
with disease in monozygotic twin pairs discordant for systemic sclerosis: Three 
further cases. Arthritis Rheum 1995; 38:1845-1850.
(121) De Juan MD, Belzunegui J, Belmonte I, Barado J, Figueroa M, Cancio J et al. 
An immunogenetic study of familial scleroderma. Ann Rheum Dis 1994; 
53:614-617.
(122) McHugh NJ, Whyte J, Artlett C, Briggs DC, Stephens CO, Olsen NJ et al. Anti­
centromere antibodies in systemic sclerosis patients and their relatives: a 
serological and HLA study. Clin Exp Immunol 1994; 96:267-274.
(123) Tan FK, Howard RF, Reveille JD, Moulds JM, Paxton G, Arnett FC. Case 
control study of systemic sclerosis among Choctaw Native Americans in 
southeastern Oklahoma. Arthritis Rheum 37, S282. 1994. Abstract.
(124) Merriman TR, Todd JA. Genetics of autoimmune disease. Curr Opin Immunol 
1995;7:786-792.
(125) Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and 
malignancy: An epidemiological study. Ann Rheum Dis 1993; 52:531-533.
(126) Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis 
Rheum 1993; 36:460-464.
(127) Higuchi M, Horiuchi T, Ishibashi N, Yoshida S, Hiho Y, Nagasawa K. 
Anticentromere antibody as a risk factor for cancer in patients with systemic 
sclerosis. Clin Rheumatol 19, 123-126. 2000.
(128) Rothfield N, Kurtzman S, Vazques-Abad D, Charron C, Daniels L, Greenberg
B. Association of anti-topoisomerase I with cancer. Arthritis Rheum 1992; 
35:724.
(129) Kuwana M, Fujii T, Mimori T, Kaburaki J. Enhancement of anti-DNA 
topoisomerase I autoantibody response after lung cancer in patients with 
systemic sclerosis. Arthritis Rheum 1996; 39:686-691.
(130) Haustein UF, Ziegler V. Envimmentally Induced systemic sclerosis-like 
disorders. International Journal of Dermatology 1985; 24:147-151.
208
(131) Silman AJ, Hochberg MC. Occupational and environmental influences on 
scleroderma. Rheum.Dis.Clin.North Am. 22, 737-749. 1996.
(132) D'Cruz D. Autoimmune disease associated with drugs, chemicals and 
environmental factors. Toxicol.Lett. 112-113,421-432. 2000.
(133) Haustein U-F, Herrmann K. Environmental scleroderma. Clinics in Dermatology 
1994; 12:467-473.
(134) Steenland K, Goldsmith DF. Silica exposure and autoimmune diseases. Am J 
Indust Med 1995; 28:603-608.
(135) McHugh NJ, Whyte J, Harvey G, Haustein U-F. Anti-topoisomerase-1 
antibodies in silica-associated systemic sclerosis. A model for autoimmunity. 
Arthritis Rheum 1994; 37:1198-1205.
(136) Haustein U-F, Ziegler V, Herrmann K, Mehlhom J, Schmidt C. Silica-induced 
scleroderma. J Am Acad Dermatol 1989; 22:444-448.
(137) Appleton BE, Lee P. The development of systemic sclerosis (scleroderma) 
following augmentation mamoplasty. J Rheumatol 1993; 20:1052-1054.
(138) Spiera H, Kerr LD. Scleroderma following silicone implantation: A cumulative 
experience of 11 cases. J Rheumatol 1993; 20:958-961.
(139) McLaughlin J, Fraumeni J, Olsen J. RE: Breast implants, cancer and systemic 
sclerosis. J Natl Cancer Inst 1994; 86:1424.
(140) Bums CJ, Laing TJ, Gillespie BW, Heeringa SG, Alcser KH, Mayes MD et al. 
The epidemiology of scleroderma among women: Assessment of risk from 
exposure to silicone and silica. J Rheumatol 1996; 23:1904-1911.
(141) Frank K-H, Fussel M, Conrad K, Rihs H-P, Kock R, Gebhardt B et al. Different 
distribution in HLA class II and tumor necrosis factor alleles (TNF-308.2, 
TNFa2 microsatellite) in anti-topoisomerase I responders among scleroderma 
patients with and without exposue to quartz/metal dust. Arthritis Rheum 1998; 
41:1306-1311.
(142) Morse JH, Fotino M, Zhang Y, Flaster ER, Peebles CL, Spiera H. Position 26 of 
the first domain of the HLA-DQB1 allele in post-silicone inplant scleroderma. J 
Rheumatol 1995; 22:1872-1875.
(143) Rein V. Sklerodermie durch trichlorathylen-einwirking? Zentralbl Arbeitsmed 
1957;7:58-60.
(144) Black CM, Welsh KI, Walker AE, Bernstein RM, Catoggio LJ, McGregor AR et 
al. Genetic susceptibility to scleroderma-like syndrome induced by vinyl 
chloride. Lancet 1983; 53-55.
(145) Nietert PJ, Sutherland SE, Silver RM, Pandey JP, Knapp.R.G, Hoel.D.G. et al. Is 
occupational organic exposure a risk factor for scleroderma? Arthritis Rheum 
1998;41:1111-1118.
209
(146) Finch WR, Rodnan GP, Buckingham RB. Bleomycin-induced scleroderma. J 
Rheumatol 1980; 7:651-659.
(147) Kilaru P, Kim W, Sequeira W. Cocaine and scleroderma: Is there an
association? J Rheumatol 1991; 18:1753-1755.
(148) Adams LE, Mongey A-B. Role of genetic factors in drug-related autoimmunity. 
Lupus 1994; 3:443-447.
(149) Dunphy J, Oliver M, Rands AL, Lovell CR, McHugh NJ. Antineutrophil 
cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus­
like syndrome. Br J Dermatol 2000; 142:461-467.
(150) Venables P, Brookes S. Retroviruses: potential aetiological agents in
autoimmune rheumatic disease. Brit J Rheumatol 1992; 31:841-846.
(151) Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D. Determination of an 
epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: 
Sequence similarity with retroviral p30gag protein suggests a possible cause for 
autoimmunity in systemic sclerosis. Proc Natl Acad Sci USA 1989; 86:8492- 
8496.
(152) Murrell DF. A radiacal proposal for the pathogenesis of scleroderma. J Am 
Acad Dermatol 1993; 28:78-85.
(153) Freedman RR, Girgis R, Mayes MD. Accute effect of nitric oxide on Raynaud's 
phenomenon in scleroderma. Lancet 1999; 354:739-740.
(154) Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by
granzyme B is strongly predictive of autoantigen status: implications for 
initiation of autoimmunity. J Exp Med 1999; 190:815-825.
(155) Rovere P, Sabbadini MG, Fausto F, Bondanza A, Zimmermann VS, Rugarli C et 
al. Remnants of suicidal cells fostering systemic autoaggression: Apoptosis in 
the origin and maintenance of autoimmunity. Arthritis Rheum 2000; 43:1663- 
1672.
(156) Masi AT, Rodnan GP, Medsger TA, Jr., Altman RD, D'Angelo WA, Fries JF et 
al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). 
Arthritis Rheum 1980; 23:581-590.
(157) Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence- 
specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing 
in clinical practice including donor-recipient matching in cadaveric 
transplantation. Tissue Antigens 1992; 39:225-235.
(158) Olerup O, Zetterquist H. DR "low-resolution" PCR-SSP typing - a correction 
and an up-date. Tissue Antigens 1994;55-56.
(159) Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR 
amplification: A sensitive, specific and rapid technique. Tissue Antigens 1991; 
37:197-204.
210
(160) Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR 
amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue 
Antigens 1993; 41:119-134.
(161) Isenberg DA, Maddison PJ. Detection of antibodies to double stranded DNA and 
extractable nuclear antigen. Assoc Clin Pathol Broadsheet 1987; 117:1-8.
(162) Hoet RM, Van Venrooij WJ. B-cell epitopes of RNA autoantigens. Mol Biol 
Rep 1992; 16:199-205.
(163) McHugh NJ, James IE, Maddison PJ. Differential isotype recognition of two 
centromere associated polypeptides by immunoblotting in connective tissue 
disease. Clin Exp Immunol 1988; 72:457-464.
(164) Whyte J, Eamshaw WC, Champoux JJ, Parker LH, Stewart L, Hall ND et al. 
Detection of anti-topoisomerase I antibodies using fiull length human 
topoisomerase I recombinant protein purified from a baculovirus expression 
system. Clin Exp Immunol 1995; 100:214-218.
(165) Black CM, Welsh KI, Maddison PJ, Jayson MIV, Bernstein RM. HLA antigens, 
autoantibodies and clinical subsets in scleroderma. Brit J Rheumatol 1984; 
23:267-271.
(166) Livingston JZ, Scott TE, Wigley FM, Anhalt GJ, Bias WB, McLean RH et al. 
Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J 
Rheumatol 1987; 14:512-518.
(167) Lowe KE, Norman AW. Vitamin D and psoriasis. Nutr Rev 1992; 50:138-142.
(168) Dransfield I, Cabanas C, Barrett J, Hogg N. Interaction of leukocyte integrins 
with ligand is necessary but not sufficient for function. J Cell Biol 1992; 
116:1527-1535.
(169) Serra CR, Rodriques SH, Szajnbok FR, Silva NP, Andrade LE. Antiperinuclear 
factor and antibodies to the stratum comeum of rat esophagus in juvenile 
idiopathic arthritis. J Pediat 1999; 134:507-509.
(170) Salvarani C, Baricchi R, Macchioni P, Carbognani R, Morelli A, Lodi L et al. 
Anticardiolipin antibodies in Northern Italian population with PMR/GCA. Am J 
Med 1992; 92:712-713.
(171) Morel PA, Chang HJ, Wilson JW, Conte C, Saidman SL, Bray JD et al. Severe 
systemic sclerosis with anti-topoisomerase I antibodies is associated with an 
HLA-DRwll allele. Hum Immunol 1994; 40:101-110.
(172) Kuwana M, Medsger TA, Jr., Wright TM. T cell proliferative response induced 
by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. 
J Clin Invest 1995; 96:586-596.
(173) Harvey G, Rands AL, McHugh NJ. Anti-RNA polymerase antibodies in 
systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and 
identification of autoreactive subunits of RNA polymerase II. Clin Exp Immunol 
1996; 105:468-474.
211
(174) Payami H, Joe S, Farid NR, Stenszky V, Chan H, Yeo PPB et al. Relative 
predispositional effects (RPEs) of marker allelles with disease: HLA-DR and 
Graves disease. Am J Hum Genet 45, 541-546. 1989.
(175) Harvey G, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serolgical 
associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin 
Exp Immunol 1999; 117:395-402.
(176) Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological 
associations with anti-RNA polymerse antibodies in systemic sclerosis. Clin Exp 
Immunol 1999; 117:395-402.
(177) Takeuchi F, Nakano K, Yamada H, Hong GH, Nabeta H, Yoshida A et al. 
Association of HLA-DR with progressive systemic sclerosis in Japanese. J 
Rheumatol 1994; 21:857-863.
(178) Whyte J, Artlett C, Harvey G, Stephens CO, Welsh K, Black C et al. HLA- 
DQB1 associations with anti-topoisomerase-1 antibodies in patients with 
systemic sclerosis and their first degree relatives. J Autoimmun 1994; 7:509- 
520.
(179) Hoffman RW, Takeda Y, Sharp GC, Lee DR, Hill DL, Kaneoka H et al. Human 
T cell clones reactive against U-small nuclear ribonucleoprotein autoantigens 
from connective tissue disease patients and healthy individuals. J Immunol 
1993; 151:6460-6469.
(180) Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: A major immunogen for 
pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177:1367- 
1381.
(181) Zanelli E, Gonzalez-Gay MA, David CS. Could HLA-DRB1 be the protective 
locus in rheumatoid arthritis. Immunol Today 1995; 16:274-278.
(182) Das P, Bradley DS, Geluk A, Griffiths MM, Luthra HS, David CS. An HLA- 
DRB 1*0402 derived peptide (HV3 65-79) prevents collagen-induced arthritis in 
HLA-DQ8 transgenic mice. Hum Immunol 1999; 60:575-582.
(183) Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic 
lupus erythematosus are clustered in two populations of surface structures on 
apoptotic keratinocytes. J Exp Med 1994; 179:1317-1330.
(184) Parodi A, Puiatti P, Rebora A. Serological profiles as prognostic clues for 
progressive systemic scleroderma: the Italian experience. Dermatologica 1991; 
183:15-20.
(185) Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Hoier-Madsen M, Wiik A 
et al. Clinical features and serum antinuclear antibodies in 230 Danish patients 
with systemic sclerosis. Br J Rheumatol 1998; 37:39-45.
(186) Arnett F, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA et al. 
Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An 
immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996; 39:1151- 
1160.
212
(187) Tager.R.E, Tikly M. Clinical and laboratory manifestations of systemic sclerosis 
(scleroderma) in Black South Africans. Brit J Rheumatol 1999; 38:397-400.
(188) Kuwana M, Inoko H, Kameda H, Nojima Y, Sato S, Nakamura K et al. 
Association of human leukocyte antigen class II alleles with autoantibody 
profiles, but not with disease susceptibility in Japanese patients with systemic 
sclerosis. Internal medicine 1999; 38:336-344.
(189) Satoh M, Akizuki M, Kuwana M, Mimori T, Yamagata H, Yoshida S et al. 
Genetic and immunological differences between Japanese patients with diffuse 
scleroderma and limited scleroderma. J Rheumatol 1994; 21:111-114.
(190) Kuwana M, Kaburaki J, Arnett F, Howard RF, Medsger TA, Jr., Wright TM. 
Influence of ethnic background on clinical and serologic features in patients with 
systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 
1999; 42:465-474.
(191) Cram DS, Fisicaro N, McNeilage LJ, Coppel RL, Harrison LC. Antibody 
specificities of Thai and Australian scleroderma sera with topoisomerase I 
recombinant fusion proteins. J Immunol 1993; 151:6872-6881.
(192) Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African- 
American race and antibodies to topoisomerase I are associated with increased 
severity of scleroderma lung disease. Chest 1998; 114:801-807.
(193) Okano Y, Steen VD, Medsger TA, Jr. Autoantibody reactive with RNA 
polymerase III in systemic sclerosis. Ann Intern Med 1993; 119:1005-1013.
(194) Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulus HM. Patients with 
anticentromere antibodies, clinical features, diagnosis and evolution. Brit J 
Rheumatol 1993; 32:297-301.
(195) Chan HL, Lee YS, Hong HS, Kuo TT. Anticentromere antibodies (ACA): 
clinical distribution and disease specificity. Clin Exp Dermatololgy 1994; 
19:298-302.
(196) McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in 
antinuclear antibody patterns and clinical manifestations of scleroderma. 
Arthritis Rheum 1989; 32:54-60.
(197) McHugh NJ, James IE, Kairbum K, Maddison PJ. Autoantibodies to 
mitochondrial and centromere antigens in primary biliary cirrhosis and systemic 
sclerosis. Clin Exp Immunol 1990; 81:244-249.
(198) Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P, Smolen JS. The 
concurrence of rheumatoid arthritis and limited systemic sclerosis. Arthritis 
Rheum 1998; 41:1938-1945.
(199) Misra R, Darton K, Jewkes RF, Black CM, Maini RN. Arthritis in scleroderma. 
Brit J Rheumatol 1995; 34:831-837.
213
(200) Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F. Clinical 
significance of anticentromere antibodies in patients with- systemic lupus 
erythematosus. J Rheumatol 2000; 27:1403-1407.
(201) Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S et al. 
Sjogren's syndrome with anticentromere antibodies. Rev Rheum Engl Ed 1997; 
64:785-788.
(202) Reveille JD, Owerbach D, Goldstein R, Moreda R, Isem RA, Arnett FC. 
Association of polar amino acids at position 26 of the HLA-DQB1 first domain 
with the anticentromere autoantibody response in systemic sclerosis 
(scleroderma). J Clin Invest 1992; 89:1208-1213.
(203) Eamshaw WC, Sullivan KF, Machlin PS, Cooke CA, Kaiser DA, Pollard TD et 
al. Molecular cloning of cDNA for CENP-B, the major human centromere 
autoantigen. J Cell Biol 1987; 104:817-829.
(204) Sugimoto K, Kuriyama K, Himeno M, Muro Y. Epitope mapping of human 
centromere autoantigen centromere protein C (CENP C); Heterogeneity of anti- 
CENP-C response in rheumatic disease. J Rheumatol 1998; 25:474-481.
(205) Rattner JB, Rees J, Arnett FC, Reveille JD, Goldstein R, Fritzler MJ. The 
centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis. 
Arthritis Rheum 1996; 39:1355-1361.
(206) Vazques-Abad D, Grodzicky T, Senecal J-L. Anticentromere autoantibodies in 
patients without Raynaud's disease or systemic sclerosis. Clinical Immunology 
1999; 90:182-189.
(207) Russo K, Hoch S, Dima C, Varga J, Teodorescu M. Circulating anticentromere 
CENP-A and CENP-B antibodies in patients with diffuse and limited systemic 
sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. J Rheumatol 
2000; 27:142-148.
(208) Ferri C, Bernini L, Cecchetti R, Latorraca A, Marotta G, Pasero G et al. 
Cutaneous and serologic subsets of systemic sclerosis. J Rheumatol 1991; 
18:1826-1832.
(209) Tubach F, Hayem G, Elias A, Nicaise P, Haim T, Kahn MF et al. 
Anticentromere antibodies in rheumatologic practice are not consistntly 
associated with scleroderma. Rev Rheum Engl Ed 1997; 64:362-367.
(210) Migliaresi S, Picillo U, Tirri G, Improta FDG, Palombara FLa, Giordano M. 
Infrequency of anticentromere antibody in patients without systemic sclerosis 
and without Raynaud's phenomenon. Arthritis Rheum 1987; 30:358-359.
(211) Picillo U, Migliaresi S, Marcialis M, Ferruzzi AM, Tirri G. Clinical setting of 
patients with systemic sclerosis by serum autoantibodies. Clinical Rheumatology 
1997; 16:378-383.
(212) Kallenberg CGM, Pastoor GW, Wouda AA, The TH. Antinuclear antibodies in 
patients with Raynaud's phenomenon: clinical significance of anticentromere 
antibodies. Ann Rheum Dis 1982; 41:382-387.
214
(213) Mitchell SR, McCarty GA, Katz P. Anticentromere antibody is not specific for 
connective tissue diseases with promising prognosis. Arthritis Rheum 1985; 
28:1076-1077.
(214) Horiki T, Moriuchi J, Takaya M, Uchiyama M, Hoshina Y, Inada K et al. The 
coexistence of systemic sclerosis and rheumatoid arthritis in five patients. 
Clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum 
1996; 39:152-156.
(215) Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Rheum Dis Clin 
North Am 1996; 22:647-674.
(216) Roberts A, Spom M, Assoian R. Transforming growth factor p: Rapid induction 
of fibrosis and angiogenesis in vivo and collagen formation in vitro. Proc Natl 
Acad Sci U S A 1986; 83:4167.
(217) Keystone EC, Lok C, Appleton B. Elevated serum levels of transforming growth 
factor P in patients with scleroderma (SSc). Arthritis Rheum 35, S206. 1992. 
Abstract.
(218) Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollbergs J. Expression of TGFpl, 
TGFp2 and TGFp3 i localised and systemic sclerosis. Journal of dermatological 
Science 1999;21:13-22.
(219) Border WA, Ruoslahti E. Transforming growth factor-p in disease: the dark side 
of tissue repair. J Clin Invest 1992; 90:1-7.
(220) Forberg K, Valyi-Nagy I, Heldin C-H, Herlyn M, Westmark B. Platelet derived 
growth factor (PDGF) in oncogenesis: development of a vascular connective 
tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc 
Natl Acad Sci U S A 1993; 90:393-397.
(221) Takemura H, Suzuki H, Fujisawa H, Yuhara T, Akama T, Yamane K et al. 
Enhanced interleukin 6 production by cultured fibroblasts from patients with 
SSc in response to platelet derived growth factor. J Rheumatol 1998; 25:1534- 
1539.
(222) Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of 
metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma 
fibroblasts. J Invest Dermatol 1997; 108:281-284.
(223) Andikopoulos K, Liu X, Kene DR, Jaenisch R, Ramirez F. Targeted mutation in 
the col5a2 gene reveals a regulatory role for type V collagen during matrix 
assembly. Nature Genet 1995; 9:31-36.
(224) Majewski S, Hunzelmann N, Schirren CG, Mauch C, Aumailley M, Krieg T. 
Increased adhesion of fibroblasts from patients with scleroderma to extracellular 
matrix components: In vitro modulation by IFN-gamma but not by TGF-p. J 
Invest Dermatol 1992; 98:86-91.
215
(225) Ford AL, Kurien BT, Harley JB, Scofield RH. Anti-centromere autoantibody in 
a patient evolving from a lupus/sjogren's overlap to the CREST varient of 
scleroderma. J Rheumatol 1998; 25:1419-1424.
(226) Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. 
Genotypic variation in the transforming growth factor-beta 1 gene: association 
with transforming growth factor beta 1 production, fibrotic lung disease, and 
graft fibrosis after lung transplantation. Transplantation 1998; 66:1014-1020.
(227) O'Kane S, Ferguson MW. Transforming growth factor betas and wound healing. 
Int J Biochem Cell Biol 1997; 29:63-78.
(228) Shah M, Forman DM, Ferguson MW. Neutralisatation of TGF-beta 1 and TGF- 
beta 2 or exogenous addition of TGF-beta 3to cutaneous rat wounds reduces 
scarring. J Cell Sci 1995; 108:985-1002.
(229) Gilchrist FC, Bunn C, Foley PJ, Black CM, Welsh KI, du Bois RM. Class II 
HLA associations with autoantibodies in scleroderma: a highly significant role 
for HLA DP. Genes Immunology 2001; 2:76-81. 2001.
th(230) HLA 1991. Proceedings of the 11 International histocompatibility Workshop 
and conference. Oxford University Press 1992. Ed: Tsuji. K., Aizawa. M., 
Sasazuki. T. pgl 166-1168.
216
